<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call February 5, 2026 8:00 AM EST<br><br>Company Participants<br><br>Charles Triano - SVP & Head of Investor Relations<br>Christopher Boerner - CEO & Chairman<br>David Elkins - Executive VP & CFO<br>Cristian Massacesi - Executive VP, Chief Medical Officer & Head of Development<br>Adam Lenkowsky - Executive VP & Chief Commercialization Officer<br><br>Conference Call Participants<br><br>Seamus Fernandez - Guggenheim Securities, LLC, Research Division<br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Courtney Breen - Bernstein Institutional Services LLC, Research Division<br>Mohit Bansal - Wells Fargo Securities, LLC, Research Division<br>Terence Flynn - Morgan Stanley, Research Division<br>Geoffrey Meacham - Citigroup Inc.</td><td># ë¸Œë¦¬ìŠ¤í†¨-ë§ˆì´ì–´ìŠ¤ ìŠ¤í… (BMY) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br>2026ë…„ 2ì›” 5ì¼ ì˜¤ì „ 8ì‹œ (ë¯¸ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>ì°°ìŠ¤ íŠ¸ë¦¬ì•„ë…¸ - ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ íˆ¬ìì ê´€ê³„ ì±…ì„ì<br>í¬ë¦¬ìŠ¤í† í¼ ë³´ì–´ë„ˆ - ìµœê³ ê²½ì˜ì ê²¸ íšŒì¥<br>ë°ì´ë¹„ë“œ ì—˜í‚¨ìŠ¤ - ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ì<br>í¬ë¦¬ìŠ¤í‹°ì•ˆ ë§ˆì‚¬ì²´ì‹œ - ì „ë¬´ì´ì‚¬, ìµœê³ ì˜ë£Œì±…ì„ì ê²¸ ê°œë°œ ì±…ì„ì<br>ì•„ë‹´ ë Œì½”ìŠ¤í‚¤ - ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³ ìƒì—…í™”ì±…ì„ì<br><br>## ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì—¬ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ì‹œë¬´ìŠ¤ í˜ë¥´ë‚œë°ìŠ¤ - êµ¬ê²í•˜ì„ ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í¬ë¦¬ìŠ¤í† í¼ ì‡¼íŠ¸ - JPëª¨ê±´ ì²´ì´ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì½”íŠ¸ë‹ˆ ë¸Œë¦° - ë²ˆìŠ¤íƒ€ì¸ ì¸ìŠ¤í‹°íŠœì…”ë„ ì„œë¹„ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ëª¨í› ë°˜ì‚´ - ì›°ìŠ¤íŒŒê³  ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í…Œë ŒìŠ¤ í”Œë¦° - ëª¨ê±´ ìŠ¤íƒ ë¦¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œí”„ë¦¬ ë¯¸ì²¨ - ì”¨í‹°ê·¸ë£¹</td></tr>
<tr><td>Exchange Research<br>Asad Haider - Goldman Sachs Group, Inc., Research Division<br>David Risinger - Leerink Partners LLC, Research Division<br>David Amsellem - Piper Sandler & Co., Research Division<br>Jason Gerberry - BofA Securities, Research Division<br>Malcolm Hoffman - BMO Capital Markets Equity Research<br>Steve Scala - TD Cowen, Research Division<br><br>Presentation<br><br>Operator<br><br>Welcome to Bristol-Myers Squibb Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note today's event is being recorded. I would now like to turn the conference over to Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead.</td><td># ë¸Œë¦¬ìŠ¤í†¨ ë§ˆì´ì–´ìŠ¤ ìŠ¤í… 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>## ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>**Asad Haider** - Goldman Sachs Group, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>**David Risinger** - Leerink Partners LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>**David Amsellem** - Piper Sandler & Co., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>**Jason Gerberry** - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>**Malcolm Hoffman** - BMO Capital Markets ì£¼ì‹ ë¦¬ì„œì¹˜<br>**Steve Scala** - TD Cowen, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>## ë°œí‘œ<br><br>**ì‚¬íšŒì**<br><br>ë¸Œë¦¬ìŠ¤í†¨ ë§ˆì´ì–´ìŠ¤ ìŠ¤í… 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ì‚¬íšŒì ì•ˆë‚´ì‚¬í•­] ì˜¤ëŠ˜ í–‰ì‚¬ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ì œ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ ì±…ì„ìì´ì‹  Chuck Trianoê»˜ ì§„í–‰ì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì‹œì‘í•˜ì‹œì£ .</td></tr>
<tr><td>Charles Triano<br>SVP & Head of Investor Relations<br><br>Thank you, and good morning, everyone. We appreciate you joining our fourth quarter 2025 earnings call. With me this morning with prepared remarks are Chris Boerner, our Board Chair and Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call is Adam Lenkowsky, our Chief Commercialization Officer; and Cristian Massacesi, our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we posted our quarterly slide presentation to bms.com that you can use to follow along with Chris and David's remarks.</td><td>ì°°ìŠ¤ íŠ¸ë¦¬ì•„ë…¸<br>ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„, ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì €í¬ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œë¥¼ í•¨ê»˜í•  ë¶„ë“¤ì€ í¬ë¦¬ìŠ¤ ë³´ì–´ë„ˆ ì´ì‚¬íšŒ ì˜ì¥ ê²¸ ìµœê³ ê²½ì˜ìì™€ ë°ì´ë¹„ë“œ ì—˜í‚¨ìŠ¤ ìµœê³ ì¬ë¬´ì±…ì„ìì…ë‹ˆë‹¤. ë˜í•œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” ì•„ë‹´ ë Œì½”ìŠ¤í‚¤ ìµœê³ ìƒì—…í™”ì±…ì„ìì™€ í¬ë¦¬ìŠ¤í‹°ì•ˆ ë§ˆì‚¬ì„¸ì‹œ ìµœê³ ì˜ë£Œì±…ì„ì ê²¸ ê¸€ë¡œë²Œ ì˜ì•½í’ˆ ê°œë°œ ì±…ì„ìë„ ì°¸ì„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ì¼ì° ì €í¬ëŠ” bms.comì— ë¶„ê¸°ë³„ í”„ë ˆì  í…Œì´ì…˜ ìë£Œë¥¼ ê²Œì‹œí–ˆìœ¼ë©°, í¬ë¦¬ìŠ¤ì™€ ë°ì´ë¹„ë“œì˜ ë°œí‘œ ë‚´ìš©ì„ ë”°ë¼ê°€ì‹œëŠ” ë° í™œìš©í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Before we get started, I'll remind everybody that during this call, we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date, and we specifically disclaim any obligation to update forward-looking statements even if our estimates change.</td><td>ì‹œì‘í•˜ê¸°ì— ì•ì„œ, ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë‹¹ì‚¬ì˜ ë¯¸ë˜ ê³„íš ë° ì „ë§ì— ê´€í•œ ì§„ìˆ ì„ í•  ì˜ˆì •ì´ë©°, ì´ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì— í•´ë‹¹í•¨ì„ ëª¨ë“  ë¶„ë“¤ê»˜ ìƒê¸°ì‹œì¼œ ë“œë¦½ë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ëŠ” ë‹¹ì‚¬ì˜ SEC ì œì¶œ ì„œë¥˜ì—ì„œ ë…¼ì˜ëœ ë‹¤ì–‘í•œ ì¤‘ìš” ìš”ì¸ë“¤ì„ í¬í•¨í•˜ì—¬, ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì—ì„œ ì œì‹œëœ ë‚´ìš©ê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì€ ì˜¤ëŠ˜ í˜„ì¬ ê¸°ì¤€ì˜ ë‹¹ì‚¬ ì¶”ì •ì¹˜ë¥¼ ë‚˜íƒ€ë‚´ëŠ” ê²ƒì´ë©°, í–¥í›„ ì–´ëŠ ì‹œì ì˜ ì¶”ì •ì¹˜ë¥¼ ëŒ€ë³€í•˜ëŠ” ê²ƒìœ¼ë¡œ ê°„ì£¼ë˜ì–´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ë˜í•œ ë‹¹ì‚¬ëŠ” ì¶”ì •ì¹˜ê°€ ë³€ê²½ë˜ë”ë¼ë„ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ëª…ì‹œì ìœ¼ë¡œ ë¶€ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com. Finally, unless otherwise stated, all comparisons are made from the same period in 2024, and sales growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange. All references to our P&L are on a non-GAAP basis. And with that, I'll hand it over to Chris. Christopher Boerner<br>CEO & Chairman<br><br>Thanks, Chuck. Welcome, and thank you for joining us this morning. 2025 was a year of focused execution across the business.</td><td>ì €í¬ëŠ” ë˜í•œ íŠ¹ì • í•­ëª©ë“¤ì„ ì œì™¸í•˜ë„ë¡ ì¡°ì •ëœ ë¹„-GAAP ì¬ë¬´ ì§€í‘œì— ëŒ€í•œ ë…¼í‰ì— ì§‘ì¤‘í•  ê²ƒì…ë‹ˆë‹¤. íŠ¹ì • ë¹„-GAAP ì¬ë¬´ ì§€í‘œì™€ ê°€ì¥ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì§€í‘œ ê°„ì˜ ì¡°ì • ë‚´ì—­ì€ bms.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ë³„ë„ë¡œ ëª…ì‹œë˜ì§€ ì•ŠëŠ” í•œ, ëª¨ë“  ë¹„êµëŠ” 2024ë…„ ë™ì¼ ê¸°ê°„ê³¼ ì´ë£¨ì–´ì§€ë©°, ë§¤ì¶œ ì„±ì¥ë¥ ì€ ì™¸í™˜ ì˜í–¥ì„ ì œì™¸í•œ ê¸°ì € ê¸°ì¤€(underlying basis)ìœ¼ë¡œ ë…¼ì˜ë  ê²ƒì…ë‹ˆë‹¤. ì†ìµê³„ì‚°ì„œì— ëŒ€í•œ ëª¨ë“  ì–¸ê¸‰ì€ ë¹„-GAAP ê¸°ì¤€ì…ë‹ˆë‹¤. ê·¸ëŸ¼ í¬ë¦¬ìŠ¤ì—ê²Œ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>Christopher Boerner<br>CEO & Chairman (ìµœê³ ê²½ì˜ì ê²¸ íšŒì¥)<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì²™. í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 2025ë…„ì€ ì‚¬ì—… ì „ë°˜ì— ê±¸ì³ ì§‘ì¤‘ëœ ì‹¤í–‰ì˜ í•œ í•´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We believe our results further demonstrate the ongoing strength in our growth portfolio as we advance our multiyear plan to rewire BMS for long-term growth. These efforts enabled us to enter 2026 with good momentum. Let me start by highlighting our recent progress on Slide 4. We closed the year with strong fourth quarter performance. Our growth portfolio grew 15% year-over-year in Q4 and 17% for the full year. In terms of building out breadth with newer products, Opdualag, Breyanzi and Camzyos each contributed over $1 billion in sales for the full year, while Reblozyl delivered over $2 billion.</td><td>ì €í¬ëŠ” ì´ë²ˆ ì‹¤ì ì´ ì¥ê¸° ì„±ì¥ì„ ìœ„í•œ BMSì˜ ë‹¤ë…„ê°„ ì¬í¸ ê³„íšì„ ì¶”ì§„í•˜ëŠ” ê³¼ì •ì—ì„œ ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì§€ì†ì ì¸ ê°•ì„¸ë¥¼ ë”ìš± ì…ì¦í•œë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë…¸ë ¥ ë•ë¶„ì— ìš°ë¦¬ëŠ” ì¢‹ì€ ëª¨ë©˜í…€ì„ ê°€ì§€ê³  2026ë…„ì„ ë§ì´í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 4ì—ì„œ ìµœê·¼ ì§„ì „ ì‚¬í•­ì„ ê°•ì¡°í•˜ë©° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 4ë¶„ê¸° ê°•ë ¥í•œ ì‹¤ì ìœ¼ë¡œ í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í–ˆìŠµë‹ˆë‹¤. ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” 4ë¶„ê¸°ì— ì „ë…„ ëŒ€ë¹„ 15% ì„±ì¥í–ˆìœ¼ë©°, ì—°ê°„ìœ¼ë¡œëŠ” 17% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì‹ ì œí’ˆë“¤ë¡œ í­ì„ ë„“íˆëŠ” ì¸¡ë©´ì—ì„œ, Opdualag, Breyanzi, CamzyosëŠ” ê°ê° ì—°ê°„ ë§¤ì¶œ 10ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ê¸°ë¡í–ˆìœ¼ë©°, Reblozylì€ 20ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These are differentiated, durable products early in their life cycles with meaningful runway ahead that further strengthen the foundation for long-term growth. And on a full year basis, it is worth pointing out that despite a decline of roughly $4 billion in revenue from our legacy portfolio, the growth portfolio nearly offset all of that. Cobenfy and Qvantig also continued to progress well and in line with our expectations. With Cobenfy, we saw steady growth as we expanded access and deepened adoption across community and hospital settings, and we expect the steady growth to continue throughout the year.</td><td>ì´ë“¤ì€ ì°¨ë³„í™”ë˜ê³  ì§€ì†ê°€ëŠ¥í•œ ì œí’ˆë“¤ë¡œ ì œí’ˆ ìˆ˜ëª…ì£¼ê¸° ì´ˆê¸° ë‹¨ê³„ì— ìˆìœ¼ë©°, ì•ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ì„±ì¥ ì—¬ë ¥ì´ ìˆì–´ ì¥ê¸° ì„±ì¥ì˜ ê¸°ë°˜ì„ ë”ìš± ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ë³¼ ë•Œ, ë ˆê±°ì‹œ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ì•½ 40ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œ ê°ì†Œê°€ ìˆì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ê±°ì˜ ì „ë¶€ë¥¼ ìƒì‡„í–ˆë‹¤ëŠ” ì ì€ ì£¼ëª©í•  ë§Œí•©ë‹ˆë‹¤. Cobenfyì™€ Qvantigë„ ìš°ë¦¬ì˜ ì˜ˆìƒì— ë¶€í•©í•˜ë©° ìˆœì¡°ë¡­ê²Œ ì§„ì „ë˜ê³  ìˆìŠµë‹ˆë‹¤. Cobenfyì˜ ê²½ìš°, ì§€ì—­ì‚¬íšŒ ë° ë³‘ì› í™˜ê²½ ì „ë°˜ì— ê±¸ì³ ì ‘ê·¼ì„±ì„ í™•ëŒ€í•˜ê³  ì±„íƒì„ ì‹¬í™”í•˜ë©´ì„œ ê¾¸ì¤€í•œ ì„±ì¥ì„ ë³´ì˜€ìœ¼ë©°, ì—°ì¤‘ ë‚´ë‚´ ì´ëŸ¬í•œ ê¾¸ì¤€í•œ ì„±ì¥ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Qvantig continued to receive positive early feedback from users with improved practice efficiency and patient preferences as the main drivers. David will provide more detail on our portfolio's performance shortly. Turning to recent clinical and regulatory highlights. In December, Breyanzi received FDA approval as the first and only CAR T cell therapy for adults with relapsed or refractory marginal zone lymphoma. It is now approved across 5 cancer types strengthening its leadership position among CD19-directed CAR Ts. In December, with our partners at BioNTech, we also shared the first global Phase II data for pumitamig in locally advanced or metastatic triple-negative breast cancer.</td><td>QvantigëŠ” ì§„ë£Œ íš¨ìœ¨ì„± ê°œì„ ê³¼ í™˜ì ì„ í˜¸ë„ë¥¼ ì£¼ìš” ë™ì¸ìœ¼ë¡œ í•˜ì—¬ ì‚¬ìš©ìë“¤ë¡œë¶€í„° ì§€ì†ì ìœ¼ë¡œ ê¸ì •ì ì¸ ì´ˆê¸° í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. Davidê°€ ê³§ í¬íŠ¸í´ë¦¬ì˜¤ ì‹¤ì ì— ëŒ€í•´ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦´ ê²ƒì…ë‹ˆë‹¤. ìµœê·¼ ì„ìƒ ë° ê·œì œ ê´€ë ¨ ì£¼ìš” ì„±ê³¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 12ì›”ì— BreyanziëŠ” ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë³€ì—°ë¶€ ë¦¼í”„ì¢… ì„±ì¸ í™˜ì ì¹˜ë£Œì œë¡œì„œ ìµœì´ˆì´ì ìœ ì¼í•œ CAR T ì„¸í¬ ì¹˜ë£Œì œë¡œ FDA ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì´ë¡œì¨ í˜„ì¬ 5ê°€ì§€ ì•” ìœ í˜•ì— ëŒ€í•œ ìŠ¹ì¸ì„ ë°›ì•„ CD19 í‘œì  CAR T ì¹˜ë£Œì œ ì¤‘ ì„ ë„ì  ì…ì§€ë¥¼ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ë˜í•œ 12ì›”ì—ëŠ” BioNTechì™€ì˜ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ êµ­ì†Œ ì§„í–‰ì„± ë˜ëŠ” ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”ì— ëŒ€í•œ pumitamigì˜ ì²« ê¸€ë¡œë²Œ 2ìƒ ì„ìƒ ë°ì´í„°ë¥¼ ê³µê°œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These data showed encouraging antitumor response and a manageable safety profile in both the first- and second-line treatment settings. Triple-negative breast cancer remains an aggressive disease where there is an urgent need for new treatment options. And within the overall pumitamig development partnership, we recently announced 3 additional planned studies, resulting in 8 registrational studies we expect to have underway by year-end. We are pleased to announce that 2 of these studies in non-small cell lung cancer are now initiating in unresectable Stage III disease and in first-line high PD-L1 expression.</td><td>ì´ëŸ¬í•œ ë°ì´í„°ëŠ” 1ì°¨ ë° 2ì°¨ ì¹˜ë£Œ í™˜ê²½ ëª¨ë‘ì—ì„œ ê³ ë¬´ì ì¸ í•­ì¢…ì–‘ ë°˜ì‘ê³¼ ê´€ë¦¬ ê°€ëŠ¥í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”ì€ ì—¬ì „íˆ ê³µê²©ì ì¸ ì§ˆí™˜ìœ¼ë¡œ, ìƒˆë¡œìš´ ì¹˜ë£Œ ì˜µì…˜ì— ëŒ€í•œ ê¸´ê¸‰í•œ í•„ìš”ì„±ì´ ìˆìŠµë‹ˆë‹¤. ì „ì²´ í‘¸ë¯¸íƒ€ë§™ ê°œë°œ íŒŒíŠ¸ë„ˆì‹­ ë‚´ì—ì„œ ìµœê·¼ 3ê°œì˜ ì¶”ê°€ ê³„íš ì—°êµ¬ë¥¼ ë°œí‘œí–ˆìœ¼ë©°, ì´ë¡œì¨ ì—°ë§ê¹Œì§€ ì§„í–‰ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ë“±ë¡ ì—°êµ¬ê°€ ì´ 8ê°œê°€ ë©ë‹ˆë‹¤. ì´ ì¤‘ ë¹„ì†Œì„¸í¬íì•”ì— ëŒ€í•œ 2ê°œ ì—°êµ¬ê°€ í˜„ì¬ ì ˆì œ ë¶ˆê°€ëŠ¥í•œ 3ê¸° ì§ˆí™˜ê³¼ PD-L1 ê³ ë°œí˜„ 1ì°¨ ì¹˜ë£Œì—ì„œ ì‹œì‘ë˜ê³  ìˆìŒì„ ë°œí‘œí•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤.</td></tr>
<tr><td>We also just posted details regarding our global Phase III study, Breakfree-SSc for Zola-cel, our CD19 CAR T, now initiating in patients with active systemic sclerosis. Finally, we very much look forward to the first oral data presentation for navlimetostat, a potential first-in-class PRMT5 inhibitor. This will be combination data in the pancreatic setting and will be showcased at the ESMO Targeted Anticancer Therapies Conference (sic) [ ESMO Targeted Anticancer Therapies Congress ] next month. These milestones reinforce the momentum of our pipeline with more readouts to come this year, which I'll talk about on Slide 5.</td><td>ë˜í•œ í™œë™ì„± ì „ì‹ ê²½í™”ì¦ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í˜„ì¬ ì‹œì‘ë˜ëŠ” CD19 CAR Tì¸ Zola-celì˜ ê¸€ë¡œë²Œ 3ìƒ ì„ìƒì‹œí—˜ Breakfree-SScì— ëŒ€í•œ ì„¸ë¶€ ì •ë³´ë¥¼ ë°©ê¸ˆ ê²Œì‹œí–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì ì¬ì  first-in-class PRMT5 ì–µì œì œì¸ navlimetostatì˜ ì²« êµ¬ë‘ ë°ì´í„° ë°œí‘œë¥¼ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì·Œì¥ì•” í™˜ê²½ì—ì„œì˜ ë³‘ìš©ìš”ë²• ë°ì´í„°ì´ë©°, ë‹¤ìŒ ë‹¬ ESMO í‘œì  í•­ì•”ì¹˜ë£Œ í•™íšŒ(ESMO Targeted Anticancer Therapies Congress)ì—ì„œ ë°œí‘œë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë§ˆì¼ìŠ¤í†¤ë“¤ì€ ìš°ë¦¬ íŒŒì´í”„ë¼ì¸ì˜ ëª¨ë©˜í…€ì„ ê°•í™”í•˜ë©°, ì˜¬í•´ ë” ë§ì€ ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì¸ë°, ì´ì— ëŒ€í•´ì„œëŠ” ìŠ¬ë¼ì´ë“œ 5ì—ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As we shared last month, this is a data-rich period for BMS, which could drive the introduction of more than 10 new medicines and over 30 meaningful launch opportunities by 2030. The increasing pace of pivotal readouts later this year will serve to better define the potential of our pipeline candidates. We are confident in our ability to deliver an attractive and durable growth profile heading into the next decade. The breadth and depth of these opportunities is illustrated on this slide.</td><td>ì§€ë‚œë‹¬ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, í˜„ì¬ëŠ” BMSì—ê²Œ ë°ì´í„°ê°€ í’ë¶€í•œ ì‹œê¸°ì´ë©°, ì´ë¥¼ í†µí•´ 2030ë…„ê¹Œì§€ 10ê°œ ì´ìƒì˜ ì‹ ì•½ê³¼ 30ê°œ ì´ìƒì˜ ì˜ë¯¸ ìˆëŠ” ì¶œì‹œ ê¸°íšŒë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ ì¤‘ì¶”ì  ì„ìƒê²°ê³¼ ë°œí‘œ ì†ë„ê°€ ë¹¨ë¼ì§€ë©´ì„œ ìš°ë¦¬ íŒŒì´í”„ë¼ì¸ í›„ë³´ë¬¼ì§ˆë“¤ì˜ ì ì¬ë ¥ì„ ë³´ë‹¤ ëª…í™•í•˜ê²Œ ê·œëª…í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¤ìŒ 10ë…„ì„ í–¥í•´ ë§¤ë ¥ì ì´ê³  ì§€ì†ê°€ëŠ¥í•œ ì„±ì¥ í”„ë¡œíŒŒì¼ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì— ìì‹ ê°ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°íšŒë“¤ì˜ í­ê³¼ ê¹Šì´ëŠ” ì´ ìŠ¬ë¼ì´ë“œì— ì˜ ë‚˜íƒ€ë‚˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This year alone, we expect to report top line registrational data for 6 potential new products: milvexian in both atrial fibrillation and secondary stroke prevention, admilparant in idiopathic pulmonary fibrosis, iberdomide, where we have already demonstrated a significant improvement in MRD negativity rates, mezigdomide and arlo-cel in relapsed or refractory multiple myeloma and RYZ101 in second-line plus GEP-NETs. We also anticipate meaningful pivotal line extension readouts for Sotyktu in lupus and Cobenfy in Alzheimer's disease psychosis. Most of these readouts will occur in the second half of the year, and we have more data readouts coming beyond 2026.</td><td>ì˜¬í•´ë§Œ í•´ë„ 6ê°œì˜ ì ì¬ì  ì‹ ì œí’ˆì— ëŒ€í•œ ìµœìƒìœ„ ë“±ë¡ ì„ìƒ ë°ì´í„°ë¥¼ ë³´ê³ í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤: ì‹¬ë°©ì„¸ë™ê³¼ ì´ì°¨ ë‡Œì¡¸ì¤‘ ì˜ˆë°© ì ì‘ì¦ì˜ ë°€ë²¡ì‹œì•ˆ(milvexian), íŠ¹ë°œì„± íì„¬ìœ ì¦ ì ì‘ì¦ì˜ ì• ë“œë°€íŒŒë€íŠ¸(admilparant), ì´ë¯¸ MRD ìŒì„±ë¥ ì—ì„œ ìœ ì˜ë¯¸í•œ ê°œì„ ì„ ì…ì¦í•œ ì´ë²„ë„ë§ˆì´ë“œ(iberdomide), ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì ì‘ì¦ì˜ ë©”ì§€ê·¸ë„ë§ˆì´ë“œ(mezigdomide)ì™€ ì•Œë¡œ-ì…€(arlo-cel), ê·¸ë¦¬ê³  2ì°¨ ì¹˜ë£Œ ì´ìƒ GEP-NET ì ì‘ì¦ì˜ RYZ101ì…ë‹ˆë‹¤. ë˜í•œ ë£¨í‘¸ìŠ¤ ì ì‘ì¦ì˜ ì†Œí‹±íˆ¬(Sotyktu)ì™€ ì•Œì¸ í•˜ì´ë¨¸ë³‘ ì •ì‹ ë³‘ ì ì‘ì¦ì˜ ì½”ë²¤í”¼(Cobenfy)ì— ëŒ€í•œ ì˜ë¯¸ ìˆëŠ” ì ì‘ì¦ í™•ëŒ€ ì„ìƒ ê²°ê³¼ë„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë°ì´í„° ë°œí‘œ ëŒ€ë¶€ë¶„ì€ í•˜ë°˜ê¸°ì— ì´ë£¨ì–´ì§ˆ ê²ƒì´ë©°, 2026ë…„ ì´í›„ì—ë„ ë” ë§ì€ ë°ì´í„° ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Together, these represent an attractive set of near-term catalysts that can meaningfully enhance the long-term growth profile of our current growth portfolio. We communicated at the start of last year that getting the long term right means executing well in the near and medium terms. As you can see from our results, we continue to deliver across the organization in 2025. Maintaining this strong say-to-do ratio by consistently delivering on our commitments has now been embedded in our culture and will continue to be core to how we operate.</td><td>ì´ëŸ¬í•œ ìš”ì†Œë“¤ì€ í•¨ê»˜ ìš°ë¦¬ì˜ í˜„ì¬ ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì¥ê¸° ì„±ì¥ í”„ë¡œí•„ì„ ì˜ë¯¸ìˆê²Œ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆëŠ” ë§¤ë ¥ì ì¸ ë‹¨ê¸° ì´‰ë§¤ì œë“¤ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‘ë…„ ì´ˆì— ì¥ê¸°ì ìœ¼ë¡œ ì˜¬ë°”ë¥¸ ë°©í–¥ì„ ì¡ê¸° ìœ„í•´ì„œëŠ” ë‹¨ê¸°ì™€ ì¤‘ê¸°ì—ì„œ ì˜ ì‹¤í–‰í•´ì•¼ í•œë‹¤ê³  ë§ì”€ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤. 2025ë…„ ì‹¤ì ì—ì„œ ë³´ì‹œëŠ” ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” ì¡°ì§ ì „ë°˜ì— ê±¸ì³ ê³„ì†í•´ì„œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì•½ì†ì„ ì¼ê´€ë˜ê²Œ ì´í–‰í•¨ìœ¼ë¡œì¨ ì´ëŸ¬í•œ ê°•ë ¥í•œ ìœ ì–¸ì‹¤í–‰ ë¹„ìœ¨(say-to-do ratio)ì„ ìœ ì§€í•˜ëŠ” ê²ƒì€ ì´ì œ ìš°ë¦¬ ê¸°ì—…ë¬¸í™”ì— ë‚´ì¬í™”ë˜ì—ˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ìš°ë¦¬ê°€ ìš´ì˜í•˜ëŠ” ë°©ì‹ì˜ í•µì‹¬ìœ¼ë¡œ ë‚¨ì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As you have seen in our financials, we delivered on our cost savings initiative in 2025, and we'll continue to expand the use of AI to help us move faster, operate leaner and reinvest strategically in growth. Our financial strength continues to allow us to invest in our business and bring exciting science into the company through the pursuit of high-return business development. Our North Star remains to deliver industry-leading sustainable growth into the 2030s and beyond. Now let me give you a high-level overview of our 2026 guidance on Slide 6, and David will speak to it in more detail shortly. We currently anticipate 2026 revenue in the range of $46 billion to $47.5 billion.</td><td>ì¬ë¬´ ìë£Œì—ì„œ ë³´ì…¨ë“¯ì´, ì €í¬ëŠ” 2025ë…„ ë¹„ìš© ì ˆê° ê³„íšì„ ì„±ê³µì ìœ¼ë¡œ ì´í–‰í–ˆìœ¼ë©°, ì•ìœ¼ë¡œë„ AI í™œìš©ì„ í™•ëŒ€í•˜ì—¬ ë” ë¹ ë¥´ê²Œ ì›€ì§ì´ê³ , ë” íš¨ìœ¨ì ìœ¼ë¡œ ìš´ì˜í•˜ë©°, ì„±ì¥ì„ ìœ„í•œ ì „ëµì  ì¬íˆ¬ìë¥¼ ì§€ì†í•  ê²ƒì…ë‹ˆë‹¤. ì €í¬ì˜ ì¬ë¬´ ê±´ì „ì„±ì€ ì‚¬ì—…ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•  ìˆ˜ ìˆê²Œ í•´ì£¼ë©°, ë†’ì€ ìˆ˜ìµë¥ ì˜ ì‚¬ì—… ê°œë°œ ì¶”ì§„ì„ í†µí•´ í¥ë¯¸ë¡œìš´ ê³¼í•™ê¸°ìˆ ì„ íšŒì‚¬ì— ë„ì…í•  ìˆ˜ ìˆê²Œ í•©ë‹ˆë‹¤. ì €í¬ì˜ ìµœìš°ì„  ëª©í‘œëŠ” 2030ë…„ëŒ€ì™€ ê·¸ ì´í›„ê¹Œì§€ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ë‹¬ì„±í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 6ì˜ 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ê°œê´„ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ê² ìœ¼ë©°, Davidê°€ ê³§ ë” ìì„¸íˆ ì„¤ëª…í•  ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” í˜„ì¬ 2026ë…„ ë§¤ì¶œì´ 460ì–µ ë‹¬ëŸ¬ì—ì„œ 475ì–µ ë‹¬ëŸ¬ ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This range reflects continued strong performance from our growth portfolio and a projected revenue decline for our legacy portfolio of between 12% and 16% given the ongoing LOE impacts. Within the legacy portfolio, we project Eliquis growth this year to be in the range of 10% to 15%. This is driven by continued global demand growth and the recent price reduction, which expands patient access and eliminates the associated inflation penalty. We expect lower operating expenses compared to last year due to our ongoing cost savings program, and we expect adjusted diluted earnings per share of between $6.05 and $6.35. With that, I'll turn it over to David.</td><td>ì´ ë²”ìœ„ëŠ” ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ì‹¤ì ê³¼ ì§€ì†ì ì¸ íŠ¹í—ˆë§Œë£Œ(LOE) ì˜í–¥ìœ¼ë¡œ ì¸í•œ ë ˆê±°ì‹œ í¬íŠ¸í´ë¦¬ì˜¤ì˜ 12%ì—ì„œ 16% ì‚¬ì´ì˜ ë§¤ì¶œ ê°ì†Œ ì „ë§ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë ˆê±°ì‹œ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œ ì˜¬í•´ ì—˜ë¦¬í€´ìŠ¤ì˜ ì„±ì¥ë¥ ì€ 10%ì—ì„œ 15% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŠ” ì§€ì†ì ì¸ ê¸€ë¡œë²Œ ìˆ˜ìš” ì¦ê°€ì™€ ìµœê·¼ ë‹¨í–‰í•œ ê°€ê²© ì¸í•˜ì— ê¸°ì¸í•˜ëŠ”ë°, ê°€ê²© ì¸í•˜ëŠ” í™˜ì ì ‘ê·¼ì„±ì„ í™•ëŒ€í•˜ê³  ê´€ë ¨ ì¸í”Œë ˆì´ì…˜ í˜ë„í‹°ë¥¼ ì œê±°í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§€ì†ì ì¸ ë¹„ìš© ì ˆê° í”„ë¡œê·¸ë¨ìœ¼ë¡œ ì¸í•´ ì „ë…„ ëŒ€ë¹„ ì˜ì—…ë¹„ìš©ì´ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 6.05ë‹¬ëŸ¬ì—ì„œ 6.35ë‹¬ëŸ¬ ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ê·¸ëŸ¼ ë°ì´ë¹„ë“œì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Elkins<br>Executive VP & CFO<br><br>Thank you, Chris, and good morning, everyone. I will begin my review of our 2025 financial results, focusing on our fourth quarter performance. I will follow up with the introduction of our non-GAAP financial guidance for 2026 and some considerations to help you better understand our financial outlook for this year. We had very strong commercial and financial performance in 2025, marked by focused execution on driving top line growth and generating strong cash flow while strengthening our balance sheet and continuing to manage our cost structure.</td><td>ë°ì´ë¹„ë“œ ì—˜í‚¨ìŠ¤<br>ì „ë¬´ì´ì‚¬ ê²¸ CFO<br><br>í¬ë¦¬ìŠ¤, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì €ëŠ” 4ë¶„ê¸° ì‹¤ì ì„ ì¤‘ì‹¬ìœ¼ë¡œ 2025ë…„ ì¬ë¬´ ì„±ê³¼ë¥¼ ê²€í† í•˜ê² ìŠµë‹ˆë‹¤. ì´ì–´ì„œ 2026ë…„ ë¹„-GAAP ì¬ë¬´ ê°€ì´ë˜ìŠ¤ë¥¼ ì†Œê°œí•˜ê³ , ì˜¬í•´ ì¬ë¬´ ì „ë§ì„ ë” ì˜ ì´í•´í•˜ì‹¤ ìˆ˜ ìˆë„ë¡ ëª‡ ê°€ì§€ ê³ ë ¤ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2025ë…„ì— ë§¤ìš° ê°•ë ¥í•œ ì˜ì—… ë° ì¬ë¬´ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë§¤ì¶œ ì„±ì¥ ê²¬ì¸ê³¼ ê°•ë ¥í•œ í˜„ê¸ˆíë¦„ ì°½ì¶œì— ì§‘ì¤‘ì ìœ¼ë¡œ ì‹¤í–‰í•˜ëŠ” í•œí¸, ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ê°•í™”í•˜ê³  ë¹„ìš© êµ¬ì¡°ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê´€ë¦¬í•œ ê²°ê³¼ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We've entered 2026 in a position of strength with a solid foundation, which we can continue to build upon to deliver on our long-term growth strategy. Starting with Slide 8. Total revenue in the fourth quarter was flat year-over-year at approximately $12.5 billion. Our growth portfolio continued its positive momentum with revenue increasing 15% to $7.4 billion and representing close to 60% of our total revenue in the quarter. Key brands, including Reblozyl, Breyanzi, Camzyos and our IO portfolio all achieved significant growth and were further supported by our early launches of Cobenfy and Qvantig.</td><td>2026ë…„ì„ ë§ì´í•˜ì—¬ ìš°ë¦¬ëŠ” ê²¬ê³ í•œ ê¸°ë°˜ì„ ë°”íƒ•ìœ¼ë¡œ ê°•ë ¥í•œ ìœ„ì¹˜ì—ì„œ ì¶œë°œí–ˆìœ¼ë©°, ì´ë¥¼ í† ëŒ€ë¡œ ì¥ê¸° ì„±ì¥ ì „ëµì„ ì§€ì†ì ìœ¼ë¡œ ì‹¤í–‰í•´ ë‚˜ê°ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 8ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì´ ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë³´í•©ì„¸ë¥¼ ìœ ì§€í•˜ë©° ì•½ 125ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ê¸ì •ì ì¸ ëª¨ë©˜í…€ì„ ì´ì–´ê°€ë©° ë§¤ì¶œì´ 15% ì¦ê°€í•œ 74ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆê³ , ì´ëŠ” ë¶„ê¸° ì „ì²´ ë§¤ì¶œì˜ 60%ì— ìœ¡ë°•í•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. Reblozyl, Breyanzi, Camzyos ë° IO í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í¬í•¨í•œ í•µì‹¬ ë¸Œëœë“œë“¤ì´ ëª¨ë‘ ì˜ë¯¸ ìˆëŠ” ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, Cobenfyì™€ Qvantigì˜ ì´ˆê¸° ì¶œì‹œê°€ ì´ë¥¼ ë”ìš± ë’·ë°›ì¹¨í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Within the legacy portfolio, higher revenue from Eliquis was offset by continued impact of increased generic volumes across several other brands. All in, we are very pleased with the results in the fourth quarter and the full year as our growth portfolio performance continues to reshape and redefine BMS as we strive to be one of the fastest-growing pharmaceutical companies into the next decade. Turning to product performance on Slide 9, starting with oncology. Opdivo again delivered solid growth in the fourth quarter with revenue up 7% to nearly $2.7 billion. This was driven by new indications and continued share growth within the first-line non-small cell lung cancer setting.</td><td>ë ˆê±°ì‹œ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œëŠ” ì—˜ë¦¬í€´ìŠ¤ì˜ ë§¤ì¶œ ì¦ê°€ê°€ ì—¬ëŸ¬ ë‹¤ë¥¸ ë¸Œëœë“œë“¤ì˜ ì œë„¤ë¦­ ë¬¼ëŸ‰ ì¦ê°€ë¡œ ì¸í•œ ì§€ì†ì ì¸ ì˜í–¥ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” 4ë¶„ê¸°ì™€ ì—°ê°„ ì‹¤ì ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì„±ê³¼ê°€ BMSë¥¼ ì§€ì†ì ìœ¼ë¡œ ì¬í¸í•˜ê³  ì¬ì •ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í–¥í›„ 10ë…„ê°„ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì œì•½íšŒì‚¬ ì¤‘ í•˜ë‚˜ê°€ ë˜ê¸° ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. 9í˜ì´ì§€ ìŠ¬ë¼ì´ë“œì˜ ì œí’ˆ ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ë¨¼ì € ì¢…ì–‘í•™ ë¶€ë¬¸ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜µë””ë³´ëŠ” 4ë¶„ê¸°ì— ë‹¤ì‹œ í•œë²ˆ ê²¬ì¡°í•œ ì„±ì¥ì„ ë‹¬ì„±í•˜ì—¬ ë§¤ì¶œì´ 7% ì¦ê°€í•œ ì•½ 27ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹ ê·œ ì ì‘ì¦ê³¼ 1ì°¨ ì¹˜ë£Œ ë¹„ì†Œì„¸í¬íì•” ì˜ì—­ ë‚´ ì§€ì†ì ì¸ ì ìœ ìœ¨ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Qvantig's launch continued to progress well with revenue of $133 million in the quarter. With Opdualag, we delivered another quarter of strong double-digit growth, driven by demand in the U.S., where it remains a standard of care in first-line melanoma. Turning to Slide 10. Reblozyl delivered 21% growth with performance reflecting solid uptake across first- and second-line MDS-associated anemia patients. Over the past 2 years, we have delivered a very strong launch for Reblozyl. In cell therapy, Breyanzi's fourth quarter revenue continued to show impressive growth with revenue up 47%, driven by its desirable profile and continued strong demand across its approved indications.</td><td>Qvantigì˜ ì¶œì‹œëŠ” ë¶„ê¸° ë§¤ì¶œ 1ì–µ 3,300ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ë©° ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ì—ˆìŠµë‹ˆë‹¤. OpdualagëŠ” 1ì°¨ ì¹˜ë£Œ í‘ìƒ‰ì¢…ì—ì„œ í‘œì¤€ ì¹˜ë£Œë²•ìœ¼ë¡œ ìë¦¬ì¡ì€ ë¯¸êµ­ ë‚´ ìˆ˜ìš”ì— í˜ì…ì–´ ë˜ í•œ ë¶„ê¸° ê°•ë ¥í•œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 10ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. Reblozylì€ 1ì°¨ ë° 2ì°¨ ì¹˜ë£Œ MDS ê´€ë ¨ ë¹ˆí˜ˆ í™˜ìë“¤ì—ì„œì˜ ê²¬ê³ í•œ ì²˜ë°© ì¦ê°€ë¥¼ ë°˜ì˜í•˜ì—¬ 21% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì§€ë‚œ 2ë…„ê°„ ìš°ë¦¬ëŠ” Reblozylì˜ ë§¤ìš° ê°•ë ¥í•œ ì¶œì‹œ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì„¸í¬ì¹˜ë£Œì œ ë¶€ë¬¸ì—ì„œëŠ” Breyanziì˜ 4ë¶„ê¸° ë§¤ì¶œì´ ìš°ìˆ˜í•œ í”„ë¡œíŒŒì¼ê³¼ ìŠ¹ì¸ëœ ì ì‘ì¦ ì „ë°˜ì— ê±¸ì¹œ ì§€ì†ì ì¸ ê°•ë ¥í•œ ìˆ˜ìš”ì— í˜ì…ì–´ 47% ì¦ê°€í•˜ë©° ì¸ìƒì ì¸ ì„±ì¥ì„¸ë¥¼ ì´ì–´ê°”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We continue to be encouraged by Breyanzi's growth prospects into 2026. Moving to cardiovascular on Slide 11. Eliquis delivered nearly $3.5 billion in the fourth quarter revenue, an increase of 6%. This was driven by demand growth and market share gains with the U.S. revenue increasing 4%. Turning to Camzyos, revenue in the fourth quarter grew 57% to $353 million, benefiting from continued demand growth globally. In the U.S., we expanded the number of physicians who are prescribing the drug. And outside of the U.S., we have now launched in over 50 countries. Now moving to immunology. Global revenue of Sotyktu grew 3%.</td><td>2026ë…„ê¹Œì§€ Breyanziì˜ ì„±ì¥ ì „ë§ì— ëŒ€í•´ ê³„ì†í•´ì„œ ê³ ë¬´ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. 11í˜ì´ì§€ ì‹¬í˜ˆê´€ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. EliquisëŠ” 4ë¶„ê¸°ì— ì•½ 35ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ë‹¬ì„±í•˜ì—¬ 6% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìˆ˜ìš” ì¦ê°€ì™€ ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, ë¯¸êµ­ ë§¤ì¶œì€ 4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. Camzyosë¡œ ë„˜ì–´ê°€ë©´, 4ë¶„ê¸° ë§¤ì¶œì€ 57% ì„±ì¥í•œ 3ì–µ 5,300ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì „ ì„¸ê³„ì ì¸ ì§€ì†ì ì¸ ìˆ˜ìš” ì¦ê°€ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” ì´ ì•½ë¬¼ì„ ì²˜ë°©í•˜ëŠ” ì˜ì‚¬ ìˆ˜ë¥¼ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” í˜„ì¬ 50ê°œêµ­ ì´ìƒì—ì„œ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ì œ ë©´ì—­í•™ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. Sotyktuì˜ ê¸€ë¡œë²Œ ë§¤ì¶œì€ 3% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We look forward to our upcoming PDUFA date for psoriatic arthritis and our Phase III readouts for lupus and Sjogren's disease. I will wrap up by reviewing our product performance for the quarter on Slide 12 with neuroscience. Cobenfy revenue in the fourth quarter was $51 million, with continued steady uptake among prescribers and patients. Cobenfy's uptake has surpassed all schizophrenia comparators and relevant analogs in the first year of launch, and we continue to expect steady growth throughout the year. Let's move to the P&L on Slide 13. As expected, gross margin declined 210 basis points in the fourth quarter to 71.9%, driven primarily by product mix, notably Eliquis and Revlimid.</td><td>ê±´ì„ ì„± ê´€ì ˆì—¼ì— ëŒ€í•œ PDUFA ìŠ¹ì¸ ì˜ˆì •ì¼ê³¼ ë£¨í‘¸ìŠ¤ ë° ì‡¼ê·¸ë Œë³‘ì— ëŒ€í•œ 3ìƒ ì„ìƒ ê²°ê³¼ ë°œí‘œë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 12ì˜ ì‹ ê²½ê³¼í•™ ë¶„ì•¼ ì œí’ˆ ì‹¤ì  ê²€í† ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° Cobenfy ë§¤ì¶œì€ 5,100ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì²˜ë°©ì˜ì™€ í™˜ìë“¤ ì‚¬ì´ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì•ˆì •ì ì¸ ì±„íƒë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. Cobenfyì˜ ì‹œì¥ ì¹¨íˆ¬ìœ¨ì€ ì¶œì‹œ ì²« í•´ì— ëª¨ë“  ì¡°í˜„ë³‘ ì¹˜ë£Œì œ ë¹„êµ ëŒ€ìƒ ë° ê´€ë ¨ ìœ ì‚¬ ì œí’ˆë“¤ì„ ëŠ¥ê°€í–ˆìœ¼ë©°, ì—°ì¤‘ ë‚´ë‚´ ê¾¸ì¤€í•œ ì„±ì¥ì„ ì§€ì†í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ìŠ¬ë¼ì´ë“œ 13ì˜ ì†ìµê³„ì‚°ì„œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì˜ˆìƒëŒ€ë¡œ 4ë¶„ê¸° ë§¤ì¶œì´ì´ìµë¥ ì€ 71.9%ë¡œ 210bp ê°ì†Œí–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ì œí’ˆ ë¯¹ìŠ¤, íŠ¹íˆ Eliquisì™€ Revlimidì˜ ì˜í–¥ì— ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Regarding our operating expenses, we made significant progress during 2025 against our $2 billion strategic productivity initiative. As of the end of the fourth quarter, we delivered on a target of approximately $1 billion in savings in 2025 and are on track to realize the remaining $1 billion over 2026 and 2027. Excluding in-process R&D, operating expenses for the full year were $16.6 billion, a decrease of $1.2 billion from 2024. This reflects our ongoing cost savings program, partially offset by continued investment behind growth initiatives.</td><td>ì˜ì—…ë¹„ìš©ê³¼ ê´€ë ¨í•˜ì—¬, ë‹¹ì‚¬ëŠ” 2025ë…„ ë™ì•ˆ 20ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì „ëµì  ìƒì‚°ì„± ê°œì„  ê³„íšì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë§ ê¸°ì¤€ìœ¼ë¡œ 2025ë…„ ì•½ 10ì–µ ë‹¬ëŸ¬ì˜ ë¹„ìš© ì ˆê° ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, 2026ë…„ê³¼ 2027ë…„ì— ê±¸ì³ ë‚˜ë¨¸ì§€ 10ì–µ ë‹¬ëŸ¬ë¥¼ ì‹¤í˜„í•  ìˆ˜ ìˆëŠ” ê¶¤ë„ì— ì˜¬ë¼ ìˆìŠµë‹ˆë‹¤. ì§„í–‰ ì¤‘ì¸ ì—°êµ¬ê°œë°œë¹„ë¥¼ ì œì™¸í•œ ì—°ê°„ ì˜ì—…ë¹„ìš©ì€ 166ì–µ ë‹¬ëŸ¬ë¡œ, 2024ë…„ ëŒ€ë¹„ 12ì–µ ë‹¬ëŸ¬ ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ì†ì ì¸ ë¹„ìš© ì ˆê° í”„ë¡œê·¸ë¨ì„ ë°˜ì˜í•œ ê²ƒì´ë©°, ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œì— ëŒ€í•œ ì§€ì†ì ì¸ íˆ¬ìë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our effective tax rate in the quarter was 22.1% compared to 19.9% in the prior year, with the effective tax rate in 2025, reflecting the onetime nontax deductible in-process R&D charge related to the Orbital acquisition. Overall, diluted earnings per share were $1.26 for the quarter and full year diluted earnings per share came in at $6.15. Both include a net charge related to in-process R&D and licensing income, which totaled $0.60 per share in the quarter and $1.40 for the full year. Now turning to the balance sheet and capital allocation highlights on Slide 14.</td><td>ë‹¹ë¶„ê¸° ìœ íš¨ì„¸ìœ¨ì€ 22.1%ë¡œ ì „ë…„ë„ 19.9% ëŒ€ë¹„ ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. 2025ë…„ ìœ íš¨ì„¸ìœ¨ì—ëŠ” Orbital ì¸ìˆ˜ì™€ ê´€ë ¨ëœ ì¼íšŒì„± ì„¸ê¸ˆ ê³µì œ ë¶ˆê°€ëŠ¥í•œ ì§„í–‰ ì¤‘ì¸ ì—°êµ¬ê°œë°œë¹„ê°€ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ë‹¹ë¶„ê¸° í¬ì„ì£¼ë‹¹ìˆœì´ìµì€ 1.26ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì—°ê°„ í¬ì„ì£¼ë‹¹ìˆœì´ìµì€ 6.15ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë‘ ìˆ˜ì¹˜ ëª¨ë‘ ì§„í–‰ ì¤‘ì¸ ì—°êµ¬ê°œë°œë¹„ì™€ ë¼ì´ì„ ì‹± ìˆ˜ìµê³¼ ê´€ë ¨ëœ ìˆœë¹„ìš©ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ë‹¹ë¶„ê¸° ì£¼ë‹¹ 0.60ë‹¬ëŸ¬, ì—°ê°„ ì£¼ë‹¹ 1.40ë‹¬ëŸ¬ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 14ì˜ ëŒ€ì°¨ëŒ€ì¡°í‘œì™€ ìë³¸ë°°ë¶„ í•˜ì´ë¼ì´íŠ¸ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our financial position remains strong with approximately $11 billion in cash equivalents and marketable securities as of December 31, 2025. We completed our targeted $10 billion of debt paydown ahead of schedule and generated strong cash flow from operations of approximately $2 billion in the fourth quarter. In terms of capital allocation, we continue to ensure we employ a strategic and balanced approach. Business development remains a top priority while also returning cash to shareholders through our commitment to the dividend. Now let me walk you through our non-GAAP 2026 guidance on Slide 15, starting with revenue.</td><td>2025ë…„ 12ì›” 31ì¼ ê¸°ì¤€ í˜„ê¸ˆì„±ìì‚° ë° ìœ ê°€ì¦ê¶Œì´ ì•½ 110ì–µ ë‹¬ëŸ¬ë¡œ ë‹¹ì‚¬ì˜ ì¬ë¬´ìƒíƒœëŠ” ê²¬ê³ í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ëª©í‘œë¡œ í–ˆë˜ 100ì–µ ë‹¬ëŸ¬ì˜ ë¶€ì±„ ìƒí™˜ì„ ì˜ˆì •ë³´ë‹¤ ì•ë‹¹ê²¨ ì™„ë£Œí–ˆìœ¼ë©°, 4ë¶„ê¸°ì— ì•½ 20ì–µ ë‹¬ëŸ¬ì˜ ê°•ë ¥í•œ ì˜ì—…í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí–ˆìŠµë‹ˆë‹¤. ìë³¸ë°°ë¶„ ì¸¡ë©´ì—ì„œëŠ” ì „ëµì ì´ê³  ê· í˜•ì¡íŒ ì ‘ê·¼ë°©ì‹ì„ ì§€ì†ì ìœ¼ë¡œ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì—…ê°œë°œì´ ìµœìš°ì„  ê³¼ì œë¡œ ë‚¨ì•„ìˆìœ¼ë©°, ë™ì‹œì— ë°°ë‹¹ ì•½ì†ì„ í†µí•´ ì£¼ì£¼ë“¤ì—ê²Œ í˜„ê¸ˆì„ í™˜ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 15ì˜ 2026ë…„ ë¹„-GAAP ê°€ì´ë˜ìŠ¤ë¥¼ ë§¤ì¶œë¶€í„° ì‹œì‘í•´ì„œ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As Chris mentioned earlier, we estimate revenue to be between $46 billion and $47.5 billion in 2026. We expect our gross margin to be between 69% to 70%. This reflects the impact of product mix, notably the combination of higher Eliquis and lower Revlimid and Pomalyst revenue. We expect total operating expenses to decline from 2025 levels to approximately $16.3 billion. Our cost savings program has provided us with the flexibility to increase commercial investment where appropriate and to support newer development programs, such as our partnership on pumitamig and our Orbital Therapeutics program. Even with these investments, we expect to reduce costs year-over-year.</td><td>í¬ë¦¬ìŠ¤ê°€ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, 2026ë…„ ë§¤ì¶œì€ 460ì–µ ë‹¬ëŸ¬ì—ì„œ 475ì–µ ë‹¬ëŸ¬ ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥ ì€ 69%ì—ì„œ 70% ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì´ëŠ” ì œí’ˆ ë¯¹ìŠ¤ì˜ ì˜í–¥ì„ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ, íŠ¹íˆ ì—˜ë¦¬í€´ìŠ¤ ë§¤ì¶œ ì¦ê°€ì™€ ë ˆë¸”ë¦¬ë¯¸ë“œ ë° í¬ë§ë¦¬ìŠ¤íŠ¸ ë§¤ì¶œ ê°ì†Œê°€ ê²°í•©ëœ íš¨ê³¼ì…ë‹ˆë‹¤. ì´ ì˜ì—…ë¹„ìš©ì€ 2025ë…„ ìˆ˜ì¤€ì—ì„œ ê°ì†Œí•˜ì—¬ ì•½ 163ì–µ ë‹¬ëŸ¬ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë¹„ìš© ì ˆê° í”„ë¡œê·¸ë¨ì„ í†µí•´ ì ì ˆí•œ ë¶€ë¶„ì—ì„œ ìƒì—…ì  íˆ¬ìë¥¼ í™•ëŒ€í•˜ê³ , í‘¸ë¯¸íƒ€ë§™ íŒŒíŠ¸ë„ˆì‹­ê³¼ ì˜¤ë¹„íƒˆ í…Œë¼í“¨í‹±ìŠ¤ í”„ë¡œê·¸ë¨ ê°™ì€ ì‹ ê·œ ê°œë°œ í”„ë¡œê·¸ë¨ì„ ì§€ì›í•  ìˆ˜ ìˆëŠ” ìœ ì—°ì„±ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ íˆ¬ìì—ë„ ë¶ˆêµ¬í•˜ê³  ì „ë…„ ëŒ€ë¹„ ë¹„ìš©ì„ ì ˆê°í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We are expecting our OI&E expense of approximately $700 million, which reflects the expiry of our royalty-bearing license of diabetes products at the end of 2025. We expect to maintain our tax rate of approximately 18%. Considering these factors, we expect to deliver non-GAAP earnings per share in the range of $6.05 to $6.35. Before closing, let me provide some insight regarding our expected quarterly progression of revenue for 2026. As it relates to quarterly phasing, we expect our typical sequential revenue decrease in the first quarter due to the seasonal inventory destocking we see each year following the build in the fourth quarter. And two points on Eliquis.</td><td>ì˜ì—…ì™¸ìˆ˜ìµ ë° ë¹„ìš©(OI&E)ì€ ì•½ 7ì–µ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 2025ë…„ ë§ ë‹¹ë‡¨ë³‘ ì œí’ˆì— ëŒ€í•œ ë¡œì—´í‹° ë¶€ë‹´ ë¼ì´ì„ ìŠ¤ ë§Œë£Œë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì„¸ìœ¨ì€ ì•½ 18% ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì„ ê³ ë ¤í•  ë•Œ, 2026ë…„ ë¹„-GAAP ì£¼ë‹¹ìˆœì´ìµì€ 6.05ë‹¬ëŸ¬ì—ì„œ 6.35ë‹¬ëŸ¬ ë²”ìœ„ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ë§ˆë¬´ë¦¬í•˜ê¸° ì „ì—, 2026ë…„ ì˜ˆìƒ ë¶„ê¸°ë³„ ë§¤ì¶œ ì¶”ì´ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¶„ê¸°ë³„ ì§„í–‰ ìƒí™©ê³¼ ê´€ë ¨í•˜ì—¬, ë§¤ë…„ 4ë¶„ê¸° ì¬ê³  ì¦ê°€ ì´í›„ ë‚˜íƒ€ë‚˜ëŠ” ê³„ì ˆì  ì¬ê³  ì¡°ì •ìœ¼ë¡œ ì¸í•´ 1ë¶„ê¸°ì—ëŠ” ì „í˜•ì ì¸ ì „ë¶„ê¸° ëŒ€ë¹„ ë§¤ì¶œ ê°ì†Œê°€ ì˜ˆìƒë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—˜ë¦¬í€´ìŠ¤(Eliquis)ì— ê´€í•œ ë‘ ê°€ì§€ ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>First, we anticipate that the second half revenue will trend higher than the first half of the year. And second, in terms of Eliquis specific updated guidance, we currently expect 2027 Eliquis sales compared to 2026 to show a step down in the range of $1.5 billion to $2 billion, which is broadly consistent with analysts' existing estimates. In closing, our strong performance in 2025 demonstrated our confidence in our ability to deliver long-term value for our patients and shareholders. We remain focused on executing our growth strategy, advancing our pipeline and optimizing our cost structure. We look forward to updating you on multiple data readouts this year.</td><td>ë¨¼ì €, í•˜ë°˜ê¸° ë§¤ì¶œì€ ìƒë°˜ê¸° ëŒ€ë¹„ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ, ì—˜ë¦¬í€´ìŠ¤ ê´€ë ¨ ì—…ë°ì´íŠ¸ëœ ê°€ì´ë˜ìŠ¤ ì¸¡ë©´ì—ì„œ, í˜„ì¬ 2027ë…„ ì—˜ë¦¬í€´ìŠ¤ ë§¤ì¶œì€ 2026ë…„ ëŒ€ë¹„ 15ì–µ ë‹¬ëŸ¬ì—ì„œ 20ì–µ ë‹¬ëŸ¬ ë²”ìœ„ì˜ ê°ì†Œë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì˜ ê¸°ì¡´ ì¶”ì •ì¹˜ì™€ ëŒ€ì²´ë¡œ ì¼ì¹˜í•©ë‹ˆë‹¤. ê²°ë¡ ì ìœ¼ë¡œ, 2025ë…„ì˜ ê°•ë ¥í•œ ì‹¤ì ì€ í™˜ìì™€ ì£¼ì£¼ë“¤ì„ ìœ„í•œ ì¥ê¸°ì  ê°€ì¹˜ë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” ìš°ë¦¬ì˜ ì—­ëŸ‰ì— ëŒ€í•œ í™•ì‹ ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„±ì¥ ì „ëµ ì‹¤í–‰, íŒŒì´í”„ë¼ì¸ ì§„ì „, ê·¸ë¦¬ê³  ë¹„ìš© êµ¬ì¡° ìµœì í™”ì— ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ì—¬ëŸ¬ ë°ì´í„° ê²°ê³¼ ë°œí‘œì— ëŒ€í•´ ì—¬ëŸ¬ë¶„ê»˜ ì—…ë°ì´íŠ¸í•´ ë“œë¦´ ê²ƒì„ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And with that, I'll now turn the call back over to Chuck for Q&A.</td><td>ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ìœ„í•´ Chuckì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Bristol-Myers Squibb Q4 2025 ì‹¤ì  ìš”ì•½<br><br>## í•µì‹¬ í¬ì¸íŠ¸<br><br>â€¢ **ì‹¤ì  ë° ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ ê°•ì„¸**: 4ë¶„ê¸° ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë³´í•©ì¸ 125ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë‚˜, ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” 15% ì¦ê°€í•œ 74ì–µ ë‹¬ëŸ¬ë¡œ ì „ì²´ ë§¤ì¶œì˜ 60%ë¥¼ ì°¨ì§€. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” 17% ì„±ì¥í•˜ì—¬ ë ˆê±°ì‹œ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì•½ 40ì–µ ë‹¬ëŸ¬ ê°ì†Œë¥¼ ê±°ì˜ ìƒì‡„. Reblozyl(20ì–µ ë‹¬ëŸ¬ ì´ìƒ), Opdualag, Breyanzi, Camzyosê°€ ê°ê° 10ì–µ ë‹¬ëŸ¬ ì´ìƒ ë§¤ì¶œ ë‹¬ì„±.<br><br>â€¢ **2026ë…„ ê°€ì´ë˜ìŠ¤**: ë§¤ì¶œ 460ì–µ~475ì–µ ë‹¬ëŸ¬ ì˜ˆìƒ(ë ˆê±°ì‹œ í¬íŠ¸í´ë¦¬ì˜¤ 12~16% ê°ì†Œ ì „ë§, EliquisëŠ” 10~15% ì„±ì¥ ì˜ˆìƒ). ì£¼ë‹¹ìˆœì´ìµ(EPS) 6.05~6.35ë‹¬ëŸ¬ ì œì‹œ. ì´ë§ˆì§„ì€ 69~70%ë¡œ í•˜ë½ ì˜ˆìƒ(ì œí’ˆ ë¯¹ìŠ¤ ì˜í–¥), ì˜ì—…ë¹„ìš©ì€ ì•½ 163ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ ê°ì†Œ ì „ë§. 2027ë…„ Eliquis ë§¤ì¶œì€ 2026ë…„ ëŒ€ë¹„ 15ì–µ~20ì–µ ë‹¬ëŸ¬ ê°ì†Œ ì˜ˆìƒ.<br><br>â€¢ **ë¹„ìš© ì ˆê° ë° í˜„ê¸ˆ íë¦„**: 20ì–µ ë‹¬ëŸ¬ ì „ëµì  ìƒì‚°ì„± ì´ë‹ˆì…”í‹°ë¸Œ ì¤‘ 2025ë…„ ëª©í‘œì¸ 10ì–µ ë‹¬ëŸ¬ ì ˆê° ë‹¬ì„±, ë‚˜ë¨¸ì§€ 10ì–µ ë‹¬ëŸ¬ëŠ” 2026~2027ë…„ ì‹¤í˜„</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Charles Triano: SVP & Head of Investor Relations [Operator Instructions] And today's first question comes from Seamus Fernandez with Guggenheim Securities.</td><td>**Charles Triano:** <budget:token_used>50000</budget:token_used><br><br>[ìš´ì˜ì ì§€ì‹œì‚¬í•­] ì˜¤ëŠ˜ ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ êµ¬ê²í•˜ì„ ì¦ê¶Œì˜ ì‹œë¨¸ìŠ¤ í˜ë¥´ë‚œë°ìŠ¤ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Seamus Fernandez: Guggenheim Securities, LLC, Research Division Congrats on the good quarter and the guide. Now that we're past the guidance, this is a question for the overall team, but it's been a long time since we've seen as an overall analyst community, a series of Phase III pivotal catalysts that Bristol has ahead of it in 2026. Chris, I know you counted 6. There may be, in addition to that, potential benefits from royalty agreements around sotatercept and CADENCE. Just wondering if you could help us position the areas that you see the most kind of relative upside, the CELMoDs are obviously something that Bristol has been working on for a very long time, and we're just on the cusp of seeing the material data. We've got milvexian and a very different approach that Bristol took to dosing in a recent publication that plays along those lines to sort of explain that. Admilparant, I think, is an underappreciated story that was maybe negatively impacted by comparisons to a competitor asset. There's just a whole host of opportunities here that we see in the overall story this year. Hoping you might be able to help position some of those for us as we move through the balance of the year.</td><td>**Seamus Fernandez:** ì¢‹ì€ ì‹¤ì ê³¼ ê°€ì´ë˜ìŠ¤ ë°œí‘œ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ ê´€ë ¨ ì§ˆë¬¸ì€ ë§ˆì³¤ìœ¼ë‹ˆ, ì´ì œ ì „ì²´ íŒ€ì— ë“œë¦¬ëŠ” ì§ˆë¬¸ì¸ë°ìš”, ì• ë„ë¦¬ìŠ¤íŠ¸ ì»¤ë®¤ë‹ˆí‹° ì „ì²´ë¡œì„œ ë¸Œë¦¬ìŠ¤í†¨ì´ 2026ë…„ì— ì•ë‘ê³  ìˆëŠ” ì¼ë ¨ì˜ 3ìƒ í”¼ë²— ì„ìƒ ì´‰ë§¤ì œë“¤ì„ ë³¸ ì§€ ì •ë§ ì˜¤ë˜ëœ ê²ƒ ê°™ìŠµë‹ˆë‹¤. Chris, 6ê°œë¥¼ ì–¸ê¸‰í•˜ì‹  ê±¸ë¡œ ì•„ëŠ”ë°ìš”. ê·¸ ì™¸ì—ë„ sotaterceptê³¼ CADENCE ê´€ë ¨ ë¡œì—´í‹° ê³„ì•½ì—ì„œ ë‚˜ì˜¬ ìˆ˜ ìˆëŠ” ì ì¬ì  ì´ìµë„ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ìƒëŒ€ì ìœ¼ë¡œ ê°€ì¥ í° ìƒìŠ¹ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë³´ì‹œëŠ” ì˜ì—­ë“¤ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? CELMoDëŠ” ë¸Œë¦¬ìŠ¤í†¨ì´ ì˜¤ë«ë™ì•ˆ ê³µë“¤ì—¬ ì˜¨ ë¶„ì•¼ì´ê³ , ì´ì œ ë§‰ ì˜ë¯¸ ìˆëŠ” ë°ì´í„°ë¥¼ ë³´ê²Œ ë  ì‹œì ì— ì™€ ìˆìŠµë‹ˆë‹¤. ë°€ë²¡ì‹œì•ˆ(milvexian)ì˜ ê²½ìš°, ë¸Œë¦¬ìŠ¤í†¨ì´ ìµœê·¼ ë°œí‘œì—ì„œ ì·¨í•œ ìš©ëŸ‰ ì„¤ì • ë°©ì‹ì´ ë§¤ìš° ì°¨ë³„í™”ë˜ì–´ ìˆìœ¼ë©°, ì´ê²ƒì´ ê·¸ëŸ¬í•œ ë§¥ë½ì—ì„œ ì„¤ëª…ë  ìˆ˜ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì• ë“œë°€íŒ¨ëŸ°íŠ¸(Admilparant)ëŠ” ê²½ìŸì‚¬ ìì‚°ê³¼ì˜ ë¹„êµë¡œ ì¸í•´ ë¶€ì •ì ì¸ ì˜í–¥ì„ ë°›ì•˜ì„ ìˆ˜ ìˆì§€ë§Œ, ì‚¬ì‹¤ ê³¼ì†Œí‰ê°€ë˜ê³  ìˆëŠ” ìŠ¤í† ë¦¬ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì˜¬í•´ ì „ì²´ì ì¸ ìŠ¤í† ë¦¬ì—ì„œ ì €í¬ê°€ ë³´ê³  ìˆëŠ” ê¸°íšŒë“¤ì´ ì •ë§ ë‹¤ì–‘í•˜ê²Œ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆ ì´ëŸ¬í•œ ê¸°íšŒë“¤ì— ëŒ€í•´ ì¢€ ë” ëª…í™•í•˜ê²Œ í¬ì§€ì…”ë‹í•´ ì£¼ì‹¤ ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Thanks for the question, Seamus. And I agree with the overall sentiment. And maybe I will start, and then I'll turn it over to Cristian and Adam, and they can provide their perspectives. I think that when we look at what's particularly exciting for this year, I would highlight a few things. First of all, we've got good growth just in the products that we have on the market today, and I think that growth is going to continue into this year. As you know, we have a slew of data readouts coming this year, now just a few months away for 6 products. And when you look at the actual number of Phase IIIs, we could have over 10 Phase III data readouts this year alone with more coming in '27 and then another big slew of them coming in 2028. The things that I think stand out for me, you've already mentioned them actually. The CELMoD program is beginning to bear fruit. We've already demonstrated PFS data for iberdomide. We'll see follow-up data on that with PFS this year. We've got admilparant data coming. We've got the milvexian data, and I agree also with your assessment of that, where I think we'll see the SSP data from a competitor today. But as I look at our profile, I think we have the potential to be best-in-class there. And of course, in AFib, we have the potential to be the only Factor XI oral therapy there, which is obviously a big opportunity. But maybe I'll ask Cristian and Adam to quickly add anything to that.</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Seamus. ì „ë°˜ì ì¸ ì˜ê²¬ì— ë™ì˜í•˜ê³ ìš”. ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦° í›„ Cristianê³¼ Adamì—ê²Œ ë„˜ê²¨ì„œ ê·¸ë“¤ì˜ ê´€ì ì„ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ íŠ¹íˆ ê¸°ëŒ€ë˜ëŠ” ë¶€ë¶„ì„ ë³´ë©´ ëª‡ ê°€ì§€ë¥¼ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ìš°ì„ , í˜„ì¬ ì‹œì¥ì— ì¶œì‹œëœ ì œí’ˆë“¤ì—ì„œ ì¢‹ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆê³ , ì´ëŸ¬í•œ ì„±ì¥ì€ ì˜¬í•´ë„ ê³„ì†ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ì˜¬í•´ 6ê°œ ì œí’ˆì— ëŒ€í•œ ë°ì´í„° ê²°ê³¼ ë°œí‘œê°€ ì˜ˆì •ë˜ì–´ ìˆìœ¼ë©° ì´ì œ ë¶ˆê³¼ ëª‡ ë‹¬ ë‚¨ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì‹¤ì œ 3ìƒ(Phase III) ì„ìƒì‹œí—˜ ìˆ˜ë¥¼ ë³´ë©´, ì˜¬í•´ë§Œ 10ê±´ ì´ìƒì˜ 3ìƒ ë°ì´í„° ê²°ê³¼ê°€ ë‚˜ì˜¬ ìˆ˜ ìˆê³ , 2027ë…„ì— ë” ë§ì€ ê²°ê³¼ê°€ ë‚˜ì˜¤ë©°, 2028ë…„ì—ëŠ” ë˜ ë‹¤ì‹œ ëŒ€ê·œëª¨ë¡œ ë°œí‘œë  ì˜ˆì •ì…ë‹ˆë‹¤. ì œê°€ ìƒê°í•˜ê¸°ì— ë‘ë“œëŸ¬ì§€ëŠ” ë¶€ë¶„ë“¤ì€ ì‚¬ì‹¤ ì´ë¯¸ ë§ì”€í•˜ì‹  ê²ƒë“¤ì…ë‹ˆë‹¤. CELMoD í”„ë¡œê·¸ë¨ì´ ê²°ì‹¤ì„ ë§ºê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ë¯¸ iberdomideì˜ PFS ë°ì´í„°ë¥¼ ì…ì¦í–ˆê³ ìš”. ì˜¬í•´ ì¶”ê°€ PFS ë°ì´í„°ë„ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. admilparant ë°ì´í„°ë„ ë‚˜ì˜¬ ê²ƒì´ê³ , milvexian ë°ì´í„°ë„ ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•œ í‰ê°€ì—ë„ ë™ì˜í•˜ëŠ”ë°, ì˜¤ëŠ˜ ê²½ìŸì‚¬ì˜ SSP ë°ì´í„°ë¥¼ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ í”„ë¡œíŒŒì¼ì„ ë³´ë©´ ë² ìŠ¤íŠ¸-ì¸-í´ë˜ìŠ¤ê°€ ë  ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  ì‹¬ë°©ì„¸ë™ì—ì„œëŠ” ìœ ì¼í•œ ê²½êµ¬ìš© Factor XI ì¹˜ë£Œì œê°€ ë  ê°€ëŠ¥ì„±ì´ ìˆëŠ”ë°, ì´ëŠ” ë¶„ëª…íˆ í° ê¸°íšŒì…ë‹ˆë‹¤. Cristianê³¼ Adamì—ê²Œ ì¶”ê°€ë¡œ ì˜ê²¬ì´ ìˆëŠ”ì§€ ë¹ ë¥´ê²Œ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development So thank you, Chris. Thank you, Seamus, for the question. Let me go a little bit more on the technical side because, as you said, we have a very data-rich year with 10 -- at least 10 pivotal readouts. I like to cluster them also in terms of area -- therapeutic areas. In hematology, I think you mentioned EXCALIBER, iberdomide, we will have the PFS. MRD is already read out positive. We didn't share the data because, of course, the PFS was coming. We wanted to preserve the integrity of the study. But we are very confident that what we have seen in MRD can translate also in benefit in PFS. We will have the second CELMod readout, MEZI. And you know, this is an add-on study. We had MEZI on top of Kd versus Kd. So considering the level of activity we have seen with this drug, I am confident on the first readout with the second CELMoD mode, a very potent drug. And then we have also arlo-cel. Arlo-cel is a Phase II registrational study, the Phase III is ongoing in myeloma in patient post-BCMA GPRC5D CAR T. This is an entry with another CAR T that is very, very relevant for us. So myeloma, very rich here. I am very, very confident in what we have seen so far and what I'm expecting. Then we go into, as you said, admilparant. Admilparant, I'm very happy because what I have seen is a Phase III conducting and enrolling patients that are very similar to what we have seen in Phase II, and you remember, in Phase II, we had a very good reduction of the risk of decline of FVC, 60% in IPF and more than 70% in PPF. So IPF is coming this year. PPF is closer. Actually, it will be very, very closer compared to what we guided before. So this is very exciting, very high medical need. Milvexian, I think Chris already spoke about. Stroke has already been derisked in my view, from the data we will see in a few hours. There is no reason to believe that we will have a different, if not better outcome. And AFib, the confidence is all there. Then I would not underestimate ADEPT program. The ADEPT program is coming by the end of the year, as we guided, we are on track. All of this is moving at pace. So as you said, 4 different therapeutic areas where we'll have a major readouts, and these are very transformative regimen. Adam, do you want to...</td><td>**Cristian Massacesi:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ê¸°ìˆ ì ì¸ ì¸¡ë©´ì—ì„œ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì˜¬í•´ëŠ” ìµœì†Œ 10ê±´ì˜ í”¼ë²— ì—°êµ¬ ê²°ê³¼ê°€ ë‚˜ì˜¤ëŠ” ë°ì´í„°ê°€ í’ë¶€í•œ í•œ í•´ì…ë‹ˆë‹¤. ì €ëŠ” ì´ë¥¼ ì¹˜ë£Œ ì˜ì—­ë³„ë¡œ ë¶„ë¥˜í•˜ëŠ” ê²ƒì„ ì„ í˜¸í•©ë‹ˆë‹¤. í˜ˆì•¡í•™ ë¶„ì•¼ì—ì„œëŠ” EXCALIBER, ì¦‰ iberdomideì˜ PFS ë°ì´í„°ê°€ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. MRDëŠ” ì´ë¯¸ ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë¬¼ë¡  PFS ê²°ê³¼ê°€ ì˜ˆì •ë˜ì–´ ìˆì—ˆê¸° ë•Œë¬¸ì— ì—°êµ¬ì˜ ë¬´ê²°ì„±ì„ ìœ ì§€í•˜ê¸° ìœ„í•´ ë°ì´í„°ë¥¼ ê³µìœ í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ MRDì—ì„œ í™•ì¸í•œ ê²°ê³¼ê°€ PFSì—ì„œë„ ìœ ìµì„±ìœ¼ë¡œ ì´ì–´ì§ˆ ê²ƒì´ë¼ê³  í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ CELMod ê²°ê³¼ì¸ MEZIë„ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì´ê²ƒì€ ì¶”ê°€ íˆ¬ì—¬ ì—°êµ¬ì…ë‹ˆë‹¤. Kd ëŒ€ë¹„ Kdì— MEZIë¥¼ ì¶”ê°€í•œ ì—°êµ¬ì˜€ìŠµë‹ˆë‹¤. ì´ ì•½ë¬¼ì—ì„œ í™•ì¸í•œ í™œì„± ìˆ˜ì¤€ì„ ê³ ë ¤í•  ë•Œ, ë‘ ë²ˆì§¸ CELMoD ê³„ì—´ì˜ ë§¤ìš° ê°•ë ¥í•œ ì•½ë¬¼ë¡œ ì²« ë²ˆì§¸ ê²°ê³¼ë¥¼ ë°œí‘œí•˜ëŠ” ê²ƒì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  arlo-celë„ ìˆìŠµë‹ˆë‹¤. Arlo-celì€ 2ìƒ ë“±ë¡ ì„ìƒì‹œí—˜ìœ¼ë¡œ, BCMA GPRC5D CAR T íˆ¬ì—¬ í›„ ê³¨ìˆ˜ì¢… í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ 3ìƒì´ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ë˜ ë‹¤ë¥¸ CAR T ì§„ì…ì…ë‹ˆë‹¤. ê³¨ìˆ˜ì¢… ë¶„ì•¼ì—ì„œ ì •ë§ í’ë¶€í•œ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ í™•ì¸í•œ ê²°ê³¼ì™€ ì•ìœ¼ë¡œ ê¸°ëŒ€í•˜ëŠ” ë°”ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ì”€í•˜ì‹  ëŒ€ë¡œ admilparantë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì•„ë“œë°€íŒŒë€íŠ¸ì— ëŒ€í•´ì„œëŠ” ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. í˜„ì¬ ì§„í–‰ ì¤‘ì¸ 3ìƒ ì„ìƒì‹œí—˜ì—ì„œ í™˜ì ë“±ë¡ ìƒí™©ì„ ë³´ë©´ 2ìƒì—ì„œ ë´¤ë˜ ê²ƒê³¼ ë§¤ìš° ìœ ì‚¬í•œ ì–‘ìƒì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. 2ìƒì—ì„œ ìš°ë¦¬ëŠ” FVC ê°ì†Œ ìœ„í—˜ì„ IPFì—ì„œ 60%, PPFì—ì„œ 70% ì´ìƒ ì¤„ì´ëŠ” ë§¤ìš° ì¢‹ì€ ê²°ê³¼ë¥¼ ì–»ì—ˆìŠµë‹ˆë‹¤. IPF ê²°ê³¼ëŠ” ì˜¬í•´ ë‚˜ì˜¬ ì˜ˆì •ì´ê³ , PPFëŠ” ë” ê°€ê¹ìŠµë‹ˆë‹¤. ì‚¬ì‹¤ ì´ì „ ê°€ì´ë˜ìŠ¤ë³´ë‹¤ í›¨ì”¬ ë” ë¹¨ë¦¬ ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ë§¤ìš° í¥ë¯¸ë¡œìš´ ì¼ì´ê³ , ì˜í•™ì  í•„ìš”ì„±ì´ ë§¤ìš° ë†’ì€ ì˜ì—­ì…ë‹ˆë‹¤.<br><br>ë°€ë²¡ì‹œì•ˆì€ í¬ë¦¬ìŠ¤ê°€ ì´ë¯¸ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ë‡Œì¡¸ì¤‘ì˜ ê²½ìš° ëª‡ ì‹œê°„ í›„ ë‚˜ì˜¬ ë°ì´í„°ë¥¼ ë³´ë©´ ì´ë¯¸ ë¦¬ìŠ¤í¬ê°€ í•´ì†Œë˜ì—ˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë” ì¢‹ì§€ëŠ” ì•Šë”ë¼ë„ ë‹¤ë¥¸ ê²°ê³¼ê°€ ë‚˜ì˜¬ ì´ìœ ê°€ ì—†ìŠµë‹ˆë‹¤. ì‹¬ë°©ì„¸ë™ì— ëŒ€í•œ í™•ì‹ ë„ ì¶©ë¶„í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ADEPT í”„ë¡œê·¸ë¨ë„ ê³¼ì†Œí‰ê°€í•´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ADEPT í”„ë¡œê·¸ë¨ì€ ì €í¬ê°€ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•œ ëŒ€ë¡œ ì—°ë§ê¹Œì§€ ì§„í–‰ë  ì˜ˆì •ì´ë©°, ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ëª¨ë“  ê²ƒì´ ê³„íšëŒ€ë¡œ ë¹ ë¥´ê²Œ ì›€ì§ì´ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ 4ê°œì˜ ì„œë¡œ ë‹¤ë¥¸ ì¹˜ë£Œ ì˜ì—­ì—ì„œ ì£¼ìš” ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì´ë©°, ì´ëŠ” ë§¤ìš° í˜ì‹ ì ì¸ ì¹˜ë£Œë²•ë“¤ì…ë‹ˆë‹¤. Adam, ì¶”ê°€ë¡œ...</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer No, I think, Chris, and you covered it extremely well. So why don't we go to the next question.</td><td>**Adam Lenkowsky:** ì•„ë‹ˆìš”, í¬ë¦¬ìŠ¤ê°€ ì´ë¯¸ ì•„ì£¼ ì˜ ì„¤ëª…í•´ ì£¼ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Charles Triano: SVP & Head of Investor Relations And our next question today comes from Chris Schott at JPMorgan.</td><td>**Charles Triano:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPëª¨ê±´ì˜ í¬ë¦¬ìŠ¤ ì‡¼íŠ¸ ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division Just 2 for me. First, just elaborate on Eliquis dynamics for 2026 contributing to growth this year? And then maybe just a bigger picture one on business development priorities. Just elaborate a little bit more in terms of your focus right now. Is this more on deepening presence in existing therapeutic areas or pursuing more corona Karuna like kind of expansions into new spaces? And maybe as part of that, I know as you just highlighted, you've got a lot of important readouts coming this year. Should we think about Bristol waiting to see how these programs pan out and that might help guide where you want to go with BD? Or is that not a rate limiter for the company?</td><td>**Christopher Schott:** 2026ë…„ ì„±ì¥ì— ê¸°ì—¬í•˜ëŠ” ì—˜ë¦¬í€´ìŠ¤ ì—­í•™ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì¢€ ë” í° ê·¸ë¦¼ì—ì„œ ì‚¬ì—… ê°œë°œ ìš°ì„ ìˆœìœ„ì— ëŒ€í•´ì„œë„ ë§ì”€ ë¶€íƒë“œë¦½ë‹ˆë‹¤. í˜„ì¬ ì§‘ì¤‘í•˜ê³  ê³„ì‹  ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê¸°ì¡´ ì¹˜ë£Œ ì˜ì—­ì—ì„œì˜ ì…ì§€ë¥¼ ê°•í™”í•˜ëŠ” ë° ë” ì§‘ì¤‘í•˜ê³  ê³„ì‹ ê°€ìš”, ì•„ë‹ˆë©´ ì½”ë¡œë‚˜ë‚˜ ì¹´ë£¨ë‚˜ì™€ ê°™ì€ ìƒˆë¡œìš´ ì˜ì—­ìœ¼ë¡œì˜ í™•ì¥ì„ ë” ì¶”êµ¬í•˜ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  ë°©ê¸ˆ ê°•ì¡°í•˜ì‹  ê²ƒì²˜ëŸ¼ ì˜¬í•´ ë§ì€ ì¤‘ìš”í•œ ì„ìƒ ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì¸ë°, ë¸Œë¦¬ìŠ¤í†¨ë§ˆì´ì–´ìŠ¤ìŠ¤í…ì´ ì´ëŸ¬í•œ í”„ë¡œê·¸ë¨ë“¤ì˜ ê²°ê³¼ë¥¼ ì§€ì¼œë³¸ í›„ ì‚¬ì—… ê°œë°œ ë°©í–¥ì„ ê²°ì •í•  ê²ƒìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”? ì•„ë‹ˆë©´ ê·¸ê²ƒì´ íšŒì‚¬ì˜ ì œì•½ ìš”ì¸ì€ ì•„ë‹Œê°€ìš”?</td></tr>
<tr><td>CEO & Chairman: Thanks for the question, Chris. I will start on the BD question, and I'll turn it over to Adam. So as was said earlier, BD continues to be a top priority. As you well know, we have always sourced innovation, both internally and externally. And the good news here is that we're in a very strong position, as you alluded to, with the late-stage pipeline. We don't need to chase deals. That said, we're going to continue to be looking out for opportunities to add strength and depth to our portfolio. In terms of the opportunities we're looking for, we've got a lot of opportunity to continue to build depth across each of our therapeutic areas. So if an opportunity is in an area that we know well scientifically where we can add clinical or commercial value and ultimately deliver that value to patients, the company and shareholders, we obviously have the financial ability and the muscle to execute. And so that's generally how we'll be approaching BD this year. And timing-wise, I think that, obviously, we're going to be opportunistic. Adam?</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Chris. BD ì§ˆë¬¸ë¶€í„° ì‹œì‘í•˜ê³  Adamì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ BDëŠ” ê³„ì†í•´ì„œ ìµœìš°ì„  ê³¼ì œì…ë‹ˆë‹¤. ì˜ ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” í•­ìƒ ë‚´ë¶€ì™€ ì™¸ë¶€ ëª¨ë‘ì—ì„œ í˜ì‹ ì„ í™•ë³´í•´ ì™”ìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ì¢‹ì€ ì†Œì‹ì€ ë§ì”€í•˜ì‹  ëŒ€ë¡œ í›„ê¸° ë‹¨ê³„ íŒŒì´í”„ë¼ì¸ìœ¼ë¡œ ë§¤ìš° ê°•ë ¥í•œ ìœ„ì¹˜ì— ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¬´ë¦¬í•˜ê²Œ ë”œì„ ì«“ì„ í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ í¬íŠ¸í´ë¦¬ì˜¤ì— ê°•ì ê³¼ ê¹Šì´ë¥¼ ë”í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê³„ì† ì°¾ì•„ë³¼ ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ì°¾ê³  ìˆëŠ” ê¸°íšŒ ì¸¡ë©´ì—ì„œ ë³´ë©´, ê° ì¹˜ë£Œ ì˜ì—­ ì „ë°˜ì— ê±¸ì³ ê¹Šì´ë¥¼ ê³„ì† êµ¬ì¶•í•  ìˆ˜ ìˆëŠ” ë§ì€ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ê³¼í•™ì ìœ¼ë¡œ ì˜ ì•Œê³  ìˆëŠ” ë¶„ì•¼ì—ì„œ ì„ìƒì  ë˜ëŠ” ìƒì—…ì  ê°€ì¹˜ë¥¼ ë”í•  ìˆ˜ ìˆê³ , ê¶ê·¹ì ìœ¼ë¡œ í™˜ìì™€ íšŒì‚¬, ì£¼ì£¼ë“¤ì—ê²Œ ê·¸ ê°€ì¹˜ë¥¼ ì „ë‹¬í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¼ë©´, ì €í¬ëŠ” ë¶„ëª…íˆ ì¬ë¬´ì  ëŠ¥ë ¥ê³¼ ì‹¤í–‰ë ¥ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¬í•´ ì‚¬ì—…ê°œë°œ(BD)ì— ëŒ€í•´ì„œë„ ì¼ë°˜ì ìœ¼ë¡œ ì´ëŸ° ë°©ì‹ìœ¼ë¡œ ì ‘ê·¼í•  ê²ƒì…ë‹ˆë‹¤. ì‹œê¸°ì™€ ê´€ë ¨í•´ì„œëŠ”, ë‹¹ì—°íˆ ê¸°íšŒì£¼ì˜ì ìœ¼ë¡œ ì ‘ê·¼í•  ê²ƒì…ë‹ˆë‹¤. Adam?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes, Chris, thanks for the question. Let me start by saying that we continue to see strong performance with Eliquis, and this performance will continue throughout 2026. We have approximately a 75% NRx share in the U.S., and we will continue to grow that. Now the broader pricing dynamics starting this year for Eliquis was the impetus for us to reevaluate our pricing strategy. And of course, there's some pushes and pulls. Recall, the IRA price was effectuated January 1, and this includes the removal of the Medicare Part D liability, both in the initiation and in the catastrophic phase. We also finalized our $0 Medicaid agreement with the administration. And we took a step back and we were able to reassess our commercial contracting strategy as well. The roughly 40% WACC reduction eliminates the inflationary penalties or CPI penalties of statutory rebates that have been accumulating over many years for the brand. And taken together, the continued increase in Eliquis market share in the United States, coupled with these net pricing changes, they're going to enable Eliquis to be an important driver of growth this year.</td><td>**Adam Lenkowsky:** ë„¤, Chris, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€ ì—˜ë¦¬í€´ìŠ¤ê°€ ê³„ì†í•´ì„œ ê°•ë ¥í•œ ì‹¤ì ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì„±ê³¼ëŠ” 2026ë…„ê¹Œì§€ ì§€ì†ë  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì•½ 75%ì˜ ì‹ ê·œ ì²˜ë°© ì ìœ ìœ¨ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ë¥¼ ê³„ì† í™•ëŒ€í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. <br><br>ì˜¬í•´ë¶€í„° ì‹œì‘ëœ ì—˜ë¦¬í€´ìŠ¤ì˜ ê´‘ë²”ìœ„í•œ ê°€ê²© ì—­í•™ ë³€í™”ê°€ ìš°ë¦¬ì˜ ê°€ê²© ì „ëµì„ ì¬í‰ê°€í•˜ê²Œ ëœ ê³„ê¸°ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì—¬ëŸ¬ ìƒì¶©ë˜ëŠ” ìš”ì¸ë“¤ì´ ìˆìŠµë‹ˆë‹¤. 1ì›” 1ì¼ë¶€í„° IRA ê°€ê²©ì´ ì‹œí–‰ë˜ì—ˆê³ , ì—¬ê¸°ì—ëŠ” ë©”ë””ì¼€ì–´ íŒŒíŠ¸D ë³¸ì¸ë¶€ë‹´ê¸ˆ ì œê±°ê°€ í¬í•¨ë˜ëŠ”ë°, ì´ˆê¸° ë‹¨ê³„ì™€ ì¬ë‚œì  ë‹¨ê³„ ëª¨ë‘ì—ì„œ ì ìš©ë©ë‹ˆë‹¤. ë˜í•œ ì •ë¶€ì™€ ë©”ë””ì¼€ì´ë“œ ë³¸ì¸ë¶€ë‹´ê¸ˆ 0ë‹¬ëŸ¬ í˜‘ì•½ë„ ìµœì¢… ì²´ê²°í–ˆìŠµë‹ˆë‹¤. í•œ ë°œ ë¬¼ëŸ¬ì„œì„œ ìš°ë¦¬ì˜ ìƒì—…ì  ê³„ì•½ ì „ëµë„ ì¬í‰ê°€í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì•½ 40%ì˜ WACC(ê°€ì¤‘í‰ê· ë¹„ìš©) ê°ì†ŒëŠ” ìˆ˜ë…„ê°„ ë¸Œëœë“œì— ëˆ„ì ë˜ì–´ ì˜¨ ë²•ì • ë¦¬ë² ì´íŠ¸ì˜ ì¸í”Œë ˆì´ì…˜ í˜ë„í‹° ë˜ëŠ” CPI í˜ë„í‹°ë¥¼ ì œê±°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì†Œë“¤ì„ ì¢…í•©í•´ë³´ë©´, ë¯¸êµ­ ë‚´ ì—˜ë¦¬í€´ìŠ¤ ì‹œì¥ì ìœ ìœ¨ì˜ ì§€ì†ì ì¸ ì¦ê°€ì™€ ìˆœê°€ê²© ë³€í™”ê°€ ê²°í•©ë˜ì–´ ì—˜ë¦¬í€´ìŠ¤ê°€ ì˜¬í•´ ì„±ì¥ì˜ ì¤‘ìš”í•œ ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Charles Triano: SVP & Head of Investor Relations And our next question today comes from Michael Lee at UBS.</td><td>**Charles Triano:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Michael Lee ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Unknown Analyst: Two questions. One on milvexian and AFib. Previously, you've suggested that there are lower blinded safety event rates bleeding, particularly. Can you just remind us how often that study is looked at and whether that generally continues with DSMB safety looks across the blinded rates into 2026 here and how you feel about that? And then second, just following up on the BD question. I know that you obviously want to focus on key strength areas. Is metabolic obesity a fair question or a fair area that investors should be understanding of? And is that still an area that actually you would engage in?</td><td>**Unknown Analyst:** ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ë°€ë²¡ì‹œì•ˆê³¼ ì‹¬ë°©ì„¸ë™ ê´€ë ¨ì…ë‹ˆë‹¤. ì´ì „ì— ë§¹ê²€ ì•ˆì „ì„± ì´ë²¤íŠ¸ ë°œìƒë¥ , íŠ¹íˆ ì¶œí˜ˆ ê´€ë ¨ ìˆ˜ì¹˜ê°€ ë‚®ë‹¤ê³  ë§ì”€í•˜ì‹  ë°” ìˆìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ë¥¼ ì–¼ë§ˆë‚˜ ìì£¼ ê²€í† í•˜ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ì¼ë°˜ì ìœ¼ë¡œ 2026ë…„ê¹Œì§€ DSMB ì•ˆì „ì„± ê²€í†  ê³¼ì •ì—ì„œ ë§¹ê²€ ë°œìƒë¥ ì´ ê³„ì† ìœ ì§€ë˜ëŠ”ì§€, ì´ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ ë‹¤ì‹œ í•œë²ˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? <br><br>ë‘ ë²ˆì§¸ëŠ” ì‚¬ì—…ê°œë°œ ì§ˆë¬¸ì— ëŒ€í•œ í›„ì†ì…ë‹ˆë‹¤. í•µì‹¬ ê°•ì  ë¶„ì•¼ì— ì§‘ì¤‘í•˜ê³  ì‹¶ì–´í•˜ì‹ ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ëŒ€ì‚¬ì§ˆí™˜ ë¹„ë§Œ ë¶„ì•¼ê°€ íˆ¬ììë“¤ì´ ì´í•´í•´ì•¼ í•  ì ì ˆí•œ ì§ˆë¬¸ì´ë‚˜ ë¶„ì•¼ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ì—¬ì „íˆ ì‹¤ì œë¡œ ì°¸ì—¬í•˜ì‹¤ ì˜í–¥ì´ ìˆëŠ” ë¶„ì•¼ì¸ì§€ìš”?</td></tr>
<tr><td>CEO & Chairman: Thanks for the questions. Let me start with metabolics, then I'll turn it over to Cristian. Look, metabolics is obviously an exciting area. You've seen it this week. We continue to pay attention to the evolution of that market and, of course, the science. That said, we're really looking at opportunities to build breadth and depth in our existing therapeutic area. These are areas we obviously know well. We can assess the science and commercial opportunities, which is significantly important, particularly as we think more broadly. And it's also an area -- the areas that we can best add value from a patient company and shareholder standpoint. So that's our primary focus. Cristian?</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ëŒ€ì‚¬ì§ˆí™˜ ê´€ë ¨í•´ì„œ ë¨¼ì € ë§ì”€ë“œë¦¬ê³ , í¬ë¦¬ìŠ¤í‹°ì•ˆì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ëŒ€ì‚¬ì§ˆí™˜ì€ ë¶„ëª…íˆ í¥ë¯¸ë¡œìš´ ë¶„ì•¼ì…ë‹ˆë‹¤. ì´ë²ˆ ì£¼ì—ë„ ë³´ì…¨ê² ì§€ë§Œ, ì €í¬ëŠ” í•´ë‹¹ ì‹œì¥ì˜ ë³€í™”ì™€ ê³¼í•™ì  ë°œì „ì„ ê³„ì† ì£¼ì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ì €í¬ëŠ” ê¸°ì¡´ ì¹˜ë£Œ ì˜ì—­ì—ì„œ í­ê³¼ ê¹Šì´ë¥¼ êµ¬ì¶•í•˜ëŠ” ê¸°íšŒì— ë” ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ì˜ì—­ë“¤ì€ ì €í¬ê°€ ì˜ ì•Œê³  ìˆëŠ” ë¶„ì•¼ì´ê³ , ê³¼í•™ì  ì¸¡ë©´ê³¼ ìƒì—…ì  ê¸°íšŒë¥¼ í‰ê°€í•  ìˆ˜ ìˆëŠ” ê³³ì…ë‹ˆë‹¤. íŠ¹íˆ ë” ë„“ì€ ê´€ì ì—ì„œ ìƒê°í•  ë•Œ ì´ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ë˜í•œ í™˜ì, íšŒì‚¬, ì£¼ì£¼ ê´€ì ì—ì„œ ì €í¬ê°€ ê°€ì¥ í° ê°€ì¹˜ë¥¼ ë”í•  ìˆ˜ ìˆëŠ” ì˜ì—­ì´ê¸°ë„ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì´ ì €í¬ì˜ ì£¼ìš” ì´ˆì ì…ë‹ˆë‹¤. í¬ë¦¬ìŠ¤í‹°ì•ˆ?</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development So thank you, Michael, for the question. As you know, we completed enrollment in Librexia atrial fibrillation study. We have more than 20,000 patients. And we well past the point, for instance, in which OCEANIC atrial fibrillation study was terminated by the DMC because of lack of efficacy. And as you said, the DMC regularly continue to endorse the tire progression, and this happened also very recently. They check efficacy and safety. We remain blinded to the study. What I can tell you is that recently, and there is a lot of data that tell us what is the bleeding rates with Eliquis. And an AFib study is net to add milvexian, Eliquis. And we remain blinded, but what the DMC is telling us and what we see in a blinded fashion in terms of bleeding rates give us confidence that we are still very much on target to achieve the benefit that we hope, showing that Eliquis and milvexian are similar in terms of efficacy, but that milvexian can bring a benefit in reducing importantly, the bleeding risks, major bleeding risk is also -- no major clinically relevant bleeding risks. These are -- we are fully on track on this and the study is coming this year.</td><td>**Cristian Massacesi:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Michael. ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” Librexia ì‹¬ë°©ì„¸ë™ ì—°êµ¬ì—ì„œ ë“±ë¡ì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. 2ë§Œ ëª… ì´ìƒì˜ í™˜ìê°€ ì°¸ì—¬í–ˆê³ ìš”. ê·¸ë¦¬ê³  ì˜ˆë¥¼ ë“¤ì–´ OCEANIC ì‹¬ë°©ì„¸ë™ ì—°êµ¬ê°€ íš¨ëŠ¥ ë¶€ì¡±ìœ¼ë¡œ DMCì— ì˜í•´ ì¤‘ë‹¨ë˜ì—ˆë˜ ì‹œì ì„ í›¨ì”¬ ì§€ë‚˜ì„°ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ DMCëŠ” ì •ê¸°ì ìœ¼ë¡œ ê³„ì†í•´ì„œ ì „ì²´ ì—°êµ¬ ì§„í–‰ì„ ìŠ¹ì¸í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì•„ì£¼ ìµœê·¼ì—ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ íš¨ëŠ¥ê³¼ ì•ˆì „ì„±ì„ ê²€í† í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì—°êµ¬ì— ëŒ€í•´ ëˆˆê°€ë¦¼ ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê²ƒì€, ìµœê·¼ì— Eliquisì˜ ì¶œí˜ˆë¥ ì´ ì–´ë–¤ì§€ì— ëŒ€í•œ ë§ì€ ë°ì´í„°ê°€ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¬ë°©ì„¸ë™ ì—°êµ¬ëŠ” Eliquisì— milvexianì„ ì¶”ê°€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì—¬ì „íˆ ëˆˆê°€ë¦¼(blinding) ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ë°ì´í„° ëª¨ë‹ˆí„°ë§ ìœ„ì›íšŒ(DMC)ê°€ ì•Œë ¤ì£¼ëŠ” ë‚´ìš©ê³¼ ìš°ë¦¬ê°€ ëˆˆê°€ë¦¼ ë°©ì‹ìœ¼ë¡œ í™•ì¸í•˜ëŠ” ì¶œí˜ˆë¥ ì„ ë³´ë©´, ìš°ë¦¬ê°€ ê¸°ëŒ€í•˜ëŠ” íš¨ê³¼ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ëŠ” í™•ì‹ ì„ ê°–ê²Œ ë©ë‹ˆë‹¤. ì—˜ë¦¬í€´ìŠ¤(Eliquis)ì™€ ë°€ë²¡ì‹œì•ˆ(milvexian)ì´ íš¨ëŠ¥ ì¸¡ë©´ì—ì„œëŠ” ìœ ì‚¬í•˜ì§€ë§Œ, ë°€ë²¡ì‹œì•ˆì´ ì¶œí˜ˆ ìœ„í—˜, íŠ¹íˆ ì£¼ìš” ì¶œí˜ˆ ìœ„í—˜ì„ í¬ê²Œ ì¤„ì´ëŠ” ë° ìˆì–´ ì´ì ì„ ê°€ì ¸ì˜¬ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ìš” ì„ìƒì ìœ¼ë¡œ ê´€ë ¨ëœ ì¶œí˜ˆ ìœ„í—˜ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì—ì„œ ìš°ë¦¬ëŠ” ì™„ì „íˆ ê³„íšëŒ€ë¡œ ì§„í–‰ ì¤‘ì´ë©°, ì—°êµ¬ëŠ” ì˜¬í•´ ì™„ë£Œë  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Charles Triano: SVP & Head of Investor Relations Our next question today comes from Courtney Breen with Bernstein.</td><td>**Charles Triano:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë²ˆìŠ¤íƒ€ì¸ì˜ Courtney Breen ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Courtney Breen: Bernstein Institutional Services LLC, Research Division I just wanted to double-click on Eliquis question as well as on cost savings in '26. I know your intention is to take more cost savings in the '26 period. And so it would be great if you can kind of perhaps characterize those relative to what you're able to achieve through the year in 2025. And then on Eliquis, thanks for giving the details around kind of some of those 2026 dynamics. I think you made some additional comments on that '26 to '27 transition of a $1.5 billion to $2 billion further step down. Can you just help us understand kind of what is driving that primary change at that moment in time relative to this new baseline on pricing that we've just spoken through now?</td><td>**Courtney Breen:** 2026ë…„ ë¹„ìš© ì ˆê° ì˜ë„ì— ëŒ€í•´ ë§ì”€í•˜ì‹  ë¶€ë¶„ê³¼ ì—˜ë¦¬í€´ìŠ¤ ì§ˆë¬¸ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. 2026ë…„ì— ë” ë§ì€ ë¹„ìš© ì ˆê°ì„ ê³„íší•˜ê³  ê³„ì‹ ë‹¤ëŠ” ì ì€ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 2025ë…„ í•œ í•´ ë™ì•ˆ ë‹¬ì„±í•˜ì‹  ê²ƒê³¼ ë¹„êµí•´ì„œ ì–´ë–¤ ìˆ˜ì¤€ì¸ì§€ ì„¤ëª…í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—˜ë¦¬í€´ìŠ¤ ê´€ë ¨í•´ì„œëŠ” 2026ë…„ ì—­í•™ê´€ê³„ì— ëŒ€í•œ ì„¸ë¶€ì‚¬í•­ì„ ì œê³µí•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 2026ë…„ì—ì„œ 2027ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ëŠ” ì‹œì ì— 15ì–µ ë‹¬ëŸ¬ì—ì„œ 20ì–µ ë‹¬ëŸ¬ì˜ ì¶”ê°€ í•˜ë½ì´ ìˆì„ ê²ƒì´ë¼ëŠ” ì–¸ê¸‰ì„ í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë°©ê¸ˆ ë…¼ì˜í•œ ìƒˆë¡œìš´ ê°€ê²© ê¸°ì¤€ì„ ê³¼ ë¹„êµí•´ì„œ, ê·¸ ì‹œì ì— ì´ëŸ¬í•œ ì£¼ìš” ë³€í™”ë¥¼ ì¼ìœ¼í‚¤ëŠ” ìš”ì¸ì´ ë¬´ì—‡ì¸ì§€ ì´í•´í•  ìˆ˜ ìˆë„ë¡ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Chairman: Thanks for the question, Courtney. I'll ask David to take both and go from there.</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Courtney. Davidì—ê²Œ ë‘ ì§ˆë¬¸ ëª¨ë‘ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Elkins: Executive VP & CFO Yes. So on the cost savings program, as you saw this year, we made really great progress against the $2 billion strategic productivity initiative, achieving over $1 billion of that. And sitting here today, we got really solid line of sight into the additional $1 billion, which will be spread over '26 and '27. So you'll continue to see a step down in our expense base. What I'd also say is it's also enabled us to reinvest in growth drivers, some of investments we did last year with Cobenfy as well as Camzyos, but also with a couple of the deals that we did with Orbital Therapeutics as well as pumitamig, you know, we'll be annualizing those costs here in '26, and we're still reducing our cost base as a result of that.</td><td>**David Elkins:** ë„¤, ë¹„ìš© ì ˆê° í”„ë¡œê·¸ë¨ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì˜¬í•´ ë³´ì‹œë‹¤ì‹œí”¼ 20ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì „ëµì  ìƒì‚°ì„± ê°œì„  ì´ë‹ˆì…”í‹°ë¸Œ(strategic productivity initiative)ì—ì„œ ì •ë§ í° ì§„ì „ì„ ì´ë¤˜ìŠµë‹ˆë‹¤. ê·¸ ì¤‘ 10ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ë‹¬ì„±í–ˆê³ ìš”. í˜„ì¬ ì‹œì ì—ì„œ ë‚˜ë¨¸ì§€ 10ì–µ ë‹¬ëŸ¬ì— ëŒ€í•´ì„œë„ ë§¤ìš° ëª…í™•í•œ ê°€ì‹œì„±ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” 26ë…„ê³¼ 27ë…„ì— ê±¸ì³ ë¶„ì‚°ë  ì˜ˆì •ì´ê³ ìš”. ë”°ë¼ì„œ ìš°ë¦¬ ë¹„ìš© ê¸°ë°˜ì´ ì§€ì†ì ìœ¼ë¡œ ê°ì†Œí•˜ëŠ” ê²ƒì„ ë³´ì‹œê²Œ ë  ê²ë‹ˆë‹¤.<br><br>ë˜í•œ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì ì€, ì´ëŸ¬í•œ ì ˆê°ì´ ì„±ì¥ ë™ë ¥ì— ëŒ€í•œ ì¬íˆ¬ìë„ ê°€ëŠ¥í•˜ê²Œ í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì‘ë…„ì— Cobenfyì™€ Camzyosì— ëŒ€í•œ íˆ¬ìë¥¼ ì§„í–‰í–ˆê³ , Orbital Therapeutics ë° pumitamig ê´€ë ¨ ê±°ë˜ë“¤ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŸ° ë¹„ìš©ë“¤ì´ 26ë…„ì— ì—°ê°„ ë¹„ìš©ìœ¼ë¡œ ë°˜ì˜ë  ì˜ˆì •ì¸ë°, ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ìš°ë¦¬ëŠ” ì—¬ì „íˆ ì „ì²´ ë¹„ìš© ê¸°ë°˜ì„ ì¤„ì—¬ë‚˜ê°€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Adam, do you want to just hit on Eliquis dynamics this year and then you and David can speak to '26 to '27.</td><td>**CEO & Chairman:** ì˜¬í•´ ì—˜ë¦¬í€´ìŠ¤ ë™í–¥ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê³ , ê·¸ ë‹¤ìŒ 26ë…„ê³¼ 27ë…„ì— ëŒ€í•´ì„œëŠ” ì•„ë‹´ê³¼ ë°ì´ë¹„ë“œê°€ í•¨ê»˜ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes. So I spoke about the Eliquis dynamics and as Courtney said, around the pricing changes that took place effective January 1, including the removal of the Medicare Part D liability and the 40% WACC reduction. And so we wanted to guide against 2026. David will talk about our decision not to guide for 2027, which had started when Chris initially became CEO and a decision not to provide longer-term guidance. But David, do you want to expand on that?</td><td>**Adam Lenkowsky:** ë„¤, ì œê°€ Eliquis ì—­í•™ ê´€ê³„ì— ëŒ€í•´ ë§ì”€ë“œë ¸ê³ , Courtneyê°€ ì–¸ê¸‰í–ˆë“¯ì´ 1ì›” 1ì¼ë¶€ë¡œ ì‹œí–‰ëœ ê°€ê²© ë³€ê²½ ì‚¬í•­ë“¤, ì¦‰ Medicare Part D ì±…ì„ ë©´ì œì™€ 40% WACC ì¸í•˜ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” 2026ë…„ì— ëŒ€í•œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ê³ ì í–ˆìŠµë‹ˆë‹¤. Davidê°€ 2027ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ì§€ ì•Šê¸°ë¡œ í•œ ì €í¬ ê²°ì •ì— ëŒ€í•´ ì„¤ëª…í•  í…ë°ìš”, ì´ëŠ” Chrisê°€ CEOë¡œ ì·¨ì„í•˜ë©´ì„œ ì‹œì‘ëœ ê²ƒìœ¼ë¡œ ì¥ê¸° ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí•˜ì§€ ì•Šê¸°ë¡œ í•œ ê²°ì •ì…ë‹ˆë‹¤. David, ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>David Elkins: Executive VP & CFO Yes, Courtney, and thanks for the question. If you remember back in August 2024, when the IRA came out, there's a lot of questions about what that impact was. So we provided guidance at that point in time. We thought it was important just to update you on that '27. So what we said this year is that we expect Eliquis to grow 10%, 15%, and as you think about next year in my prepared remarks, I said that you should expect a similar step down about $1.5 billion to $2 billion from '26 to '27, which is consistent with the step down consensus has now. So hopefully, that's helpful.</td><td>**David Elkins:** ë„¤, Courtney, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 2024ë…„ 8ì›”ì— IRAê°€ ë°œí‘œë˜ì—ˆì„ ë•Œë¥¼ ê¸°ì–µí•˜ì‹¤ í…ë°ìš”, ê·¸ ì˜í–¥ì— ëŒ€í•´ ë§ì€ ì§ˆë¬¸ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë‹¹ì‹œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí–ˆì—ˆê³ , ì´ë²ˆì— 27ë…„ë„ì— ëŒ€í•´ì„œë„ ì—…ë°ì´íŠ¸ë¥¼ ë“œë¦¬ëŠ” ê²ƒì´ ì¤‘ìš”í•˜ë‹¤ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ EliquisëŠ” 10~15% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ë‚´ë…„ì— ëŒ€í•´ì„œëŠ” ì œ ë°œí‘œì—ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ 26ë…„ì—ì„œ 27ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ë©´ì„œ ì•½ 15ì–µ~20ì–µ ë‹¬ëŸ¬ ì •ë„ì˜ ê°ì†Œë¥¼ ì˜ˆìƒí•˜ì‹œë©´ ë©ë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì»¨ì„¼ì„œìŠ¤ê°€ ì˜ˆìƒí•˜ëŠ” ê°ì†Œí­ê³¼ ì¼ì¹˜í•©ë‹ˆë‹¤. ë„ì›€ì´ ë˜ì…¨ê¸°ë¥¼ ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Charles Triano: SVP & Head of Investor Relations And Courtney, just a reminder, Chuck here. Remember, the EU patents largely expire late in '26. So that's going to be a factor in '27 that we'll see as well in terms of driving the step down.</td><td>**Charles Triano:** ì½”íŠ¸ë‹ˆ, ì²™ì…ë‹ˆë‹¤. í•œ ê°€ì§€ ìƒê¸°ì‹œì¼œ ë“œë¦¬ìë©´, EU íŠ¹í—ˆê°€ ëŒ€ë¶€ë¶„ 26ë…„ ë§ì— ë§Œë£Œë©ë‹ˆë‹¤. ë”°ë¼ì„œ 27ë…„ì—ë„ ì´ ë¶€ë¶„ì´ í•˜ë½ ìš”ì¸ìœ¼ë¡œ ì‘ìš©í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Operator, you can take the next question.</td><td>**CEO & Chairman:** êµí™˜ì›ë‹˜, ë‹¤ìŒ ì§ˆë¬¸ ë°›ì•„ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Mohit Bansal with Wells Fargo.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Wells Fargoì˜ Mohit Bansalë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Mohit Bansal: Wells Fargo Securities, LLC, Research Division I have a question on LPA1. So from the feedback we have received from some KOLs is that the toxicity burden that is associated with the existing standard of care, combo therapy may be reserved for more severe patients. And for the widespread use of LPA1 monotherapy, patients may still want to see some kind of efficacy benefit over existing therapies here. I don't know how you are thinking about it, but would love to get your thoughts on like what it takes for a new therapy like LPA1 to become a new standard of care, either as a monotherapy or a combo therapy in this space.</td><td>**Mohit Bansal:** LPA1ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ê°€ ì¼ë¶€ ì£¼ìš” ì˜¤í”¼ë‹ˆì–¸ ë¦¬ë”(KOL)ë“¤ë¡œë¶€í„° ë°›ì€ í”¼ë“œë°±ì— ë”°ë¥´ë©´, ê¸°ì¡´ í‘œì¤€ì¹˜ë£Œì¸ ë³‘ìš©ìš”ë²•ê³¼ ê´€ë ¨ëœ ë…ì„± ë¶€ë‹´ ë•Œë¬¸ì— ì´ ì¹˜ë£Œë²•ì€ ë³´ë‹¤ ì¤‘ì¦ í™˜ìë“¤ì—ê²Œ ì‚¬ìš©ì´ ì œí•œë  ìˆ˜ ìˆë‹¤ê³  í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  LPA1 ë‹¨ë…ìš”ë²•ì˜ ê´‘ë²”ìœ„í•œ ì‚¬ìš©ì„ ìœ„í•´ì„œëŠ” í™˜ìë“¤ì´ ì—¬ì „íˆ ê¸°ì¡´ ì¹˜ë£Œë²• ëŒ€ë¹„ ì–´ëŠ ì •ë„ì˜ íš¨ëŠ¥ ê°œì„ ì„ ê¸°ëŒ€í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ëª¨ë¥´ê² ì§€ë§Œ, LPA1ê³¼ ê°™ì€ ì‹ ê·œ ì¹˜ë£Œì œê°€ ë‹¨ë…ìš”ë²•ì´ë“  ë³‘ìš©ìš”ë²•ì´ë“  ì´ ë¶„ì•¼ì—ì„œ ìƒˆë¡œìš´ í‘œì¤€ì¹˜ë£Œë¡œ ìë¦¬ì¡ê¸° ìœ„í•´ ë¬´ì—‡ì´ í•„ìš”í•œì§€ì— ëŒ€í•œ ê²¬í•´ë¥¼ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Thanks for the question, Mohit. Adam?</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. Adam?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Mohit, thanks for the question. So IPF and PPF are progressive pulmonary diseases and prognosis for these diseases is not dissimilar to what we see with some metastatic cancer diagnosis. In fact, there's less than 50% 5-year overall survival rate. So there's a significant need for newer therapies that provide greater efficacy and tolerability. What we're excited about with admilparant, which is our LPA1 is that this is a potential first-in-class product that we believe could redefine the standard of care in pulmonary fibrosis, offering improved efficacy and improved tolerability profile. Remember, admilparant works by slowing the progression and could actually potentially halt the progression of disease. And when we look at the adverse event profile, we're seeing low rates of GI tolerability, which has been a real challenge for some of the older therapies as well as some of the newer therapies that have recently introduced to the market to help manage their disease. In fact, about 50% of patients abandoned treatment by 12 months. We've also seen some newer agents, have some formulations that may limit uptake. So we would expect to see admilparant used in combination and as a monotherapy similar to how we're studying the drug, and we really look forward to the data readout in the second half of this year.</td><td>**Adam Lenkowsky:** IPFì™€ PPFëŠ” ì§„í–‰ì„± íì§ˆí™˜ìœ¼ë¡œ, ì´ë“¤ ì§ˆí™˜ì˜ ì˜ˆí›„ëŠ” ì¼ë¶€ ì „ì´ì„± ì•” ì§„ë‹¨ê³¼ í¬ê²Œ ë‹¤ë¥´ì§€ ì•ŠìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ 5ë…„ ì „ì²´ ìƒì¡´ìœ¨ì´ 50% ë¯¸ë§Œì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë” ìš°ìˆ˜í•œ íš¨ëŠ¥ê³¼ ë‚´ì•½ì„±ì„ ì œê³µí•˜ëŠ” ìƒˆë¡œìš´ ì¹˜ë£Œì œì— ëŒ€í•œ ìƒë‹¹í•œ ìˆ˜ìš”ê°€ ìˆìŠµë‹ˆë‹¤.<br><br>ì €í¬ê°€ ê°œë°œ ì¤‘ì¸ LPA1 ì–µì œì œì¸ ì• ë“œë°€íŒŒë€íŠ¸(admilparant)ì— ëŒ€í•´ ê¸°ëŒ€í•˜ëŠ” ì´ìœ ëŠ”, ì´ê²ƒì´ ì ì¬ì ìœ¼ë¡œ ë™ì¢… ìµœì´ˆ(first-in-class) ì œí’ˆìœ¼ë¡œì„œ íì„¬ìœ ì¦ì˜ í‘œì¤€ ì¹˜ë£Œë²•ì„ ì¬ì •ì˜í•˜ê³ , ê°œì„ ëœ íš¨ëŠ¥ê³¼ í–¥ìƒëœ ë‚´ì•½ì„± í”„ë¡œíŒŒì¼ì„ ì œê³µí•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì• ë“œë°€íŒŒë€íŠ¸ëŠ” ì§ˆë³‘ ì§„í–‰ì„ ëŠ¦ì¶”ê³ , ì‹¤ì œë¡œ ì§ˆë³‘ ì§„í–‰ì„ ì¤‘ë‹¨ì‹œí‚¬ ê°€ëŠ¥ì„±ë„ ìˆë‹¤ëŠ” ì ì„ ê¸°ì–µí•˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ìƒë°˜ì‘ í”„ë¡œíŒŒì¼ì„ ì‚´í´ë³´ë©´, ìœ„ì¥ê´€ ë‚´ì•½ì„± ë¬¸ì œê°€ ë§¤ìš° ë‚®ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ê¸°ì¡´ ì¹˜ë£Œì œë“¤ì€ ë¬¼ë¡  ìµœê·¼ ì‹œì¥ì— ì¶œì‹œëœ ì¼ë¶€ ì‹ ê·œ ì¹˜ë£Œì œë“¤ì´ ì§ˆí™˜ ê´€ë¦¬ì— ìˆì–´ ê²ªê³  ìˆëŠ” ì‹¤ì§ˆì ì¸ ê³¼ì œì˜€ìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ í™˜ìì˜ ì•½ 50%ê°€ 12ê°œì›” ì´ë‚´ì— ì¹˜ë£Œë¥¼ ì¤‘ë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì¼ë¶€ ì‹ ê·œ ì•½ë¬¼ë“¤ì˜ ê²½ìš° ì œí˜•ìƒì˜ ë¬¸ì œë¡œ ì¸í•´ ì²˜ë°©ì´ ì œí•œë  ìˆ˜ ìˆëŠ” ìƒí™©ë„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ admilparantëŠ” ë³‘ìš©ìš”ë²•ê³¼ ë‹¨ë…ìš”ë²• ëª¨ë‘ì—ì„œ ì‚¬ìš©ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” í˜„ì¬ ì €í¬ê°€ ì„ìƒì‹œí—˜ì„ ì§„í–‰í•˜ê³  ìˆëŠ” ë°©ì‹ê³¼ë„ ì¼ì¹˜í•©ë‹ˆë‹¤. ì˜¬í•´ í•˜ë°˜ê¸° ë°ì´í„° ê²°ê³¼ ë°œí‘œë¥¼ ì •ë§ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from Terence Flynn at Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ í…Œë ŒìŠ¤ í”Œë¦° ì• ë„ë¦¬ìŠ¤íŠ¸ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Terence Flynn: Morgan Stanley, Research Division I just had two. One is just on the milvexian AFib study. Cristian, wondering if you can speak to what you view as a clinically meaningful delta versus Eliquis that would be enough to support broader payer coverage there. And then just, David, on the guidance, the math that we're doing suggests kind of mid-single-digit growth year-over-year on the growth portfolio, which includes Opdivo. So I just want to know that we're in the right ballpark there.</td><td>**Terence Flynn:** ë°€ë²¡ì‹œì•ˆ ì‹¬ë°©ì„¸ë™ ì—°êµ¬ì— ëŒ€í•´ ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í¬ë¦¬ìŠ¤í‹°ì•ˆ, ë” ê´‘ë²”ìœ„í•œ ë³´í—˜ ì ìš©ì„ ë°›ê¸° ìœ„í•´ ì—˜ë¦¬í€´ìŠ¤(Eliquis) ëŒ€ë¹„ ì–´ëŠ ì •ë„ì˜ ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ì°¨ì´ê°€ í•„ìš”í•˜ë‹¤ê³  ë³´ì‹œëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ë°ì´ë¹„ë“œ, ê°€ì´ë˜ìŠ¤ ê´€ë ¨í•´ì„œ ì €í¬ê°€ ê³„ì‚°í•œ ë°”ë¡œëŠ” ì˜µë””ë³´(Opdivo)ë¥¼ í¬í•¨í•œ ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ì „ë…„ ëŒ€ë¹„ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ë‚˜ì˜¤ëŠ”ë°, ì €í¬ê°€ ì˜¬ë°”ë¥¸ ë²”ìœ„ì—ì„œ ê³„ì‚°í•˜ê³  ìˆëŠ” ê²ƒì¸ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Thanks for the question, Terence. Maybe Cristian and Adam combine on milvexian and then David.</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Terence. ë°€ë²¡ì‹œì•ˆ(milvexian)ì— ëŒ€í•´ì„œëŠ” Cristianê³¼ Adamì´ í•¨ê»˜ ë‹µë³€ë“œë¦¬ê³ , ê·¸ ë‹¤ìŒ Davidê°€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development Thank you, Terence, for the question. The study primary endpoint is showing non-inferiority versus Eliquis versus apixaban on efficacy. And you know, Terence, we selected a dose that is -- was very scrutinized to balance activity -- potential activity and, of course, bleeding risks. This is why we are using 100-milligram BID. It is a dose much higher than, for instance, we use in stroke prevention. So I would say there is a possibility that, of course, milvexian show a better outcome, but the real first endpoint is showing non-inferiority. Let's not forget the OCEANIC Afib actually did not -- was able to show that level of similar activity versus apixaban. Then after the noninferiority will be met, we're going to test superiority for bleeding. So this is also where we want to show a clinically meaningful differentiation on the bleeding rates. I don't give you the deltas and everything. Of course, we believe that if the study will be a target, it will be seen as a clinically meaningful. Adam, do you want to.</td><td>**Cristian Massacesi:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Terence. ì´ë²ˆ ì—°êµ¬ì˜ ì£¼ìš” í‰ê°€ë³€ìˆ˜ëŠ” Eliquis, ì¦‰ ì•„í”½ì‚¬ë°˜ ëŒ€ë¹„ íš¨ëŠ¥ì—ì„œ ë¹„ì—´ë“±ì„±ì„ ì…ì¦í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. Terence, ì €í¬ê°€ ì„ íƒí•œ ìš©ëŸ‰ì€ ì ì¬ì  í™œì„±ê³¼ ë¬¼ë¡  ì¶œí˜ˆ ìœ„í—˜ ê°„ì˜ ê· í˜•ì„ ë§ì¶”ê¸° ìœ„í•´ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ê²€í† í•œ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì €í¬ê°€ 100mgì„ 1ì¼ 2íšŒ íˆ¬ì—¬í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤. ì´ëŠ” ì˜ˆë¥¼ ë“¤ì–´ ë‡Œì¡¸ì¤‘ ì˜ˆë°©ì— ì‚¬ìš©í•˜ëŠ” ìš©ëŸ‰ë³´ë‹¤ í›¨ì”¬ ë†’ì€ ìš©ëŸ‰ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë°€ë²¡ì‹œì•ˆì´ ë” ë‚˜ì€ ê²°ê³¼ë¥¼ ë³´ì¼ ê°€ëŠ¥ì„±ì€ ë¬¼ë¡  ìˆì§€ë§Œ, ì‹¤ì œ ì²« ë²ˆì§¸ ëª©í‘œëŠ” ë¹„ì—´ë“±ì„±ì„ ì…ì¦í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. OCEANIC Afib ì—°êµ¬ê°€ ì‹¤ì œë¡œ ì•„í”½ì‚¬ë°˜ ëŒ€ë¹„ ìœ ì‚¬í•œ í™œì„± ìˆ˜ì¤€ì„ ë³´ì—¬ì£¼ì§€ ëª»í–ˆë‹¤ëŠ” ì ì„ ìŠì§€ ë§ì•„ì•¼ í•©ë‹ˆë‹¤. ë¹„ì—´ë“±ì„±ì´ ì…ì¦ëœ í›„ì—ëŠ” ì¶œí˜ˆì— ëŒ€í•œ ìš°ì›”ì„±ì„ ê²€ì¦í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ì¶œí˜ˆë¥ ì— ìˆì–´ ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ì°¨ë³„í™”ë¥¼ ë³´ì—¬ì£¼ê³ ì í•©ë‹ˆë‹¤. êµ¬ì²´ì ì¸ ë¸íƒ€ ìˆ˜ì¹˜ ë“±ì€ ë§ì”€ë“œë¦¬ì§€ ì•Šê² ìŠµë‹ˆë‹¤ë§Œ, ë¬¼ë¡  ì €í¬ëŠ” ì´ë²ˆ ì—°êµ¬ê°€ ëª©í‘œë¥¼ ë‹¬ì„±í•œë‹¤ë©´ ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ê²°ê³¼ë¡œ ì¸ì •ë°›ì„ ê²ƒì´ë¼ í™•ì‹ í•©ë‹ˆë‹¤. Adam, ì¶”ê°€ ì„¤ëª… ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes, Terence, thanks for the question. So milvexian represents a significant commercial opportunity, particularly in Afib. Afib is a very large market, and we believe that milvexian has the potential to replace first-generation DOACs. And this is a market that we know very well. Fear of bleeding continues to be the main reason why clinicians hold back from using Factor Xs in more patients. Roughly 40% of patients remain either untreated or undertreated, leaving them at risk for a stroke. And they have significant concerns around bleeding. And so we know safety is important. We believe a differentiated bleeding profile will drive demand versus standard of care. We've had a number of payer discussions already that suggest that the potential of improved benefit risk profile will be a strong value proposition. And we would also expect there to be an economic benefit of using milvexian over Eliquis in terms of bleeding events that are avoided. So we look forward to the data readout at the end of 2026. And we're confident that this product has multibillion-dollar potential.</td><td>**Adam Lenkowsky:** ë„¤, í…Œë ŒìŠ¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë°€ë²¡ì‹œì•ˆì€ íŠ¹íˆ ì‹¬ë°©ì„¸ë™(Afib) ì˜ì—­ì—ì„œ ìƒë‹¹í•œ ìƒì—…ì  ê¸°íšŒë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì‹¬ë°©ì„¸ë™ì€ ë§¤ìš° í° ì‹œì¥ì´ë©°, ì €í¬ëŠ” ë°€ë²¡ì‹œì•ˆì´ 1ì„¸ëŒ€ DOAC(ì§ì ‘ ê²½êµ¬ í•­ì‘ê³ ì œ)ë¥¼ ëŒ€ì²´í•  ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì €í¬ê°€ ë§¤ìš° ì˜ ì•Œê³  ìˆëŠ” ì‹œì¥ì…ë‹ˆë‹¤. <br><br>ì¶œí˜ˆì— ëŒ€í•œ ìš°ë ¤ëŠ” ì—¬ì „íˆ ì„ìƒì˜ë“¤ì´ ë” ë§ì€ í™˜ìì—ê²Œ Factor X ì–µì œì œ ì‚¬ìš©ì„ ì£¼ì €í•˜ëŠ” ì£¼ëœ ì´ìœ ì…ë‹ˆë‹¤. ëŒ€ëµ 40%ì˜ í™˜ìë“¤ì´ ì¹˜ë£Œë¥¼ ë°›ì§€ ì•Šê±°ë‚˜ ë¶ˆì¶©ë¶„í•œ ì¹˜ë£Œë¥¼ ë°›ê³  ìˆì–´ ë‡Œì¡¸ì¤‘ ìœ„í—˜ì— ë…¸ì¶œë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜ì‚¬ë“¤ì€ ì¶œí˜ˆì— ëŒ€í•´ ìƒë‹¹í•œ ìš°ë ¤ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì•ˆì „ì„±ì´ ì¤‘ìš”í•˜ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì°¨ë³„í™”ëœ ì¶œí˜ˆ í”„ë¡œíŒŒì¼ì´ í‘œì¤€ ì¹˜ë£Œ ëŒ€ë¹„ ìˆ˜ìš”ë¥¼ ê²¬ì¸í•  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ì´ë¯¸ ì—¬ëŸ¬ ë³´í—˜ì‚¬ë“¤ê³¼ ë…¼ì˜ë¥¼ ì§„í–‰í–ˆëŠ”ë°, ê°œì„ ëœ í¸ìµ-ìœ„í—˜ í”„ë¡œíŒŒì¼(benefit-risk profile)ì˜ ì ì¬ë ¥ì´ ê°•ë ¥í•œ ê°€ì¹˜ ì œì•ˆì´ ë  ê²ƒì´ë¼ëŠ” ë°˜ì‘ì„ ì–»ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ ì¶œí˜ˆ ì‚¬ê±´ ê°ì†Œ ì¸¡ë©´ì—ì„œ ì—˜ë¦¬í€´ìŠ¤ ëŒ€ë¹„ ë°€ë²¡ì‹œì•ˆ ì‚¬ìš© ì‹œ ê²½ì œì  ì´ì ë„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ ë§ ë°ì´í„° ê²°ê³¼ ë°œí‘œë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ ì œí’ˆì´ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>David Elkins: Executive VP & CFO Yes. And Terence, you're absolutely right in your math and thinking about the growth portfolio. We feel really good about the growth portfolio, mid-single-digit growth. But also, we have the risk of Orencia generics coming this year, which would impact that growth portfolio. But we feel really good about where we exited '25 and about the prospects heading into '26 now.</td><td>**David Elkins:** ë„¤, ë§ìŠµë‹ˆë‹¤. í…Œë ŒìŠ¤, ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•œ ê³„ì‚°ê³¼ ë¶„ì„ì´ ì •í™•í•˜ì‹­ë‹ˆë‹¤. ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì˜¬í•´ ì˜¤ë Œì‹œì•„ ì œë„¤ë¦­ ì¶œì‹œ ë¦¬ìŠ¤í¬ê°€ ìˆì–´ ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ì— ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  25ë…„ì„ ë§ˆë¬´ë¦¬í•œ ì‹¤ì ê³¼ 26ë…„ìœ¼ë¡œ í–¥í•˜ëŠ” ì „ë§ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from Geoff Meacham at Citi.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ Citiì˜ Geoff Meachamë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Meacham: Citigroup Inc. Exchange Research I have a couple. So one for Adam, I guess, on Cobenfy. There's a lot of excitement earlier last year, just given its mechanism and lack of innovation in the category, but we really haven't seen an inflection point in sales. I guess, is there a bottleneck and access that you really have to still work through? I'm just trying to figure out the steps to see sequential acceleration. And then on pumitamig, I guess for -- maybe for Chris or Cristian, is there a data set, a tipping point maybe of data that you want to see before you really scale up the Phase III investment? Just given its foundational mechanism, what's the upper end of either Phase III studies or tumor types that you ultimately have capacity for, for the drug?</td><td>**Geoffrey Meacham:** ë¨¼ì € Adamì—ê²Œ Cobenfyì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‘ë…„ ì´ˆì— ìƒˆë¡œìš´ ê¸°ì „ê³¼ í•´ë‹¹ ì¹´í…Œê³ ë¦¬ì—ì„œì˜ í˜ì‹  ë¶€ì¡±ìœ¼ë¡œ ë§ì€ ê¸°ëŒ€ê°€ ìˆì—ˆëŠ”ë°, ì•„ì§ ë§¤ì¶œì—ì„œ ë³€ê³¡ì ì„ ë³´ì§€ ëª»í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì ‘ê·¼ì„±ì— ë³‘ëª©í˜„ìƒì´ ìˆì–´ì„œ ì—¬ì „íˆ í•´ê²°í•´ì•¼ í•  ë¶€ë¶„ì´ ìˆëŠ” ê±´ê°€ìš”? ìˆœì°¨ì ì¸ ê°€ì†í™”ë¥¼ ë³´ê¸° ìœ„í•œ ë‹¨ê³„ë“¤ì´ ë¬´ì—‡ì¸ì§€ íŒŒì•…í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  pumitamigì— ëŒ€í•´ì„œëŠ” Chrisë‚˜ Cristianì—ê²Œ ì§ˆë¬¸ë“œë¦½ë‹ˆë‹¤. 3ìƒ íˆ¬ìë¥¼ ë³¸ê²©ì ìœ¼ë¡œ í™•ëŒ€í•˜ê¸° ì „ì— ë³´ê³  ì‹¶ìœ¼ì‹  ë°ì´í„°ì…‹ì´ë‚˜ ì „í™˜ì ì´ ë˜ëŠ” ë°ì´í„°ê°€ ìˆìœ¼ì‹ ê°€ìš”? ê¸°ë³¸ì ì¸ ê¸°ì „ì„ ê³ ë ¤í•  ë•Œ, ê¶ê·¹ì ìœ¼ë¡œ ì—­ëŸ‰ì„ íˆ¬ì…í•  ìˆ˜ ìˆëŠ” 3ìƒ ì„ìƒì‹œí—˜ì´ë‚˜ ì¢…ì–‘ ìœ í˜•ì˜ ìƒí•œì„ ì€ ì–´ëŠ ì •ë„ì¸ê°€ìš”?</td></tr>
<tr><td>CEO & Chairman: I'll start with Adam and then Cristian can handle the pumitamig question.</td><td>**CEO & Chairman:** ë¨¼ì € Adamì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³ , ê·¸ ë‹¤ìŒ Cristianì´ pumitamig ê´€ë ¨ ì§ˆë¬¸ì— ë‹µë³€í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Great. Thank you, Geoff. So we're pleased with the progress that we made in Cobenfy's first full year on the market. In fact, Cobenfy delivered over 100,000 TRxs since launch, and that surpassed all relevant schizophrenia analogs. We have very strong access, virtually 100% access across Medicaid and Medicare, and now we're approaching 70% commercial access. So that is certainly not a bottleneck. We made good progress in Q4, as you're able to see with an acceleration of NRxs as well as increases in both new and repeat trialists after our full field force expansion was in place in both the community and in the hospitals. So we see continued opportunity for growth in schizophrenia, as we stated, we're confident in our ability to deliver continued steady growth and new indications are going to be the driver of inflections there. But we hear from physicians, the feedback continues to remain positive. We are making very good progress with adding the number of trialists, which continue to grow steadily. And importantly, what we have seen is that those physicians who've had a positive experience with Cobenfy have shown an increased propensity to repeat prescribing. So this year, we'll present several new Phase IV studies, including a switch study later on in the quarter, which is the top question that we get from physicians on how to switch from a D2 over to Cobenfy. We'll have real-world data as well to support that, and we're increasing investment in peer-to-peer activity. So taken together, we are making good progress. And based on all the leading indicators we're seeing, we believe Cobenfy has the potential to become a leading treatment in schizophrenia over time, and we're confident this could be a big drug for the company.</td><td>**Adam Lenkowsky:** ê°ì‚¬í•©ë‹ˆë‹¤, Geoff. ì½”ë²¤í”¼ì˜ ì‹œì¥ ì¶œì‹œ í›„ ì²« í•´ ë™ì•ˆ ì´ë£¬ ì§„ì „ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ì½”ë²¤í”¼ëŠ” ì¶œì‹œ ì´í›„ 10ë§Œ ê±´ ì´ìƒì˜ ì´ ì²˜ë°©(TRx)ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ê´€ë ¨ëœ ëª¨ë“  ì¡°í˜„ë³‘ ì¹˜ë£Œì œ ìœ ì‚¬ ì œí’ˆë“¤ì„ ëŠ¥ê°€í•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œì™€ ë©”ë””ì¼€ì–´ì—ì„œ ì‚¬ì‹¤ìƒ 100%ì— ê°€ê¹Œìš´ ì ‘ê·¼ì„±ì„ í™•ë³´í–ˆê³ , í˜„ì¬ ìƒì—… ë³´í—˜ì—ì„œë„ 70%ì— ê·¼ì ‘í•œ ì ‘ê·¼ì„±ì„ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë¶€ë¶„ì€ í™•ì‹¤íˆ ì¥ì•  ìš”ì¸ì´ ì•„ë‹™ë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” ì§€ì—­ì‚¬íšŒì™€ ë³‘ì› ëª¨ë‘ì—ì„œ ì˜ì—… ì¸ë ¥ í™•ëŒ€ê°€ ì™„ë£Œëœ í›„, ì‹ ê·œ ì²˜ë°©(NRx)ì´ ê°€ì†í™”ë˜ê³  ì‹ ê·œ ë° ì¬ì‹œë„ í™˜ì ëª¨ë‘ ì¦ê°€í•˜ë©´ì„œ ì¢‹ì€ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. ì¡°í˜„ë³‘ ë¶„ì•¼ì—ì„œ ì§€ì†ì ì¸ ì„±ì¥ ê¸°íšŒê°€ ìˆë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, ë§ì”€ë“œë¦° ëŒ€ë¡œ ê¾¸ì¤€í•œ ì„±ì¥ì„ ì´ì–´ê°ˆ ìˆ˜ ìˆë‹¤ëŠ” í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ìƒˆë¡œìš´ ì ì‘ì¦ë“¤ì´ ì„±ì¥ ì „í™˜ì˜ í•µì‹¬ ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì˜ì‚¬ë“¤ë¡œë¶€í„° ë°›ëŠ” í”¼ë“œë°±ë„ ê³„ì†í•´ì„œ ê¸ì •ì ì…ë‹ˆë‹¤. ì‹œí—˜ ì²˜ë°© ì˜ì‚¬ ìˆ˜ë¥¼ ëŠ˜ë¦¬ëŠ” ë° ìˆì–´ì„œë„ ë§¤ìš° ì¢‹ì€ ì§„ì „ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ê¾¸ì¤€íˆ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì¤‘ìš”í•œ ì ì€, Cobenfyì— ëŒ€í•´ ê¸ì •ì ì¸ ê²½í—˜ì„ í•œ ì˜ì‚¬ë“¤ì´ ì¬ì²˜ë°© ì„±í–¥ì´ ë†’ì•„ì§€ëŠ” ê²ƒì„ í™•ì¸í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì˜¬í•´ëŠ” ì—¬ëŸ¬ ê±´ì˜ ìƒˆë¡œìš´ 4ìƒ ì„ìƒì‹œí—˜ ê²°ê³¼ë¥¼ ë°œí‘œí•  ì˜ˆì •ì¸ë°, ì´ë²ˆ ë¶„ê¸° í›„ë°˜ì—ëŠ” ì „í™˜ ì—°êµ¬(switch study) ê²°ê³¼ë„ ê³µê°œí•  ê³„íšì…ë‹ˆë‹¤. ì´ëŠ” ì˜ì‚¬ë“¤ì´ ê°€ì¥ ë§ì´ ë¬¸ì˜í•˜ëŠ” ì‚¬í•­ìœ¼ë¡œ, D2 ê¸¸í•­ì œì—ì„œ Cobenfyë¡œ ì–´ë–»ê²Œ ì „í™˜í•˜ëŠ”ì§€ì— ëŒ€í•œ ë‚´ìš©ì…ë‹ˆë‹¤. ì´ë¥¼ ë’·ë°›ì¹¨í•  ì‹¤ì œ ì„ìƒ ë°ì´í„°(real-world data)ë„ í™•ë³´í•˜ê²Œ ë  ê²ƒì´ë©°, í™˜ì ê°„ ì†Œí†µ í™œë™ì— ëŒ€í•œ íˆ¬ìë„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë…¸ë ¥ë“¤ì„ ì¢…í•©í•´ë³¼ ë•Œ, ìš°ë¦¬ëŠ” ìˆœì¡°ë¡œìš´ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ í™•ì¸í•˜ê³  ìˆëŠ” ëª¨ë“  ì„ í–‰ ì§€í‘œë“¤ì„ ë°”íƒ•ìœ¼ë¡œ, CobenfyëŠ” ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì¡°í˜„ë³‘ ì¹˜ë£Œì˜ ì„ ë„ì ì¸ ì¹˜ë£Œì œê°€ ë  ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë¯¿ê³  ìˆìœ¼ë©°, ì´ ì œí’ˆì´ íšŒì‚¬ì— í° ì˜ë¯¸ê°€ ìˆëŠ” ì˜ì•½í’ˆì´ ë  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development Thanks for the question, Geoff. The -- let me break down your question in -- the first thing is the confidence. First of all, we have data sets in triple-negative and in small cell lung cancer showing that the drug is active. And there are also very large data sets from competitive assets that reinforce the message. The second thing is more on -- these are 2 very well clinically validated targets, PD-1, PD-L1 and VEGF. And you know that when you deliver mechanism through bispecifics, sometimes you increase the selectivity, and this can be even more powerful than just delivering the 2 mechanisms through 2 different drugs. Now when you look, we are actually already scaled up the development of this drug. The confidence is very high. We believe -- the strategy is very simple. We want to replace and then we want to expand. We want to replace where PD-1, PD-L1 inhibitors are playing today in those indications through this bispecific. And then we want to expand because we believe bringing VEGF on top of PD-L1 inhibition, we can also tackle some of the indications where PD-1, PD-L1 inhibitors are not working well enough or not at all. So this is the reason why we already have started or are in flight to start 7 pivotal studies across multiple indications. And there is an 8th one that we announced in head and neck. And when you look at the indication we have, of course, there is a concentration in non-small cell lung cancer, very important indication, but this goes beyond gastric, colon, head and neck, breast. So this is a program that has a top priority in oncology and we represent the backbone of our portfolio. The next wave will be to novel-novel, and that will be the next wave of studies where we will continue to improve on regimens that we are creating today.</td><td>**Cristian Massacesi:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Geoff. ì§ˆë¬¸ì„ ë‚˜ëˆ ì„œ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € í™•ì‹ ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ìš°ì„  ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”ê³¼ ì†Œì„¸í¬ íì•”ì—ì„œ ì•½ë¬¼ì´ í™œì„±ì„ ë³´ì¸ë‹¤ëŠ” ë°ì´í„° ì„¸íŠ¸ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ê²½ìŸ ìì‚°ë“¤ë¡œë¶€í„° ë‚˜ì˜¨ ë§¤ìš° ë°©ëŒ€í•œ ë°ì´í„° ì„¸íŠ¸ë“¤ì´ ì´ëŸ¬í•œ ë©”ì‹œì§€ë¥¼ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ì´ ë‘ ê°€ì§€ê°€ ì„ìƒì ìœ¼ë¡œ ë§¤ìš° ì˜ ê²€ì¦ëœ íƒ€ê²Ÿì´ë¼ëŠ” ì ì…ë‹ˆë‹¤ - PD-1, PD-L1 ê·¸ë¦¬ê³  VEGF ë§ì…ë‹ˆë‹¤. ì´ì¤‘íŠ¹ì´í•­ì²´(bispecifics)ë¥¼ í†µí•´ ë©”ì»¤ë‹ˆì¦˜ì„ ì „ë‹¬í•  ë•Œ, ë•Œë¡œëŠ” ì„ íƒì„±ì´ ì¦ê°€í•˜ë©°, ì´ëŠ” ë‘ ê°€ì§€ ë©”ì»¤ë‹ˆì¦˜ì„ ì„œë¡œ ë‹¤ë¥¸ ë‘ ì•½ë¬¼ë¡œ ì „ë‹¬í•˜ëŠ” ê²ƒë³´ë‹¤ í›¨ì”¬ ë” ê°•ë ¥í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ì•„ì‹¤ ê²ë‹ˆë‹¤. ì‹¤ì œë¡œ ì €í¬ëŠ” ì´ë¯¸ ì´ ì•½ë¬¼ì˜ ê°œë°œ ê·œëª¨ë¥¼ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. í™•ì‹ ì€ ë§¤ìš° ë†’ìŠµë‹ˆë‹¤. ì €í¬ ì „ëµì€ ë§¤ìš° ë‹¨ìˆœí•©ë‹ˆë‹¤. ë¨¼ì € ëŒ€ì²´í•˜ê³ , ê·¸ ë‹¤ìŒ í™•ì¥í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ PD-1, PD-L1 ì–µì œì œê°€ ì‚¬ìš©ë˜ê³  ìˆëŠ” ì ì‘ì¦ë“¤ì„ ì´ ì´ì¤‘íŠ¹ì´í•­ì²´ë¡œ ëŒ€ì²´í•˜ê³ ì í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‚˜ì„œ í™•ì¥í•˜ë ¤ê³  í•˜ëŠ”ë°, PD-L1 ì–µì œ ìœ„ì— VEGFë¥¼ ê²°í•©í•¨ìœ¼ë¡œì¨ PD-1, PD-L1 ì–µì œì œê°€ ì¶©ë¶„íˆ íš¨ê³¼ë¥¼ ë‚´ì§€ ëª»í•˜ê±°ë‚˜ ì „í˜€ ì‘ë™í•˜ì§€ ì•ŠëŠ” ì ì‘ì¦ë“¤ë„ ê³µëµí•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì €í¬ê°€ ì´ë¯¸ ì—¬ëŸ¬ ì ì‘ì¦ì— ê±¸ì³ 7ê°œì˜ í”¼ë²— ì—°êµ¬ë¥¼ ì‹œì‘í–ˆê±°ë‚˜ ì‹œì‘í•˜ë ¤ëŠ” ì´ìœ ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ê²½ë¶€ì•”ì—ì„œ ë°œí‘œí•œ 8ë²ˆì§¸ ì—°êµ¬ë„ ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ë‹¤ë£¨ê³  ìˆëŠ” ì ì‘ì¦ì„ ë³´ì‹œë©´, ë¬¼ë¡  ë¹„ì†Œì„¸í¬íì•”ì— ì§‘ì¤‘ë˜ì–´ ìˆëŠ”ë° ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ì ì‘ì¦ì´ì§€ë§Œ, ìœ„ì•”, ëŒ€ì¥ì•”, ë‘ê²½ë¶€ì•”, ìœ ë°©ì•”ê¹Œì§€ ê·¸ ë²”ìœ„ê°€ í™•ì¥ë©ë‹ˆë‹¤. <response><br><br>ì´ê²ƒì€ ì¢…ì–‘í•™(oncology) ë¶„ì•¼ì—ì„œ ìµœìš°ì„  ìˆœìœ„ë¥¼ ê°€ì§„ í”„ë¡œê·¸ë¨ì´ë©°, ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê·¼ê°„ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ìŒ ë‹¨ê³„ëŠ” ì‹ ì•½-ì‹ ì•½ ì¡°í•©ì´ ë  ê²ƒì´ë©°, ì´ëŠ” í˜„ì¬ ìš°ë¦¬ê°€ ë§Œë“¤ì–´ê°€ê³  ìˆëŠ” ì¹˜ë£Œë²•ì„ ì§€ì†ì ìœ¼ë¡œ ê°œì„ í•´ ë‚˜ê°ˆ ì°¨ì„¸ëŒ€ ì—°êµ¬ê°€ ë  ê²ƒì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Operator: And our next question today comes from Asad Haider with Goldman Sachs.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ì•„ì‚¬ë“œ í•˜ì´ë” ì• ë„ë¦¬ìŠ¤íŠ¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Asad Haider: Goldman Sachs Group, Inc., Research Division Congrats on the quarter. Most of my questions have been answered, but maybe one for Adam. Just any update on how the Opdivo subcu formulation launch is progressing? We've had 4 quarters on the market now, 2 with the J-code. Do you believe you're still on track for the 30% to 40% patient conversion by 2028? And any color on the types of patients who are utilizing it would be helpful.</td><td>**Asad Haider:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ì§ˆë¬¸ì€ ë‹µë³€ì„ ë“¤ì—ˆëŠ”ë°, Adamê»˜ í•œ ê°€ì§€ë§Œ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. Opdivo í”¼í•˜ì£¼ì‚¬ ì œí˜• ì¶œì‹œ ì§„í–‰ ìƒí™©ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ë¶€íƒë“œë¦½ë‹ˆë‹¤. ì´ì œ ì‹œì¥ì— ì¶œì‹œëœ ì§€ 4ë¶„ê¸°ê°€ ë˜ì—ˆê³ , J-codeë¥¼ ë°›ì€ ì§€ëŠ” 2ë¶„ê¸°ê°€ ì§€ë‚¬ìŠµë‹ˆë‹¤. 2028ë…„ê¹Œì§€ í™˜ì ì „í™˜ìœ¨ 30~40% ëª©í‘œëŠ” ì—¬ì „íˆ ë‹¬ì„± ê°€ëŠ¥í•˜ë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ì´ ì œí˜•ì„ ì‚¬ìš©í•˜ëŠ” í™˜ì ìœ í˜•ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Great. Thanks. So we're very pleased with the Qvantig launch performance in its first full year on the market. We're encouraged as we're seeing use across multiple tumor types. We're seeing uptake across monotherapy indications as well as in the combination setting. So patients who are treated for RCC, GI, metastatic melanoma. As you said, we did receive our permanent J-code last July, which eased the reimbursement process for physicians. And post that, we've seen a nice acceleration of new accounts adopting. We're focused on continuing to drive depth and breadth of account conversion and reinforcing the benefits that we know are there for both practices and for patients. And we're tracking well against our expectations and remain very confident in our expectation that physicians will convert 30% to 40% of the IV business ahead of the LOE. So we're pleased with the performance and what this means for patients and for physicians.</td><td>**Adam Lenkowsky:** ê°ì‚¬í•©ë‹ˆë‹¤. Qvantigì˜ ì‹œì¥ ì¶œì‹œ ì²« í•´ ì „ì²´ ì‹¤ì ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì—¬ëŸ¬ ì¢…ì–‘ ìœ í˜•ì— ê±¸ì³ ì‚¬ìš©ë˜ê³  ìˆë‹¤ëŠ” ì ì´ ê³ ë¬´ì ì…ë‹ˆë‹¤. ë‹¨ë…ìš”ë²• ì ì‘ì¦ë¿ë§Œ ì•„ë‹ˆë¼ ë³‘ìš©ìš”ë²• í™˜ê²½ì—ì„œë„ ì±„íƒì´ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì‹ ì„¸í¬ì•”(RCC), ìœ„ì¥ê´€ì•”(GI), ì „ì´ì„± í‘ìƒ‰ì¢… ì¹˜ë£Œë¥¼ ë°›ëŠ” í™˜ìë“¤ì—ê²Œ ì‚¬ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì§€ë‚œ 7ì›” ì˜êµ¬ J-codeë¥¼ ë°›ì•˜ê³ , ì´ë¥¼ í†µí•´ ì˜ì‚¬ë“¤ì˜ ìƒí™˜ ì ˆì°¨ê°€ ê°„ì†Œí™”ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ ì´í›„ë¡œ ì‹ ê·œ ì˜ë£Œê¸°ê´€ì˜ ì±„íƒì´ í¬ê²Œ ê°€ì†í™”ë˜ëŠ” ê²ƒì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì˜ë£Œê¸°ê´€ ì „í™˜ì˜ ê¹Šì´ì™€ í­ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³ , ì˜ë£Œê¸°ê´€ê³¼ í™˜ì ëª¨ë‘ì—ê²Œ ìˆëŠ” í˜œíƒì„ ê°•í™”í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì˜ˆìƒ ëŒ€ë¹„ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìœ¼ë©°, LOE ì´ì „ì— ì˜ì‚¬ë“¤ì´ ì •ë§¥ì£¼ì‚¬(IV) ì‚¬ì—…ì˜ 30%ì—ì„œ 40%ë¥¼ ì „í™˜í•  ê²ƒì´ë¼ëŠ” ê¸°ëŒ€ì— ëŒ€í•´ ì—¬ì „íˆ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì´ëŸ¬í•œ ì„±ê³¼ì™€ ì´ê²ƒì´ í™˜ìì™€ ì˜ì‚¬ë“¤ì—ê²Œ ê°–ëŠ” ì˜ë¯¸ì— ëŒ€í•´ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from David Risinger with Leerink Partners.</td><td>**Operator:** <budget:token_used>30000</budget:token_used><br><br>ë‹¤ìŒ ì§ˆë¬¸ì€ Leerink Partnersì˜ David Risingerë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Risinger: Leerink Partners LLC, Research Division So I have 2 questions, please. First, with respect to admilparant, could you just talk about the hypotension risk and how you would contextualize that for us? And then second, it would be helpful to just better understand what is in the guidance and what you're assuming for generic competition. So for Eliquis, could you just talk us through when you're expecting generic entry in major markets ex U.S. in '26 and '27? And then for Orencia, how many players do you anticipate launching and when?</td><td>**David Risinger:** ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € admilparant ê´€ë ¨í•´ì„œ, ì €í˜ˆì•• ìœ„í—˜ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê³  ì´ë¥¼ ì–´ë–»ê²Œ ì´í•´í•´ì•¼ í• ì§€ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ë¡œ, ê°€ì´ë˜ìŠ¤ì— ë¬´ì—‡ì´ í¬í•¨ë˜ì–´ ìˆê³  ì œë„¤ë¦­ ê²½ìŸì— ëŒ€í•´ ì–´ë–¤ ê°€ì •ì„ í•˜ê³  ê³„ì‹ ì§€ ì¢€ ë” ì˜ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. Eliquisì˜ ê²½ìš°, 2026ë…„ê³¼ 2027ë…„ì— ë¯¸êµ­ ì™¸ ì£¼ìš” ì‹œì¥ì—ì„œ ì œë„¤ë¦­ ì§„ì…ì„ ì–¸ì œ ì˜ˆìƒí•˜ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  Orenciaì˜ ê²½ìš°, ëª‡ ê°œ ì—…ì²´ê°€ ì¶œì‹œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œê³  ì–¸ì œì¯¤ìœ¼ë¡œ ë³´ì‹œë‚˜ìš”?</td></tr>
<tr><td>CEO & Chairman: Thanks for the question. I'll ask Cristian to start and then David.</td><td>**CEO & Chairman:** <budget:token_used>10</budget:token_used><br><br>ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € Cristianì´ ë‹µë³€í•˜ê³  Davidê°€ ì´ì–´ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development Thanks, David, for the question. The hypotension and syncopal episodes was one of the tolerability risks that we had with admilparant in the Phase II. But what I can tell you that actually, in the context of the Phase III, this is going very well. Let me give you a little bit more context. When we run the Phase II, we tested 2 doses, 30 and 60 milligrams. And of course, there was a dose relation outcome in terms of efficacy, but also safety. But then when we completed the study, we have seen that the risk of syncopy was well managed. And actually, we decided to -- because there was a dose relation on efficacy, we decided to introduce in the Phase III 120 milligram. And actually, we are running the Phase III studies, IPF and PPF with 120 mg and 60 mg. And the 120 mg that was running just to assess the safety and the risk of hypotension, the DMC allowed us to go in Phase III. And in a blinded fashion, we didn't see any rate that raised any concern. So this is definitely associated to the profile of the drug. It's very well managed even when you go with a higher dose that, of course, can translate to a better efficacy.</td><td>**Cristian Massacesi:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, David. ì €í˜ˆì••ê³¼ ì‹¤ì‹  ì—í”¼ì†Œë“œëŠ” 2ìƒì—ì„œ admilparantì˜ ë‚´ì•½ì„± ë¦¬ìŠ¤í¬ ì¤‘ í•˜ë‚˜ì˜€ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 3ìƒ ì‹œí—˜ì—ì„œëŠ” ì´ ë¶€ë¶„ì´ ë§¤ìš° ì˜ ê´€ë¦¬ë˜ê³  ìˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì¢€ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>2ìƒ ì‹œí—˜ì„ ì§„í–‰í•  ë‹¹ì‹œ, ì €í¬ëŠ” 30mgê³¼ 60mg ë‘ ê°€ì§€ ìš©ëŸ‰ì„ í…ŒìŠ¤íŠ¸í–ˆìŠµë‹ˆë‹¤. ë‹¹ì—°íˆ íš¨ëŠ¥ ì¸¡ë©´ì—ì„œ ìš©ëŸ‰ ê´€ë ¨ ê²°ê³¼ê°€ ë‚˜íƒ€ë‚¬ê³ , ì•ˆì „ì„± ì¸¡ë©´ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì˜€ìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì‹œí—˜ì„ ì™„ë£Œí•œ í›„, ì‹¤ì‹  ìœ„í—˜ì´ ì˜ ê´€ë¦¬ë˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¤ì œë¡œ íš¨ëŠ¥ì—ì„œ ìš©ëŸ‰ ê´€ë ¨ì„±ì´ ìˆì—ˆê¸° ë•Œë¬¸ì—, 3ìƒ ì‹œí—˜ì—ëŠ” 120mgì„ ë„ì…í•˜ê¸°ë¡œ ê²°ì •í–ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì €í¬ëŠ” IPFì™€ PPFì—ì„œ 120mgê³¼ 60mgìœ¼ë¡œ 3ìƒ ì„ìƒì‹œí—˜ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. 120mgì€ ì•ˆì „ì„±ê³¼ ì €í˜ˆì•• ìœ„í—˜ì„±ì„ í‰ê°€í•˜ê¸° ìœ„í•´ ì§„í–‰í–ˆëŠ”ë°, ë°ì´í„° ëª¨ë‹ˆí„°ë§ ìœ„ì›íšŒ(DMC)ì—ì„œ 3ìƒ ì§„í–‰ì„ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤. ëˆˆê°€ë¦¼ ë°©ì‹ìœ¼ë¡œ ì§„í–‰í•œ ê²°ê³¼, ìš°ë ¤í•  ë§Œí•œ ë°œìƒë¥ ì€ ì „í˜€ ë³´ì´ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì´ëŠ” ë¶„ëª…íˆ ì•½ë¬¼ì˜ íŠ¹ì„±ê³¼ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ë” ë†’ì€ ìš©ëŸ‰ìœ¼ë¡œ ì§„í–‰í•˜ë”ë¼ë„ ë§¤ìš° ì˜ ê´€ë¦¬ë˜ê³  ìˆìœ¼ë©°, ë‹¹ì—°íˆ ì´ëŠ” ë” ë‚˜ì€ íš¨ëŠ¥ìœ¼ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes. Just to add, Cristian, what we're hearing from physicians is that this is a very manageable side effect. And when you look at the totality of the drug, not only have we seen exciting results around FVC. But I talked about earlier, when you look at the rate of GI toxicity that have really plagued some of the assets that are out there today as well as some of the newer products that are coming to the market that have significant cough issues or dyspnea issues that can lead to significant exacerbations. I think we have an opportunity to truly be a best-in-class product, both from an efficacy and a safety standpoint.</td><td>**Adam Lenkowsky:** ë„¤, ë§ë¶™ì´ìë©´ í¬ë¦¬ìŠ¤í‹°ì•ˆ, ì˜ì‚¬ë“¤ë¡œë¶€í„° ë“£ëŠ” ë°”ë¡œëŠ” ì´ê²ƒì€ ë§¤ìš° ê´€ë¦¬ ê°€ëŠ¥í•œ ë¶€ì‘ìš©ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ì•½ë¬¼ì„ ì „ì²´ì ìœ¼ë¡œ ì‚´í´ë³´ë©´, FVCì™€ ê´€ë ¨í•˜ì—¬ ê³ ë¬´ì ì¸ ê²°ê³¼ë¥¼ ë³´ì•˜ì„ ë¿ë§Œ ì•„ë‹ˆë¼, ì œê°€ ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ í˜„ì¬ ì‹œì¥ì— ë‚˜ì™€ ìˆëŠ” ì¼ë¶€ ì œí’ˆë“¤ê³¼ ì‹¬ê°í•œ ê¸°ì¹¨ì´ë‚˜ í˜¸í¡ê³¤ë€ ë¬¸ì œë¥¼ ì¼ìœ¼ì¼œ ìƒë‹¹í•œ ì•…í™”ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆëŠ” ì‹ ê·œ ì œí’ˆë“¤ì„ ê´´ë¡­í˜€ì˜¨ ìœ„ì¥ê´€ ë…ì„± ë°œìƒë¥ ì„ ë³´ë©´, ìš°ë¦¬ëŠ” íš¨ëŠ¥ê³¼ ì•ˆì „ì„± ì¸¡ë©´ ëª¨ë‘ì—ì„œ ì§„ì •í•œ ë™ê¸‰ ìµœê³ (best-in-class) ì œí’ˆì´ ë  ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>David Elkins: Executive VP & CFO Yes. And the question on Eliquis, I talked about in total, that $1.5 billion to $2 billion step down as we go into '26, and that is driven by generic entries that we're assuming are going to happen. It's really spread throughout. It's a country-by-country basis on how that goes in. We're in litigation. We're in appeals in several of those markets. So we have to see how that plays out, but we made broad-based assumptions about generic entry.</td><td>**David Elkins:** ë„¤, ê·¸ë¦¬ê³  ì—˜ë¦¬í€´ìŠ¤ì— ëŒ€í•œ ì§ˆë¬¸ ë§ì”€ì´ì‹ ë°ìš”, 26ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ë©´ì„œ 15ì–µ~20ì–µ ë‹¬ëŸ¬ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ì´ëŠ” ì œë„¤ë¦­ ì§„ì…ì„ ê°€ì •í•œ ê²ƒì…ë‹ˆë‹¤. ì‹¤ì œë¡œëŠ” ì „ë°˜ì ìœ¼ë¡œ ë¶„ì‚°ë˜ì–´ ìˆê³ , êµ­ê°€ë³„ë¡œ ìƒí™©ì´ ë‹¤ë¥´ê²Œ ì „ê°œë©ë‹ˆë‹¤. í˜„ì¬ ì—¬ëŸ¬ ì‹œì¥ì—ì„œ ì†Œì†¡ ì¤‘ì´ê³  í•­ì†Œ ì¤‘ì¸ ê³³ë“¤ë„ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì–´ë–»ê²Œ ì§„í–‰ë ì§€ ì§€ì¼œë´ì•¼ í•˜ì§€ë§Œ, ì œë„¤ë¦­ ì§„ì…ì— ëŒ€í•´ì„œëŠ” í­ë„“ì€ ê°€ì •ì„ ì ìš©í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer And I guess the last part of the question, David, was around Orencia. So Orencia continues to perform well with great cash flow for the organization. As far as a biosimilar for Orencia, we do know that Dr. Reddy's Labs has posted an opportunity to file. Their manufacturing facility is out of India. And we had this product now since 2006, and we recognize the challenges that it takes to manufacture a product like Orencia. And so we do expect to see continued cash flow from this important product for patients.</td><td>**Adam Lenkowsky:** ì˜¤ë Œì‹œì•„ëŠ” ì¡°ì§ì— í›Œë¥­í•œ í˜„ê¸ˆ íë¦„ì„ ì°½ì¶œí•˜ë©° ê³„ì†í•´ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ë Œì‹œì•„ ë°”ì´ì˜¤ì‹œë°€ëŸ¬(biosimilar)ì™€ ê´€ë ¨í•´ì„œëŠ”, ë‹¥í„° ë ˆë””ìŠ¤ ë©(Dr. Reddy's Labs)ì´ ì‹ ì²­ ê°€ëŠ¥ì„±ì„ ê³µì‹œí•œ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì˜ ì œì¡° ì‹œì„¤ì€ ì¸ë„ì— ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” 2006ë…„ë¶€í„° ì´ ì œí’ˆì„ ë³´ìœ í•´ì™”ê³ , ì˜¤ë Œì‹œì•„ì™€ ê°™ì€ ì œí’ˆì„ ì œì¡°í•˜ëŠ” ë° ë”°ë¥´ëŠ” ì–´ë ¤ì›€ì„ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í™˜ìë“¤ì„ ìœ„í•œ ì´ ì¤‘ìš”í•œ ì œí’ˆì—ì„œ ì§€ì†ì ì¸ í˜„ê¸ˆ íë¦„ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: And Dave, I would just underscore in the EU, it's country by country for sure. The bigger countries are clustered around late in the year, in the November time frame, late in the year. And with that, please go to our next question, please.</td><td>**CEO & Chairman:** ë°ì´ë¸Œ, EUì˜ ê²½ìš° í™•ì‹¤íˆ êµ­ê°€ë³„ë¡œ ë‹¤ë¥´ë‹¤ëŠ” ì ì„ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·œëª¨ê°€ í° êµ­ê°€ë“¤ì€ ì—°ë§, 11ì›” ì •ë„ì— ì§‘ì¤‘ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today comes from David Amsellem with Piper Sandler.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ Piper Sandlerì˜ David Amsellemì´ í•˜ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Amsellem: Piper Sandler & Co., Research Division So I wanted to ask about Cobenfy and a bigger picture question. There are a number of companies developing their own M1, M4s, and in some cases, without a peripherally acting anticholinergic. So I wonder how you think those agents down the road could impact Cobenfy growth, if at all? That's number one. And then number two is, can you just talk more to how big of a priority is it to add a late-stage or commercial-ready psychiatry-focused asset or assets where you could leverage the commercial infrastructure that you've built to support Cobenfy? Again, how big of a priority? How aggressive do you want to be here?</td><td>**David Amsellem:** ì½”ë²¤í”¼ì™€ ê´€ë ¨í•´ì„œ í° ê·¸ë¦¼ì—ì„œ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜„ì¬ ì—¬ëŸ¬ íšŒì‚¬ë“¤ì´ ìì²´ì ìœ¼ë¡œ M1, M4 ì‘ìš©ì œë¥¼ ê°œë°œí•˜ê³  ìˆê³ , ì¼ë¶€ëŠ” ë§ì´ˆ ì‘ìš© í•­ì½œë¦°ì œ ì—†ì´ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ ì´ëŸ¬í•œ ì•½ë¬¼ë“¤ì´ ì½”ë²¤í”¼ ì„±ì¥ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ ì§ˆë¬¸ì…ë‹ˆë‹¤. <br><br>ë‘ ë²ˆì§¸ë¡œ, ì½”ë²¤í”¼ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ êµ¬ì¶•í•œ ìƒì—… ì¸í”„ë¼ë¥¼ í™œìš©í•  ìˆ˜ ìˆëŠ” í›„ê¸° ë‹¨ê³„ ë˜ëŠ” ìƒì—…í™” ì¤€ë¹„ê°€ ëœ ì •ì‹ ì˜í•™ ì¤‘ì‹¬ ìì‚°ì„ ì¶”ê°€í•˜ëŠ” ê²ƒì´ ì–¼ë§ˆë‚˜ í° ìš°ì„ ìˆœìœ„ì¸ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ë‹¤ì‹œ ë§í•´, ì–¼ë§ˆë‚˜ ìš°ì„ ìˆœìœ„ê°€ ë†’ì€ì§€, ê·¸ë¦¬ê³  ì´ ë¶€ë¶„ì—ì„œ ì–¼ë§ˆë‚˜ ì ê·¹ì ìœ¼ë¡œ ë‚˜ì„œì‹¤ ê³„íšì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Well, let me start on the business development question, then I'll ask Adam and Cristian to address the specifics of the Cobenfy pipeline question or competitive question. So from a business development standpoint, as I said earlier, our focus is on continuing to build out breadth and depth in each of our therapeutic areas. Obviously, we've shown a willingness to do business development to build out our presence in neuroscience. And I think you can expect that if there are attractive opportunities where the science is compelling and where the financials allow us to add value to the company and ultimately to shareholders in the neuroscience space, we would certainly be looking at it. Adam?</td><td>**CEO & Chairman:** ë¹„ì¦ˆë‹ˆìŠ¤ ê°œë°œ ì§ˆë¬¸ë¶€í„° ë¨¼ì € ë‹µë³€ë“œë¦¬ê³ , Cobenfy íŒŒì´í”„ë¼ì¸ì´ë‚˜ ê²½ìŸ ê´€ë ¨ êµ¬ì²´ì ì¸ ì§ˆë¬¸ì€ Adamê³¼ Cristianì—ê²Œ ë‹µë³€ì„ ë¶€íƒí•˜ê² ìŠµë‹ˆë‹¤. ë¹„ì¦ˆë‹ˆìŠ¤ ê°œë°œ ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìš°ë¦¬ì˜ ì´ˆì ì€ ê° ì¹˜ë£Œ ì˜ì—­ì—ì„œ í­ê³¼ ê¹Šì´ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ì¥í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ìš°ë¦¬ëŠ” ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì—ì„œì˜ ì…ì§€ë¥¼ ê°•í™”í•˜ê¸° ìœ„í•´ ë¹„ì¦ˆë‹ˆìŠ¤ ê°œë°œì„ ì ê·¹ì ìœ¼ë¡œ ì¶”ì§„í•´ì™”ìŠµë‹ˆë‹¤. ê³¼í•™ì ìœ¼ë¡œ ì„¤ë“ë ¥ì´ ìˆê³ , ì¬ë¬´ì ìœ¼ë¡œ íšŒì‚¬ì™€ ê¶ê·¹ì ìœ¼ë¡œëŠ” ì£¼ì£¼ë“¤ì—ê²Œ ê°€ì¹˜ë¥¼ ë”í•  ìˆ˜ ìˆëŠ” ë§¤ë ¥ì ì¸ ê¸°íšŒê°€ ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì— ìˆë‹¤ë©´, ë‹¹ì—°íˆ ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. Adam?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes. Thanks for the question. When we were doing the work for Karuna, we were really excited by the novel mechanism of action, not just the fact that it was working on muscarinic, but the fact that the M1, M4 component of that, which we saw brings an opportunity for increased and improved cognitive benefit and schizophrenia as well as negative symptoms. And we're seeing that in the market today. Additionally, when you look at the incredible life cycle management program that we have in place with a significant number of studies that are ongoing in Alzheimer's disease, in Alzheimer's disease psychosis, Alzheimer's disease cognition as well as agitation, coupled with bipolar disorder, this has the opportunity to be a very significant drug in the neuropsychiatric space. And we also have a very significant head start on other competitors coming. And I'll turn it to Cristian to talk about Cobenfy and also the pipeline as well that we have from the Karuna acquisition.</td><td>**Adam Lenkowsky:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì¹´ë£¨ë‚˜ ì‘ì—…ì„ ì§„í–‰í•  ë‹¹ì‹œ, ì €í¬ëŠ” ë‹¨ìˆœíˆ ë¬´ìŠ¤ì¹´ë¦° ìˆ˜ìš©ì²´ì— ì‘ìš©í•œë‹¤ëŠ” ì‚¬ì‹¤ë¿ë§Œ ì•„ë‹ˆë¼, íŠ¹íˆ M1, M4 ì„±ë¶„ì´ ì¡°í˜„ë³‘ í™˜ìì˜ ì¸ì§€ ê¸°ëŠ¥ ê°œì„ ê³¼ ìŒì„± ì¦ìƒ ì™„í™”ì— ë” ë‚˜ì€ íš¨ê³¼ë¥¼ ê°€ì ¸ì˜¬ ìˆ˜ ìˆë‹¤ëŠ” ì ì—ì„œ ì´ ìƒˆë¡œìš´ ì‘ìš© ê¸°ì „ì— ë§¤ìš° ê³ ë¬´ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜„ì¬ ì‹œì¥ì—ì„œ ì‹¤ì œë¡œ ê·¸ëŸ¬í•œ ê²°ê³¼ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ì•Œì¸ í•˜ì´ë¨¸ë³‘, ì•Œì¸ í•˜ì´ë¨¸ë³‘ ì •ì‹ ì¦, ì•Œì¸ í•˜ì´ë¨¸ë³‘ ì¸ì§€ê¸°ëŠ¥ ë° ì´ˆì¡°ì¦, ê·¸ë¦¬ê³  ì–‘ê·¹ì„± ì¥ì• ì— ëŒ€í•œ ìƒë‹¹ìˆ˜ì˜ ì„ìƒì‹œí—˜ì„ í¬í•¨í•œ ìš°ë¦¬ì˜ íƒì›”í•œ ì œí’ˆ ìˆ˜ëª…ì£¼ê¸° ê´€ë¦¬ í”„ë¡œê·¸ë¨ì„ ë³´ì‹œë©´, ì´ ì•½ë¬¼ì€ ì‹ ê²½ì •ì‹ ì˜í•™ ë¶„ì•¼ì—ì„œ ë§¤ìš° ì¤‘ìš”í•œ ì¹˜ë£Œì œê°€ ë  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ë‹¤ë¥¸ ê²½ìŸì‚¬ë“¤ì— ë¹„í•´ ìƒë‹¹í•œ ì„ ë°œ ìš°ìœ„ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. Cobenfyì™€ Karuna ì¸ìˆ˜ë¥¼ í†µí•´ í™•ë³´í•œ íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ì„œëŠ” Cristianì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development So David, you raised an important point. There are many -- there are M4 agonists, there are M4 PAM, positive allosteric modulators. You have other M1/M4 that are emerging. First of all, we are ahead of everybody else. This is the first point. The second is we still don't know how M4 agonist or M4 PAMs can play out versus an M1/M4 inhibitor like Cobenfy. And we still don't know if you change your peripheral anticholinergic drug, how this can impact the brain penetration and additional the control of some of the cholinergic symptoms. We believe that Cobenfy with xanomeline and trospium has the right approach. As Adam said, we have a very rich pipeline coming from Karuna from our internal research that, of course, keep investigating these mechanisms. And we will disclose at the right time how these programs are progressing. And we are focusing very much on these receptors. And of course, we have assets that go beyond that because some of them are to control symptoms in Alzheimer's, others are disease-modifier assets. So our Alzheimer's pipeline is very rich, and we are very excited about it, actually.</td><td>**Cristian Massacesi:** ë°ì´ë¹„ë“œê°€ ì¤‘ìš”í•œ ì§€ì ì„ ì§šì–´ì£¼ì…¨ìŠµë‹ˆë‹¤. ì‹œì¥ì—ëŠ” M4 ì‘ìš©ì œ(agonist)ë„ ìˆê³ , M4 PAM, ì¦‰ ì–‘ì„± ì•Œë¡œìŠ¤í…Œë¦­ ì¡°ì ˆì œ(positive allosteric modulators)ë„ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  M1/M4 ë³µí•©ì œë“¤ë„ ë“±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ì„  ì²« ë²ˆì§¸ë¡œ, ìš°ë¦¬ê°€ ëª¨ë“  ê²½ìŸì‚¬ë“¤ë³´ë‹¤ ì•ì„œ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ, M4 ì‘ìš©ì œë‚˜ M4 PAMë“¤ì´ ì½”ë²¤í”¼(Cobenfy)ì™€ ê°™ì€ M1/M4 ì–µì œì œì™€ ë¹„êµí•´ì„œ ì–´ë–¤ ê²°ê³¼ë¥¼ ë³´ì¼ì§€ ì•„ì§ ì•Œ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë˜í•œ ë§ì´ˆ í•­ì½œë¦°ì„± ì•½ë¬¼ì„ ë³€ê²½í–ˆì„ ë•Œ ë‡Œ ì¹¨íˆ¬ë„ì™€ ì¼ë¶€ ì½œë¦°ì„± ì¦ìƒ ì¡°ì ˆì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹ ì§€ë„ ì•„ì§ ëª¨ë¦…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìë…¸ë©œë¦°(xanomeline)ê³¼ íŠ¸ë¡œìŠ¤í”¼ì›€(trospium)ì„ ê²°í•©í•œ ì½”ë²¤í”¼ê°€ ì˜¬ë°”ë¥¸ ì ‘ê·¼ë²•ì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. Adamì´ ë§í–ˆë“¯ì´, Karunaë¡œë¶€í„° ë§¤ìš° í’ë¶€í•œ íŒŒì´í”„ë¼ì¸ì„ í™•ë³´í•˜ê³  ìˆìœ¼ë©°, ë¬¼ë¡  ì €í¬ ë‚´ë¶€ ì—°êµ¬ì—ì„œë„ ì´ëŸ¬í•œ ë©”ì»¤ë‹ˆì¦˜ë“¤ì„ ì§€ì†ì ìœ¼ë¡œ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í”„ë¡œê·¸ë¨ë“¤ì˜ ì§„í–‰ ìƒí™©ì€ ì ì ˆí•œ ì‹œê¸°ì— ê³µê°œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ëŸ¬í•œ ìˆ˜ìš©ì²´ë“¤ì— ë§¤ìš° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ê·¸ ë²”ìœ„ë¥¼ ë„˜ì–´ì„œëŠ” ìì‚°ë“¤ë„ ë³´ìœ í•˜ê³  ìˆëŠ”ë°, ì¼ë¶€ëŠ” ì•Œì¸ í•˜ì´ë¨¸ ì¦ìƒì„ ì¡°ì ˆí•˜ê¸° ìœ„í•œ ê²ƒì´ê³ , ë‹¤ë¥¸ ê²ƒë“¤ì€ ì§ˆë³‘ ì¡°ì ˆ ìì‚°(disease-modifier assets)ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ ì•Œì¸ í•˜ì´ë¨¸ íŒŒì´í”„ë¼ì¸ì€ ë§¤ìš° í’ë¶€í•˜ë©°, ì‹¤ì œë¡œ ì´ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from Jason Gerberry with Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ ì œì´ìŠ¨ ê±°ë² ë¦¬ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jason Gerberry: BofA Securities, Research Division So just for me on milvexian, can you remind us why you opted not to enrich in the SSP trial for atherosclerosis? And do you think that in any way poses a risk in terms of reading across from the positive efficacy result from the Bayer data later today in SSP? And then my second question is just as we look at the CELMoDs in the second-line plus refractory multiple myeloma space, it's obviously getting increasingly complicated with recent data from the bispecifics. And so I'm just kind of curious how you guys are thinking about the relative positioning here if data are confirmatory on Phase III. Obviously, there's a lot to be kind of assessed out with your data. But do you see these as agents that maybe appeal more to community providers, more as like third, fourth line drugs? Or do you think they get used earlier? Just any color on how you see it kind of positioning within an increasingly complicated space?</td><td>**Jason Gerberry:** milvexianì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. SSP ì„ìƒì‹œí—˜ì—ì„œ ì£½ìƒë™ë§¥ê²½í™”ì¦ í™˜ìë¥¼ ë†ì¶•(enrich)í•˜ì§€ ì•Šê¸°ë¡œ ê²°ì •í•œ ì´ìœ ë¥¼ ë‹¤ì‹œ ì„¤ëª…í•´ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì´ê²ƒì´ ì˜¤ëŠ˜ ëŠ¦ê²Œ ë°œí‘œë  Bayerì˜ SSP ê¸ì •ì  íš¨ëŠ¥ ê²°ê³¼ë¥¼ í•´ì„í•˜ëŠ” ë° ìˆì–´ ì–´ë–¤ ë¦¬ìŠ¤í¬ê°€ ë  ìˆ˜ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? <br><br>ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ 2ì°¨ ì¹˜ë£Œ ì´ìƒ ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ë¶„ì•¼ì˜ CELMoDì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ìµœê·¼ ì´ì¤‘íŠ¹ì´í•­ì²´(bispecific) ë°ì´í„°ë“¤ë¡œ ì¸í•´ ê²½ìŸ í™˜ê²½ì´ ì ì  ë” ë³µì¡í•´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë§Œì•½ 3ìƒ ë°ì´í„°ê°€ í™•ì¦ì ìœ¼ë¡œ ë‚˜ì˜¨ë‹¤ë©´, ì´ ë¶„ì•¼ì—ì„œì˜ ìƒëŒ€ì  í¬ì§€ì…”ë‹ì„ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë¬¼ë¡  ê·€ì‚¬ì˜ ë°ì´í„°ë¡œ í‰ê°€í•´ì•¼ í•  ë¶€ë¶„ë“¤ì´ ë§ì´ ìˆê² ì§€ë§Œìš”. <response><br><br>ì´ ì•½ì œë“¤ì´ ì§€ì—­ì‚¬íšŒ ì˜ë£Œê¸°ê´€(community providers)ì— ë” ì–´í•„í•  ìˆ˜ ìˆëŠ”, 3ì°¨ë‚˜ 4ì°¨ ì¹˜ë£Œì œ ì •ë„ë¡œ ë³´ì‹œëŠ” ê±´ê°€ìš”? ì•„ë‹ˆë©´ ë” ì¡°ê¸°ì— ì‚¬ìš©ë  ê²ƒìœ¼ë¡œ ë³´ì‹œë‚˜ìš”? ì ì  ë³µì¡í•´ì§€ëŠ” ì‹œì¥ í™˜ê²½ì—ì„œ ì´ ì•½ì œë“¤ì˜ í¬ì§€ì…”ë‹ì„ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>CEO & Chairman: Well, let me start, and I'm going to ask Adam and then Cristian can chime in on your milvexian question. As we look at the CELMoD program generally, we're very excited about the data that we've already seen and about the commercial potential, particularly in light of some of the changes taking place in that landscape. But Adam, do you want to elaborate?</td><td>**CEO & Chairman:** ë¨¼ì € ì œê°€ ë§ì”€ë“œë¦¬ê³ , Adamì—ê²Œ ì§ˆë¬¸ì„ ë“œë¦° ë‹¤ìŒ Cristianì´ ë°€ë²¡ì‹œì•ˆ ê´€ë ¨ ì§ˆë¬¸ì— ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. CELMoD í”„ë¡œê·¸ë¨ ì „ë°˜ì„ ë³´ë©´, ì €í¬ëŠ” ì´ë¯¸ í™•ì¸í•œ ë°ì´í„°ì™€ ìƒì—…ì  ì ì¬ë ¥ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ í•´ë‹¹ ì‹œì¥ í™˜ê²½ì—ì„œ ì¼ì–´ë‚˜ê³  ìˆëŠ” ì—¬ëŸ¬ ë³€í™”ë“¤ì„ ê³ ë ¤í•˜ë©´ ë”ìš± ê·¸ë ‡ìŠµë‹ˆë‹¤. Adam, ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes, Jason, thanks for the question. Just building on Chris' comment. We've got good momentum coming off the ASH meeting last year, and we see excitement building around our overall CELMoD portfolio, iberdomide, mezigdomide and golcadomide in hematology. And this is a market, Jason, that we know very well. This is a competitive market. It's a fragmented market, but there remains a need for more effective and safe treatment options that can address the majority of patients, particularly those that are treated in the community setting. And roughly 70% to 80% of patients are treated in the community. Now while rev and pom based combinations are the backbone of treatment across early lines of multiple myeloma, there's an opportunity to improve upon their depth and durability. There's an opportunity to improve on their tolerability. And we expect iberdomide will provide that balance of high potency, a manageable toxicity profile, combinability with anti-CD38 with the convenience of an oral treatment. And we continue to hear positive feedback from physicians. So our goal is to make both, iber and mezi foundational in multiple myeloma, replacing IMiDs in earlier lines of treatment. So this is going to be for iberdomide, a second-line product largely used in the community in combination with daratumumab. Ultimately, longer term, we believe that these can serve as partners for TCEs and cell therapy. So we'll be studying that there. We presented data with Pfizer's TCE at ASH. So once approved, we expect good adoption over time in the community in second line as most patients just don't have access to cell therapies or bispecifics due to safety and accessibility challenges. So our teams are ready for the launch of iberdomide. We know the work that we need to do to establish both iber and mezi in this competitive market, and we're excited to bring them to patients.</td><td>**Adam Lenkowsky:** ë„¤, Jason, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. Chrisì˜ ë§ì”€ì— ë§ë¶™ì´ìë©´, ì‘ë…„ ASH ë¯¸íŒ… ì´í›„ ì¢‹ì€ ëª¨ë©˜í…€ì„ ì´ì–´ê°€ê³  ìˆìœ¼ë©°, í˜ˆì•¡í•™ ë¶„ì•¼ì—ì„œ ì €í¬ ì „ì²´ CELMoD í¬íŠ¸í´ë¦¬ì˜¤ì¸ iberdomide, mezigdomide, golcadomideì— ëŒ€í•œ ê¸°ëŒ€ê°ì´ ë†’ì•„ì§€ê³  ìˆìŠµë‹ˆë‹¤. Jason, ì´ ì‹œì¥ì€ ì €í¬ê°€ ë§¤ìš° ì˜ ì•Œê³  ìˆëŠ” ì‹œì¥ì…ë‹ˆë‹¤. ê²½ìŸì´ ì¹˜ì—´í•˜ê³  ì„¸ë¶„í™”ëœ ì‹œì¥ì´ì§€ë§Œ, ì—¬ì „íˆ ëŒ€ë‹¤ìˆ˜ í™˜ìë“¤, íŠ¹íˆ ì§€ì—­ì‚¬íšŒ ì˜ë£Œê¸°ê´€ì—ì„œ ì¹˜ë£Œë°›ëŠ” í™˜ìë“¤ì„ ìœ„í•œ ë” íš¨ê³¼ì ì´ê³  ì•ˆì „í•œ ì¹˜ë£Œ ì˜µì…˜ì— ëŒ€í•œ ìˆ˜ìš”ê°€ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•½ 70%ì—ì„œ 80%ì˜ í™˜ìë“¤ì´ ì§€ì—­ì‚¬íšŒ ì˜ë£Œê¸°ê´€ì—ì„œ ì¹˜ë£Œë¥¼ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë ˆë‚ ë¦¬ë„ë§ˆì´ë“œ(rev)ì™€ í¬ë§ë¦¬ë„ë§ˆì´ë“œ(pom) ê¸°ë°˜ ë³‘ìš©ìš”ë²•ì´ ë‹¤ë°œê³¨ìˆ˜ì¢… ì´ˆê¸° ì¹˜ë£Œ ë¼ì¸ì˜ ê·¼ê°„ì„ ì´ë£¨ê³  ìˆì§€ë§Œ, ë°˜ì‘ì˜ ê¹Šì´ì™€ ì§€ì†ì„±ì„ ê°œì„ í•  ì—¬ì§€ê°€ ìˆìŠµë‹ˆë‹¤. ë‚´ì•½ì„± ì¸¡ë©´ì—ì„œë„ ê°œì„ ì˜ ê¸°íšŒê°€ ìˆê³ ìš”. ì €í¬ëŠ” ì´ë²„ë„ë§ˆì´ë“œê°€ ë†’ì€ íš¨ëŠ¥, ê´€ë¦¬ ê°€ëŠ¥í•œ ë…ì„± í”„ë¡œíŒŒì¼, í•­CD38 í•­ì²´ì™€ì˜ ë³‘ìš© ê°€ëŠ¥ì„±, ê·¸ë¦¬ê³  ê²½êµ¬ íˆ¬ì—¬ì˜ í¸ì˜ì„±ì´ë¼ëŠ” ê· í˜•ì„ ì œê³µí•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ì˜ì‚¬ë“¤ë¡œë¶€í„° ê³„ì†í•´ì„œ ê¸ì •ì ì¸ í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì €í¬ ëª©í‘œëŠ” ì´ë²„ë„ë§ˆì´ë“œì™€ ë©”ì§€ë„ë§ˆì´ë“œ ëª¨ë‘ë¥¼ ë‹¤ë°œê³¨ìˆ˜ì¢…ì˜ í•µì‹¬ ì¹˜ë£Œì œë¡œ ìë¦¬ë§¤ê¹€ì‹œì¼œ, ì´ˆê¸° ì¹˜ë£Œ ë¼ì¸ì—ì„œ IMiD ê³„ì—´ ì•½ë¬¼ì„ ëŒ€ì²´í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë²„ë„ë§ˆì´ë“œì˜ ê²½ìš°, ë‹¤ë¼íˆ¬ë¬´ë§™ê³¼ ë³‘ìš©í•˜ì—¬ ì£¼ë¡œ ì§€ì—­ì‚¬íšŒ ì˜ë£Œê¸°ê´€ì—ì„œ ì‚¬ìš©ë˜ëŠ” 2ì°¨ ì¹˜ë£Œì œê°€ ë  ê²ƒì…ë‹ˆë‹¤. ê¶ê·¹ì ìœ¼ë¡œ ì¥ê¸°ì ìœ¼ë¡œëŠ” ì´ë“¤ ì œí’ˆì´ TCE ë° ì„¸í¬ì¹˜ë£Œì œì˜ íŒŒíŠ¸ë„ˆ ì—­í• ì„ í•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ë¶€ë¶„ì„ ì—°êµ¬í•  ì˜ˆì •ì…ë‹ˆë‹¤. ASHì—ì„œ í™”ì´ìì˜ TCEì™€ ê´€ë ¨ëœ ë°ì´í„°ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ìŠ¹ì¸ì´ ë‚˜ë©´ 2ì°¨ ì¹˜ë£Œì œë¡œì„œ ì§€ì—­ì‚¬íšŒì—ì„œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì¢‹ì€ ì±„íƒë¥ ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ í™˜ìë“¤ì´ ì•ˆì „ì„±ê³¼ ì ‘ê·¼ì„± ë¬¸ì œë¡œ ì¸í•´ ì„¸í¬ì¹˜ë£Œì œë‚˜ ì´ì¤‘íŠ¹ì´í•­ì²´ì— ì ‘ê·¼í•˜ì§€ ëª»í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ì €í¬ íŒ€ì€ iberdomide ì¶œì‹œ ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê²½ìŸì´ ì¹˜ì—´í•œ ì‹œì¥ì—ì„œ iberì™€ mezi ëª¨ë‘ë¥¼ í™•ë¦½í•˜ê¸° ìœ„í•´ í•´ì•¼ í•  ì¼ë“¤ì„ ì˜ ì•Œê³  ìˆìœ¼ë©°, ì´ë¥¼ í™˜ìë“¤ì—ê²Œ ì œê³µí•˜ê²Œ ë˜ì–´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤.</td></tr>
<tr><td>Cristian Massacesi: Executive VP, Chief Medical Officer & Head of Development So Jason, thank you. It's a very good technical question you're asking. But let me help you to clarify. Some of the eligibility criteria from the stroke study that Bayer is running and our Librexia stroke studies can be different. But when you look -- we didn't disclose our baseline patient and disease characteristics like they did. And in a few hours, we will see also the outcome. But I can tell you that the 2 studies are very similar in the patient population. When you look at the events that are causing the stroke, you have 3 categories: Large artery sclerosis, these are events that are coming faster. You have events that are coming from lacunar strokes. These are when you have the occlusion of small arteries in the brain. And they have strokes that are coming from embolic events that you don't know the source, unknown source. So this is -- will not be very different between the two studies. And we believe that there is nothing -- and by the way, we control the number of events coming from lacunar. So we will not have a disproportion of that because it's capped in terms of event. So this gives us confidence that the 2 studies and the way we run our study at least is the right way.</td><td>**Cristian Massacesi:** ì œì´ìŠ¨, ê°ì‚¬í•©ë‹ˆë‹¤. ë§¤ìš° ì¢‹ì€ ê¸°ìˆ ì  ì§ˆë¬¸ì…ë‹ˆë‹¤. ëª…í™•íˆ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë°”ì´ì—˜ì´ ì§„í–‰ ì¤‘ì¸ ë‡Œì¡¸ì¤‘ ì—°êµ¬ì™€ ìš°ë¦¬ Librexia ë‡Œì¡¸ì¤‘ ì—°êµ¬ì˜ ì¼ë¶€ ì ê²©ì„± ê¸°ì¤€ì€ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ì”€ë“œë¦¬ìë©´, ìš°ë¦¬ëŠ” ë°”ì´ì—˜ì²˜ëŸ¼ ê¸°ì € í™˜ì ë° ì§ˆí™˜ íŠ¹ì„±ì„ ê³µê°œí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ëª‡ ì‹œê°„ í›„ë©´ ê²°ê³¼ë„ í™•ì¸í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ë‘ ì—°êµ¬ì˜ í™˜ìêµ°ì€ ë§¤ìš° ìœ ì‚¬í•˜ë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë‡Œì¡¸ì¤‘ì„ ìœ ë°œí•˜ëŠ” ì‚¬ê±´ë“¤ì„ ë³´ë©´ 3ê°€ì§€ ë²”ì£¼ê°€ ìˆìŠµë‹ˆë‹¤. ëŒ€ë™ë§¥ ê²½í™”ì¦(Large artery sclerosis)ì´ ìˆëŠ”ë°, ì´ëŠ” ë” ë¹ ë¥´ê²Œ ë°œìƒí•˜ëŠ” ì‚¬ê±´ë“¤ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—´ê³µì„± ë‡Œì¡¸ì¤‘(lacunar stroke)ì—ì„œ ë°œìƒí•˜ëŠ” ì‚¬ê±´ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‡Œì˜ ì‘ì€ ë™ë§¥ì´ íìƒ‰ë  ë•Œ ë°œìƒí•©ë‹ˆë‹¤. ìƒ‰ì „ì„± ì‚¬ê±´(embolic events)ìœ¼ë¡œ ì¸í•œ ë‡Œì¡¸ì¤‘ì´ ë°œìƒí•˜ëŠ”ë° ê·¸ ì›ì¸ì„ ì•Œ ìˆ˜ ì—†ëŠ” ê²½ìš°ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë‘ ì—°êµ¬ ê°„ì— í° ì°¨ì´ëŠ” ì—†ì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—´ê³µì„± ë‡Œì¡¸ì¤‘(lacunar stroke)ì—ì„œ ë°œìƒí•˜ëŠ” ì‚¬ê±´ ìˆ˜ë¥¼ í†µì œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ê±´ ìˆ˜ì— ìƒí•œì„ ì„ ë‘ê³  ìˆê¸° ë•Œë¬¸ì— ë¶ˆê· í˜•ì´ ë°œìƒí•˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì ë“¤ì´ ë‘ ì—°êµ¬ì™€ ìš°ë¦¬ê°€ ì—°êµ¬ë¥¼ ì§„í–‰í•˜ëŠ” ë°©ì‹ì´ ì˜¬ë°”ë¥´ë‹¤ëŠ” í™•ì‹ ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from Evan Seigerman at BMO Capital Markets.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ BMO ìºí”¼íƒˆ ë§ˆì¼“ì˜ ì—ë°˜ ì‚¬ì´ê±°ë¨¼ì—ê²Œì„œ ë“¤ì–´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Malcolm Hoffman: BMO Capital Markets Equity Research Malcolm Hoffman on for Evan. I wanted to ask 2 commercial questions real quick. So first on Opdualag, in the fourth quarter, we saw in the U.S., particularly strong growth even relative to maybe prior years in 2024. Can you talk about some of the dynamics that may be contributing here? Obviously, the standard of care in melanoma, but are there particular physician engagement efforts that are contributing in the U.S.? And then secondarily, on Reblozyl, I know highly penetrated in MDS anemia. Can you just help contextualize how much more room there is for growth in this indication?</td><td>**Malcolm Hoffman:** ë§ì½¤ì…ë‹ˆë‹¤. ì—ë°˜ì„ ëŒ€ì‹ í•´ì„œ ì§ˆë¬¸ë“œë¦½ë‹ˆë‹¤. ìƒì—…ì  ì¸¡ë©´ì—ì„œ ë‘ ê°€ì§€ ì§ˆë¬¸ì„ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € Opdualag ê´€ë ¨í•´ì„œ, 4ë¶„ê¸°ì— ë¯¸êµ­ì—ì„œ 2024ë…„ ì´ì „ ì—°ë„ë“¤ê³¼ ë¹„êµí•´ë„ íŠ¹íˆ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ì— ê¸°ì—¬í•˜ê³  ìˆëŠ” ìš”ì¸ë“¤ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? í‘ìƒ‰ì¢…ì—ì„œ í‘œì¤€ì¹˜ë£Œì œ(standard of care)ë¼ëŠ” ì ì€ ë¶„ëª…í•˜ì§€ë§Œ, ë¯¸êµ­ì—ì„œ íŠ¹ë³„íˆ ê¸°ì—¬í•˜ê³  ìˆëŠ” ì˜ì‚¬ ì°¸ì—¬ ë…¸ë ¥(physician engagement efforts)ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ Reblozylì˜ ê²½ìš°, MDS ë¹ˆí˜ˆì—ì„œ ì´ë¯¸ ë†’ì€ ì¹¨íˆ¬ìœ¨ì„ ë³´ì´ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ ì ì‘ì¦ì—ì„œ ì¶”ê°€ ì„±ì¥ ì—¬ë ¥ì´ ì–¼ë§ˆë‚˜ ë” ìˆëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Yes, thanks for the question. So Opdualag has become a standard of care in first-line metastatic melanoma in the United States. Opdualag is now approaching 4 years post launch and has over 30% market share. In fact, when you look at the totality of BMS market share in metastatic melanoma, we're now over 65%. So our objective is to continue to expand our share. There's still roughly 15% of patients that continue on PD-1 monotherapy. And so there's an opportunity there to source that business this year. Additionally, we started to launch internationally in markets like Australia, U.K. and France that will contribute to growth in 2026. We also expect an all-comers indication in Europe in Q2, which will drive significant growth internationally. So we see opportunities to increase sales of Opdualag in the U.S. and as well as ex U.S. with a broader label. As far as Reblozyl, as you mentioned, Reblozyl delivered continued strong growth. As you heard from both David and Chris, Reblozyl is now annualizing over $2 billion of sales worldwide. We're continuing to drive demand across first-line RS-positive and first-line RS-negative patients. We expect to see continued strong growth, particularly in the RS-negative patients where there's an opportunity for growth. We saw a very rapid uptake initially post COMMANDS in RS-positive and RS-negative provides the greatest opportunity for growth in the United States. And outside of the U.S., in many markets, we're just starting to launch and get reimbursed in first line. So overall, we see continued solid growth for Reblozyl in first line this year, and we expect strong performance.</td><td>**Adam Lenkowsky:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜µë‘ì•Œë¼ê·¸ëŠ” ë¯¸êµ­ì—ì„œ 1ì°¨ ì „ì´ì„± í‘ìƒ‰ì¢… ì¹˜ë£Œì˜ í‘œì¤€ìš”ë²•(standard of care)ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ì˜µë‘ì•Œë¼ê·¸ëŠ” ì¶œì‹œ í›„ 4ë…„ì— ê°€ê¹Œì›Œì§€ê³  ìˆìœ¼ë©° 30% ì´ìƒì˜ ì‹œì¥ì ìœ ìœ¨ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì „ì´ì„± í‘ìƒ‰ì¢… ì‹œì¥ì—ì„œ BMSì˜ ì „ì²´ ì‹œì¥ì ìœ ìœ¨ì„ ë³´ë©´ í˜„ì¬ 65%ë¥¼ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ìš°ë¦¬ì˜ ëª©í‘œëŠ” ì ìœ ìœ¨ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì—¬ì „íˆ ì•½ 15%ì˜ í™˜ìë“¤ì´ PD-1 ë‹¨ë…ìš”ë²•ì„ ê³„ì† ì‚¬ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¬í•´ í•´ë‹¹ ì‹œì¥ì„ í™•ë³´í•  ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. <br><br>ë˜í•œ í˜¸ì£¼, ì˜êµ­, í”„ë‘ìŠ¤ì™€ ê°™ì€ ì‹œì¥ì—ì„œ í•´ì™¸ ì¶œì‹œë¥¼ ì‹œì‘í–ˆìœ¼ë©°, ì´ëŠ” 2026ë…„ ì„±ì¥ì— ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤. 2ë¶„ê¸°ì—ëŠ” ìœ ëŸ½ì—ì„œ ì „ì²´ í™˜ì ëŒ€ìƒ(all-comers) ì ì‘ì¦ì„ íšë“í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” í•´ì™¸ ì‹œì¥ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒì…ë‹ˆë‹¤. Opdualagì˜ ê²½ìš°, ë” ë„“ì€ ì ì‘ì¦ í—ˆê°€ë¥¼ í†µí•´ ë¯¸êµ­ ë‚´ ë§¤ì¶œ ì¦ëŒ€ ê¸°íšŒë¥¼ ë³´ê³  ìˆìœ¼ë©°, ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. Reblozyl ê´€ë ¨í•´ì„œ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. Davidì™€ Chris ëª¨ë‘ ì–¸ê¸‰í–ˆë“¯ì´, Reblozylì€ í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì—°ê°„ 20ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ë§¤ì¶œì„ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ì°¨ ì¹˜ë£Œì œë¡œì„œ RS ì–‘ì„± í™˜ìì™€ RS ìŒì„± í™˜ì ëª¨ë‘ì—ì„œ ìˆ˜ìš”ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ RS ìŒì„± í™˜ìêµ°ì—ì„œ ì„±ì¥ ê¸°íšŒê°€ ìˆì–´ ê°•ë ¥í•œ ì„±ì¥ì„¸ê°€ ê³„ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. COMMANDS ì„ìƒ ê²°ê³¼ ë°œí‘œ ì§í›„ RS ì–‘ì„± í™˜ìêµ°ì—ì„œ ë§¤ìš° ë¹ ë¥¸ ì²˜ë°© ì¦ê°€ë¥¼ ë³´ì˜€ê³ , ë¯¸êµ­ ë‚´ì—ì„œëŠ” RS ìŒì„± í™˜ìêµ°ì´ ê°€ì¥ í° ì„±ì¥ ê¸°íšŒë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ ì§€ì—­ì˜ ê²½ìš°, ë§ì€ ì‹œì¥ì—ì„œ ì´ì œ ë§‰ 1ì°¨ ì¹˜ë£Œì œë¡œ ì¶œì‹œë˜ê³  ê¸‰ì—¬ ë“±ì¬ë¥¼ ë°›ê¸° ì‹œì‘í•˜ëŠ” ë‹¨ê³„ì…ë‹ˆë‹¤. <budget:token_used>50000</token_used><br><br>ì „ë°˜ì ìœ¼ë¡œ ì˜¬í•´ 1ì°¨ ì¹˜ë£Œì œë¡œì„œ Reblozylì˜ ì§€ì†ì ì´ê³  ê²¬ê³ í•œ ì„±ì¥ì„¸ë¥¼ ë³´ê³  ìˆìœ¼ë©°, ê°•ë ¥í•œ ì‹¤ì ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Charles Triano: SVP & Head of Investor Relations Thanks, Adam. And operator, we'll have one more question, and Chris will make a brief closing. Thank you.</td><td>**Charles Triano:** ê°ì‚¬í•©ë‹ˆë‹¤, Adam. ê·¸ë¦¬ê³  êµí™˜ì›ë‹˜, ì§ˆë¬¸ í•œ ê°œë§Œ ë” ë°›ê² ìŠµë‹ˆë‹¤. ê·¸ í›„ Chrisê°€ ê°„ë‹¨íˆ ë§ˆë¬´ë¦¬ ë§ì”€ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our final question today comes from Stephen Scala with TD Cowen.</td><td>**Operator:** ì˜¤ëŠ˜ ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ TD Cowenì˜ Stephen Scalaë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Steve Scala: TD Cowen, Research Division Apologies, this is Eliquis question. But I don't think this product has grown double digit in several years, but then will in 2026. And it's still not absolutely clear why there will be a step down in '27. If the 2026 is boosted by a higher commercial price, why won't that also boost 2027? I understand about OUS patent expirations, but OUS in its totality is only $4 billion, and I think some patents have been off for years. I would -- I think it's striking for a product to go from double digit in 1 year to $1 billion declines in the following. So it seems like what you're really saying is U.S. prices coming down in '27 too, and it's not clear why. And related to this, how did the contributing $7 billion of Eliquis API to the U.S. government impact the P&L?</td><td>**Steve Scala:** ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ, ì´ê±´ Eliquis ì§ˆë¬¸ì…ë‹ˆë‹¤. ì´ ì œí’ˆì´ ìˆ˜ë…„ê°„ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ í•˜ì§€ ëª»í–ˆë‹¤ê°€ 2026ë…„ì— ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ í•  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°ìš”. ê·¸ëŸ°ë° 27ë…„ì— ì™œ ê°ì†Œí•  ê²ƒì¸ì§€ê°€ ì—¬ì „íˆ ëª…í™•í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§Œì•½ 2026ë…„ì´ ë” ë†’ì€ ìƒì—…ìš© ê°€ê²©ìœ¼ë¡œ ì¸í•´ ìƒìŠ¹í•œë‹¤ë©´, ì™œ ê·¸ê²ƒì´ 2027ë…„ë„ ëŒì–´ì˜¬ë¦¬ì§€ ëª»í•˜ëŠ” ê±´ê°€ìš”? í•´ì™¸ íŠ¹í—ˆ ë§Œë£Œì— ëŒ€í•´ì„œëŠ” ì´í•´í•˜ì§€ë§Œ, í•´ì™¸ ì „ì²´ ë§¤ì¶œì´ 40ì–µ ë‹¬ëŸ¬ì— ë¶ˆê³¼í•˜ê³ , ì¼ë¶€ íŠ¹í—ˆëŠ” ì´ë¯¸ ìˆ˜ë…„ ì „ì— ë§Œë£Œë˜ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•œ ì œí’ˆì´ í•œ í•´ì—ëŠ” ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ í•˜ë‹¤ê°€ ë‹¤ìŒ í•´ì— 10ì–µ ë‹¬ëŸ¬ ê°ì†Œí•œë‹¤ëŠ” ê²ƒì€ ìƒë‹¹íˆ ì´ë¡€ì ì´ë¼ê³  ë´…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì‹¤ì œë¡œ ë§ì”€í•˜ì‹œëŠ” ê²ƒì€ 27ë…„ì— ë¯¸êµ­ ê°€ê²©ë„ í•˜ë½í•œë‹¤ëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, ì™œ ê·¸ëŸ°ì§€ê°€ ëª…í™•í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨í•´ì„œ, ë¯¸êµ­ ì •ë¶€ì— 70ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ Eliquis APIë¥¼ ê³µê¸‰í•œ ê²ƒì´ ì†ìµê³„ì‚°ì„œì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì³¤ë‚˜ìš”?</td></tr>
<tr><td>Adam Lenkowsky: Executive VP & Chief Commercialization Officer Great, Steve. Thanks for the question. Just at a higher level. Number one, we continue to see strong demand performance with Eliquis, and that's going to continue in '26. When you look at the price reduction that took place in the United States, that will eliminate the inflationary penalties, CPI penalties of the rebates this year and into next year. When we look at in totality, you're right, roughly 70% of the Eliquis business is in the U.S. This is a very large brand. And so we expect in November of this year that we will lose exclusivity in Europe, and we would expect rapid and steep decline like we have seen with other small molecules outside of the U.S. And so that's why we would expect to see that step down in 2027.</td><td>**Adam Lenkowsky:** ë„¤, ìŠ¤í‹°ë¸Œ. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ì „ë°˜ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ì—˜ë¦¬í€´ìŠ¤ì˜ ìˆ˜ìš” ì‹¤ì ì´ ê³„ì† ê²¬ì¡°í•˜ê²Œ ìœ ì§€ë˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 26ë…„ì—ë„ ì§€ì†ë  ê²ƒì…ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ë°œìƒí•œ ê°€ê²© ì¸í•˜ëŠ” ì˜¬í•´ì™€ ë‚´ë…„ì˜ ë¦¬ë² ì´íŠ¸ì—ì„œ ì¸í”Œë ˆì´ì…˜ í˜ë„í‹°, ì¦‰ CPI í˜ë„í‹°ë¥¼ ì œê±°í•˜ê²Œ ë©ë‹ˆë‹¤. ì „ì²´ì ìœ¼ë¡œ ë³´ë©´, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì—˜ë¦¬í€´ìŠ¤ ë§¤ì¶œì˜ ì•½ 70%ê°€ ë¯¸êµ­ì—ì„œ ë°œìƒí•©ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° í° ê·œëª¨ì˜ ë¸Œëœë“œì…ë‹ˆë‹¤. ì˜¬í•´ 11ì›”ì— ìœ ëŸ½ì—ì„œ ë…ì ê¶Œì„ ìƒì‹¤í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ ì™¸ ì§€ì—­ì˜ ë‹¤ë¥¸ ì €ë¶„ì ì˜ì•½í’ˆë“¤ì—ì„œ ë´¤ë˜ ê²ƒì²˜ëŸ¼ ë¹ ë¥´ê³  ê¸‰ê²©í•œ í•˜ë½ì´ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 2027ë…„ì— ê·¸ëŸ¬í•œ ë§¤ì¶œ ê°ì†Œê°€ ë‚˜íƒ€ë‚  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ” ê²ƒì…ë‹ˆï¿½ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: And just on your question on the strategic reserve, that's not a material impact on the overall business, just given the magnitude of the business as well as just the amount of product that will be provided in that reserve. So no impact there. So thanks for the questions. And maybe just in conclusion, we have spent, as we've discussed on these calls for the last number of quarters, significant time on execution as a company across functions. And I think what you see in the numbers we put up today is that we're doing what we said we would do. We've become much more focused. We strengthened execution across all of the relevant functions in the organization. We've built a growth portfolio that has very strong momentum coming into the year. We have a pipeline, as has been discussed on this call, of differentiated assets that is now within months of meaningful data readouts. And finally, we've continued to strengthen the company financially. And that, of course, gives us strategic flexibility to not only return capital to shareholders, but continue to add substrate for growth. I'm incredibly proud of the strong foundation we have coming into this year, which we couldn't have contributed to without the commitment and dedication of my colleagues at BMS. So thank you all for joining us today. As always, the team is going to be available for any follow-ups, and have a great rest of the day.</td><td>**CEO & Chairman:** ì „ëµì  ë¹„ì¶•ë¶„ ê´€ë ¨ ì§ˆë¬¸ì— ëŒ€í•´ì„œëŠ”, ì „ì²´ ì‚¬ì—… ê·œëª¨ì™€ ë¹„ì¶•ë¶„ìœ¼ë¡œ ì œê³µë  ì œí’ˆëŸ‰ì„ ê³ ë ¤í•  ë•Œ ì „ì²´ ì‚¬ì—…ì— ì¤‘ìš”í•œ ì˜í–¥ì„ ë¯¸ì¹˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì˜í–¥ì€ ì—†ë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. <br><br>ë§ˆì§€ë§‰ìœ¼ë¡œ ì •ë¦¬í•˜ìë©´, ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” íšŒì‚¬ ì „ë°˜ì˜ ê¸°ëŠ¥ ë¶€ë¬¸ì—ì„œ ì‹¤í–‰ë ¥ ê°•í™”ì— ìƒë‹¹í•œ ì‹œê°„ì„ íˆ¬ìí•´ì™”ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œí•œ ì‹¤ì  ìˆ˜ì¹˜ë¥¼ ë³´ì‹œë©´ ìš°ë¦¬ê°€ ì•½ì†í•œ ëŒ€ë¡œ ì‹¤í–‰í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í›¨ì”¬ ë” ì§‘ì¤‘ë ¥ì„ ë†’ì˜€ê³ , ì¡°ì§ ë‚´ ëª¨ë“  í•µì‹¬ ê¸°ëŠ¥ ë¶€ë¬¸ì˜ ì‹¤í–‰ë ¥ì„ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ë“¤ì–´ ë§¤ìš° ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ê°€ì§„ ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ì½œì—ì„œ ë…¼ì˜ëœ ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” ì°¨ë³„í™”ëœ ìì‚° íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ì œ ëª‡ ê°œì›” ë‚´ì— ì˜ë¯¸ ìˆëŠ” ë°ì´í„° ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ëŠ” íšŒì‚¬ì˜ ì¬ë¬´ ê±´ì „ì„±ì„ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•´ ì™”ìŠµë‹ˆë‹¤. ì´ëŠ” ë¬¼ë¡  ì£¼ì£¼ë“¤ì—ê²Œ ìë³¸ì„ í™˜ì›í•  ë¿ë§Œ ì•„ë‹ˆë¼ ì„±ì¥ì„ ìœ„í•œ ê¸°ë°˜ì„ ê³„ì† ì¶”ê°€í•  ìˆ˜ ìˆëŠ” ì „ëµì  ìœ ì—°ì„±ì„ ì œê³µí•©ë‹ˆë‹¤. ì˜¬í•´ë¥¼ ë§ì´í•˜ëŠ” ìš°ë¦¬ì˜ íƒ„íƒ„í•œ ê¸°ë°˜ì´ ë§¤ìš° ìë‘ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ì´ëŠ” BMS ë™ë£Œë“¤ì˜ í—Œì‹ ê³¼ ë…¸ë ¥ ì—†ì´ëŠ” ë¶ˆê°€ëŠ¥í–ˆì„ ê²ƒì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì–¸ì œë‚˜ì²˜ëŸ¼, íŒ€ì€ ì¶”ê°€ ë¬¸ì˜ì‚¬í•­ì— ëŒ€í•´ ì–¸ì œë“ ì§€ ë„ì›€ì„ ë“œë¦´ ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‚¨ì€ í•˜ë£¨ ì¢‹ì€ ì‹œê°„ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. That concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œì— ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë˜ë©°, ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Bristol Myers Squibb ì‹¤ì  ë°œí‘œ ìš”ì•½ (2026ë…„ ê°€ì´ë˜ìŠ¤)<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **2026ë…„ ê°€ì´ë˜ìŠ¤ ë° ì„±ì¥ ì „ë§**: Eliquisê°€ IRA ê°€ê²© ì¡°ì •(ì•½ 40% WACC ê°ì†Œ) ë° Medicare Part D ë¶€ë‹´ ì œê±°ì—ë„ ë¶ˆêµ¬í•˜ê³  10-15% ì„±ì¥ ì˜ˆìƒ. ì„±ì¥ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” mid-single digit ì„±ì¥ ì „ë§. 2027ë…„ì—ëŠ” Eliquisê°€ $15-20ì–µ ê°ì†Œ ì˜ˆìƒ(EU íŠ¹í—ˆ ë§Œë£Œ ì˜í–¥ í¬í•¨).<br><br>â€¢ **2026ë…„ ì„ìƒ ë°ì´í„° ì´‰ë§¤ì œ**: 6ê°œ ì‹ ì•½ í›„ë³´ì—ì„œ 10ê°œ ì´ìƒì˜ Phase III ë°ì´í„° ë°œí‘œ ì˜ˆì •. ì£¼ìš” ìì‚°ìœ¼ë¡œëŠ” â–²CELMoD ê³„ì—´(iberdomide, mezigdomide) â–²milvexian(Factor XI ì–µì œì œ, AFib ë° ë‡Œì¡¸ì¤‘) â–²admilparant(LPA1, IPF/PPF) â–²pumitamig(PD-L1/VEGF ì´ì¤‘í•­ì²´) ë“±ì´ í¬í•¨ë˜ë©°, ê²½ì˜ì§„ì€ ì´ë“¤ì˜ ìƒì—…ì  ì ì¬ë ¥ì— ë†’ì€ ìì‹ ê° í‘œëª….<br><br>â€¢ **Cobenfy ì„±ì¥ ë‘”í™” ìš°ë ¤ ëŒ€ì‘**: ì¶œì‹œ ì²«í•´ 100,000 TRx ë‹¬ì„±í•˜ë©° ìœ ì‚¬ ìì‚° ëŒ€ë¹„ ìš°ìˆ˜í•œ ì„±ê³¼. ì ‘ê·¼ì„±ì€ ë¬¸ì œ ì•„ë‹ˆë©°(Medicaid/Medicare 100%, ìƒì—… ë³´í—˜ 70%), ì²˜ë°© ê²½í—˜ì´ ê¸ì •ì ì¸ ì˜ì‚¬ë“¤ì˜ ì¬ì²˜ë°©ë¥  ì¦ê°€ ì¶”ì„¸. Phase IV ìŠ¤ìœ„ì¹­ ì—°êµ¬ ë“± ì¶”ê°€ ë°ì´</p>
    <hr style="margin:50px 0;">
    
</body></html>